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ABSTRACT 
 Halima Samsodien 
 
SUPRAMOLECULAR DERIVATIVES OF SELECTED 
BIOACTIVE COMPOUNDS:  A  PHYSICOCHEMICAL STUDY 
 
The author’s objective was to prepare new solid phases of three bioactive compounds: the 
steroidal anticancer agent 2-methoxyestradiol [polymorphs and cyclodextrin (CD) inclusion 
complexes], its derivative 2-methoxyestradiol-bis-sulfamate (polymorphs), and the 
antiretroviral agent, nevirapine (co-crystals). The solubility and dissolution profiles of the three 
compounds and those of selected ‘supramolecularly-derived’ species were also assessed. 
 
Three distinct phases of 2-methoxyestradiol (2ME) were successfully isolated, the most stable 
form (a polymorph) by the recrystallisation method, an amorph by melt studies and a solvated 
form by recrystallisation. 2-methoxyestradiol-bis-sulfamate (2MES), in the form of a 
hemihydrate, remained unchanged when recrystallised from various solvents. Several CDs were 
used for possible 2-methoxyestradiol inclusion; these were α-, -, -CD, and nine derivatised 
cyclodextrins. Co-precipitation and kneading techniques were employed in attempts to produce 
inclusion complexes. An inclusion complex of 2ME was isolated with each of the following: -
CD, HPBCD, RAMEB, DIMEB and TRIMEB.  
 
Co-crystallisation of nevirapine was attempted using twelve potential co-formers with GRAS 
status. Two co-crystals, one with saccharin and one with rac-tartaric acid, were isolated by the 
co-precipitation method.   
 
Physicochemical characterisation techniques used to assess the thermal behaviour of the 
products included hot stage microscopy, differential scanning calorimetry and 
thermogravimetric analysis. UV spectrophotometry and elemental analysis were used for host-
guest stoichiometric assay and purity determination respectively. X-ray powder diffraction and 
single crystal X-ray structure determination were used for structural analysis. 
 
The aqueous solubility of the derivative 2MES was found to be twice that of 2ME and this was 
confirmed by in vitro dissolution studies. The amorphous 2ME preparation had the most 
promising profile, indicating a dissolution rate double that of untreated 2ME. 
 
S tructural elucidation by X-ray diffraction of CD inclusion complexes of a classical steroid, 
represented by 2ME, was achieved for the first time and the solubility and comparative 
dissolution profiles of non-toxic oral CD complexes with 2ME versus untreated 2ME and its 
derivative 2MES were established. A marked increase in the aqueous solubility and dissolution 
profiles of the CD complexes relative to the untreated 2ME was established.  
 
In the two nevirapine co-crystals, the API molecule retained the usual ‘butterfly’ conformation, 
a feature essential for antiretroviral activity. Single crystal X-ray analysis proved that these 
species were both genuine co-crystals, as opposed to salts.  
The aqueous solubility and dissolution rate of nevirapine were significantly enhanced by both 
co-formers, saccharin and rac-tartaric acid. 
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 2
Chapter 1 presents a literature synopsis of polymorphism, cyclodextrin inclusion and 
pharmaceutical co-crystallisation. These phenomena are aspects of supramolecular chemistry 
which is the study of non-covalent interactions between molecules, ions or radicals. More 
specifically, supramolecular chemistry deals with hydrogen bonding π···π, C-H···π, van der 
Waals and hydrophobic interactions. Furthermore, Chapter 1 provides the motivation for the 
study of selected drugs 2-methoxyestradiol, 2-methoxyestradiol-bis-sulfamate and nevirapine. 
 
1.1 POLYMORPHISM 
A polymorph is defined as a ‘solid crystalline phase of a given compound resulting from 
the possibility of at least two different arrangements of the molecules of that compound 
in the solid state’.1 These forms are identical in the liquid and vapour states but differ in 
the way the molecules in each polymorph pack in the solid state. Owing to the differing 
packing arrangements, resulting physical properties which may differ between 
polymorphs are solubility, melting point, density, hardness, crystal shape, optical and 
electrical properties, vapour pressure, hygroscopicity, dissolution rate and ultimately 
bioavailability. Hence, polymorphs are chemically identical but may be as different in 
structure and physical properties as the crystals of two different compounds. A very 
large number of compounds, organic and inorganic, as well as elements themselves, 
have been shown to crystallise in two or more different crystalline arrangements, 
depending on conditions under which crystallisation occurs. It appears that many 
organic materials exist in several polymorphic forms with the number of forms found 
depending on the effort spent searching for them. Hence, scientists studying the concept 
of polymorphism emphasise the importance of applying ‘due diligence’1,2 since 
compounds exhibiting polymorphism demand much time for investigation. Most of 
these polymorphs, especially the organic ones, do not have special names but are 
referred to as α, β, γ etc. or I, II, III, etc. The Roman numerals are preferred and by 
convention Form I represents the most stable form at room temperature. Assignment of 
the higher numerals proceeds in order of discovery, which in general should follow their 
order of stability. The possibility of discovery of intermediate forms always exists. 
Unstable polymorphs, as a result of their greater thermodynamic activity (higher Gibbs 
free energy), will tend to transform to more stable forms. An intermediate form, the 
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 3
metastable polymorph, is often the polymorph of choice to be incorporated into 
pharmaceutical preparations since, in comparison to the stable form, it has a higher 
solubility. Polymorphism is remarkably common, particularly within certain structural 
groups: 63% of barbiturates, 67% of steroids and 40% of sulphonamides exhibit 
polymorphism. Five polymorphs have been identified for progesterone, whereas four 
polymorphs and three solvates have been identified for the sulphonamide 
sulphabenzamide.3 Generally polymorphs are obtained by recrystallisation from various 
solvents or solvent mixtures. Others can be produced without the presence of solvent by 
thermal techniques, particularly sublimation and re-crystallisation from the melt. 
Supercooling of the melt is particularly useful as well in discovering unstable 
modifications.3 
 
Materials in the solid state can be crystalline or amorphous (or a combination of both). 
The crystalline materials are those in which the molecules are packed in a defined order, 
and this same order repeats over and over again throughout the particle. In Figure 1.1, 
(a) represents an ordered packing of a hypothetical molecule; here the shape of the 
molecule is represented by a ‘hockey-stick’ style image, illustrating a planar structure 
with a functional group pointing up at the end; (b) represents an alternative packing 
arrangement and (c) represents the inclusion of a solvent molecule, to produce a 
solvated crystalline form. 
      
 
       (a)       (b)            (c) 
            Solvate 
         
Polymorphism of molecule             Solvent molecule 
 
Figure 1.1 Schematic diagram illustrating polymorphism and solvatomorphism. 
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A characteristic property of a crystal is that it has a distinctive melting point. This is the 
temperature at which the crystal breaks down, owing to the molecules having gained 
sufficient energy from the heating process to overcome the attractive forces that hold 
the crystal together. It follows that crystals with weak forces holding the molecules 
together (such as paraffins, which only have van der Waals interactions) have low 
melting points, whereas crystals with strong intermolecular forces (e.g. extensive 
hydrogen bonding) have high melting points.3 
 
If the crystallisation conditions are changed in any way, it is possible that the molecules 
may start to form crystals with a different packing pattern from that which occurred 
when the original conditions were used. The change in conditions could be a different 
solvent, or a change in the stirring rate, or different impurities being present. Figure 
1.1(b) shows an alternative packing arrangement from that which occurred for the same 
molecule in Figure 1.1(a). As both the packing arrangements in Figure 1.1(a) and (b) are 
repeating ordered systems, they are both crystals; these would be called polymorphic 
forms.3 
 
By looking at the packing arrangements in Figure 1.1 it can be seen that the molecules 
in (a) are more spaced out than those in (b), which means that the two crystal forms 
would have different densities (i.e. the same mass of material would be accommodated in 
different volumes). It looks as though it would be easier to physically pull a molecule off 
structure (a) than off (b), as the molecules in (b) are more interwoven into the structure. 
If this were the case then (a) would have a lower melting point than (b) and might 
dissolve more easily. Also, if an attempt were made to mill the two crystals, it appears 
that (a) would break easily, as there are natural break lines (either vertically or 
horizontally), whereas (b) does not seem to have an obvious weak line to allow easy 
cleavage. This could mean that the milling and compaction (for example: tabletting) 
properties of the two forms will differ.3 
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Brief Historical Overview 
1822 Mitscherlich4 - first recognition of the phenomenon of polymorphism; 
discovered that the salt NaH2PO4·H2O crystallises with different crystal 
morphologies due to differences in the internal structural arrangements 
of the constituent ions. 
1839 Frankenheim5 - suggested principles for the transition of one polymorph 
into a second. 
 Lehman6 - coined the irreversible and reversible transitions as 
monotropic and enantiotropic respectively. 
1844  Polarizing microscope invented5,7 
1897 Ostwald8 - addressed the relative stabilities of polymorphs using 
thermodynamics. It was established that the metastable form has the 
higher solubility and crystallises first, eventually transforming via a 
solution-mediated process into a more stable form. 
1926 Tammann9 - considered polymorphs as identical molecular species 
arranged on different lattices using X-ray crystallography. 
 
Preparation and Analysis of Polymorphs 
Preparation and investigation of pol morphs is a fundamental step in preformulation 
studies. Manufacturers of pharmaceuticals are required to prove that potential 
polymorphism of marketed drugs has been investigated so that an unwanted polymorph 
does not filter through to the consumer. Thus, it is significant to know which methods 
are likely to yield polymorphs and to employ them in the search for potential 
polymorphs.  
 
A number of methods were suggested by Guillory for generating polymorphs, solvates 
or amorphous forms of a particular compound.2 Amongst these methods are 
sublimation, crystallisation from a single or binary solvent system, vapour diffusion, 
thermal treatment, crystallisation from the melt, rapid pH changes, thermal desolvation 
of crystalline solvates, growth in the presence of additives, and grinding. Of these 
methods crystallisation from a variety of solvents is usually the first step in the search 
for polymorphic forms of a compound and has been very successful in many cases. In 
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addition, desolvation of crystalline solvates may also be included in these methods since 
it was reported10 that the method resulted in the improvement of certain properties such 
as flowability and uniformity of particle size. 
 
The first step to identifying a polymorph is describing the physical morphology of the 
crystal or powder. A microscope is employed in this instance. However, different 
morphologies may not necessarily indicate different forms and therefore we employ 
further analytical techniques. The second step is to determine the melting points of the 
various forms generated. A hot stage microscope or a differential scanning calorimeter 
may be employed in this instance. However, differing melting points may not prove the 
existence of distinct forms (polymorphs) unequivocally. The third step, which is much 
more informative, involves application of X-ray diffraction, thermal and spectroscopic 
techniques, which are respectively used to characterise the polymorphs in terms of their 
structures, thermodynamic stabilities and spectral energies. Once there is a clear 
indication that polymorphs of a compound have been found, the several analytical 
methods employed to characterise their individual properties will provide further 
information regarding properties related to each other, for example stability 
relationships. The range of analytical techniques used should be as broad as possible as 
the information obtained from them is often complementary, as suggested by 
Bernstein.1 The reader is referred to Chapter 2 for a more extensive discussion on the 
preparation of polymorphs and the analytical tools used in their study. 
 
Thermodynamic Stability Relationship11  
As suggested earlier, with thermal analytical studies, the thermodynamic stability 
relationships between polymorphs can be established. At specified temperature and 
pressure, only one polymorph of a given compound is thermodynamically stable (i.e. has 
the minimum Gibbs free energy), and all other polymorphs are metastable to varying 
degrees. If this factor alone determined the outcome of crystallisation, then only one 
polymorph (the most stable) should appear. However, because the nuclei of different 
polymorphs have unique structural and interfacial properties, their free energies of 
activation differ, and hence, the nucleation rates of different polymorphs of the same 
compound generally differ.11 
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Enantiotropy vs Monotropy 
Enantiotropy and monotropy are terms used to describe the reversibility or lack thereof 
of the phase transition between polymorphs.6 Phase transitions are restricted 
thermodynamically to occur spontaneously in the direction of the stable form only. 
Monotropy (irreversible transition) implies that one form is the thermodynamically 
stable form at all temperatures. Enantiotropy (reversible phase transition) implies the 
presence of a transition point where the stability order of the polymorphs is reversed. 
The most widely used thermodynamic relationship for the treatment of stability is:  
G = H – TS, where G = Gibbs free energy, H = enthalpy, T = absolute temperature 
and S = entropy. This relationship is used to construct diagrams that illustrate the 
variation of G and H with temperature to establish the stability relationship of 
polymorphs from zero Kelvin to just beyond their melting temperatures. Figure 1.2 
illustrates these stability relationships where the subscripts ‘1’ and ‘2’ denote the 
polymorph to which the function refers, [the lower melting polymorph is denoted ‘2’], 
whilst ‘L’ refers to the supercooled liquid. The subscri ts ‘f’ and ‘tr’ refer to ‘fusion’ and 
‘transition’ respectively. 
 
Figure 1.2 Schematic diagrams showing the variation of G and H with temperature for (a) an 
enantiotropic and (b) a monotropic dimorphic system.  
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The G curve can only have a negative slope and intersect another curve at most once, 
whilst the H curves have a positive slope and it is assumed that they never intersect,1 
which leads to one of the Burger and Ramberger rules.11 which is termed the ‘Heat of 
Transition Rule’. This states that if an endothermic phase change is observed at a 
particular temperature, the stability relationship is enantiotropic, otherwise it is 
monotropic.11 
Other rules suggested by Burger and Ramberger include: 
- Heat of fusion rule: 
If the higher melting polymorph has the higher heat of fusion, the 
stability relationship is monotropic, otherwise it is enantiotropic 
- Entropy of fusion rule: 
If the higher melting polymorph has the higher entropy of fusion, the 
stability relationship is monotropic, otherwise it is enantiotropic 
- Heat capacity rule: 
If the higher melting polymorph has the higher heat capacity at a given 
temperature then the stability relationship is enantiotropic, otherwise it 
is monotropic 
- Density rule: 
The more stable polymorph at the absolute zero of temperature should 
have the higher density 
- Infrared rule: 
For polymorphs with strong hydrogen bonds the one with the larger 
frequency for the highest frequency infrared absorption band, will have 
the larger entropy. 
 
The Burger and Ramberger rules are based on statistical mechanical arguments of an 
ideal model of molecular crystals. Yu12 used pure thermodynamic arguments to infer the 
stability relationship from melting data and derived thermodynamic formulae for 
calculation of ΔG0, the difference in Gibbs free energy of the polymorphs, and their 
temperature slopes at the melting point of the lower melting polymorph. Extrapolation 
of the ΔG0 temperature slopes to their point of intersection then yields the transition 
temperature, Ttr. The advantage of Yu’s treatment is that both the stability relationship 
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and Ttr can be obtained from it. The equations necessary for the determination of the 
transition temperature for the process 
 
Form 2 (Tf,2) → Form 1 (Tf,2)     are: 
∆H0 = ∆Hf,2 - ∆Hf,1 + (Cp,L – Cp,1) (Tf,1 – Tf,2) 
∆S0 = ∆Hf,2/Tf,2 - ∆Hf,1/Tf,1 + (Cp,L – Cp,1) ln (Tf,1/Tf,2)  and 
∆G0 = ∆Hf,1(Tf,2/Tf,1-1) + (Cp,L – Cp,1) [Tf,1 – Tf,2 – Tf,2 ln (Tf,1/Tf,2)] 
 
where the subscript 0 denotes the function at the melting temperature of the lower 
melting form and (Cp,L – Cp,1) is the difference between the heat capacities of the 
supercooled liquid and Form 1 between the temperatures Tf,2 and Tf,1. If ∆G(T) has a 
linear dependence, then 
 
∆G(T) = ∆G0 - ∆S0(T-Tf,2)      and the condition  
∆G(Ttr) = 0        yields  
Ttr = ∆H0/∆S0 
 
All the parameters for these equations are obtained directly from conventional 
differential scanning calorimetric data, except for the (Cp,L – Cp,1) parameter. Yu 
estimated the latter from the following derived equation: 
 
k = (Cp,L – Cp,1)/∆Hf,1 
 
where the value of k, based on an empirical study of several polymorphic systems, is 
approximated to 0.003/K.12 
 
Kinetic Considerations 
Kinetic factors may also determine the polymorphic form that crystallises from solution. 
Figure 1.3 illustrates the Gibbs free energy vs reaction coordinate graph for a 
dimorphic system. It shows that even though Form 1 is the thermodynamically stable 
polymorph, its higher associated Gibbs free energy of activation might prevent its 
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formation. However, it is the rates of nucleation of the respective polymorphs that 
determine which one precipitates from solution and the associated Gibbs free energy of  
activation is merely one of the factors that determine these rates. Competitive kinetic 
and thermodynamic factors complicate the prediction of the form that will precipitate 
first. The concept of crystal size is one of the key factors of kinetic nucleation as 
proposed by Volmer in 1939.13 According to this concept, a critical size of aggregated 
molecules must exist in solution before further growth is stabilised. This critical size is 
usually different for the respective polymorphs, which would thus account for different 
crystallisation rates. Some of the other factors influencing nucleation rates are 
molecular volume, surface free energy, temperature, degree of supersaturation and 
solubility. 
 
 
 
 
 
 
Figure 1.3 Free energy vs reaction coordinate diagrams for two polymorphs 
illustrating the influence of kinetics on their formation. G*-G0 represents the 
activation free energy for nucleation. 
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Structural Features of Polymorphs 
The structure of polymorphs of a single compound is a fundamental property as it is this 
feature that differentiates them. Both X-ray crystallographic techniques and solid-state 
NMR spectroscopy are key analytical techniques employed for structural elucidation of 
polymorphs, with X-ray diffraction being the preferred technique. Polymorphic 
molecules may be classified into ‘rigid’ molecules or those with conformational 
‘flexibility’. In cases where different conformations of the molecules are adopted in 
different crystal structures, the phenomenon is referred to as conformational 
polymorphism.14 
 
There are various methods available for visual comparison of polymorphic structures. 
For polymorphs with no common unit cell parameters the traditional method was to 
prepare packing diagrams with a view down an arbitrary crystallographic axis, but this 
usually conveyed little information about their similarities or differences. It is often 
more useful to choose a common molecular reference plane and orientate it the same for 
all the structures. This gives an indication of the immediate environment around the 
chosen reference plane.1 Viewing down a common crystallographic axis, i.e. in 
polymorphic structures that have similar unit cell parameters and/or symmetry 
elements, may also allow a basis for comparison.  
The concept of graph set analysis has in recent years proved to be very useful in 
comparing polymorphic structures.15,16 This concept is applied to hydrogen bonds 
which are very often a common feature of polymorphic structures. In this approach the 
hydrogen bonding is easily simplified and reduced to four basic patterns, viz. chains (C), 
rings (R), intramolecular hydrogen-bonded patterns (S) and other finite patterns (D). 
These designators are superscripted a and subscripted d for the number of hydrogen-
bond acceptors and donors respectively. This is followed by the descriptor (n) which 
indicates the total number of atoms involved in the pattern. The general graph set 
descriptor is thus G ad(n) and examples of assignments are given in Figure 1.4. 
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Figure 1.4 Schematic diagrams showing the four basic patterns using graph-set 
analysis. If no a, d or (n) descriptor is present, the value is assumed to be 1. 
 
Polymorphism in Pharmaceutical Formulations 
Careful consideration must be given to the crystal properties and solid state of drugs 
since practically all drug substances are handled in powder form during their 
manufacture into dosage forms. Differing crystalline forms can greatly affect 
formulation, stability and biological activity of the drug. For example, metastable 
polymorphic forms have higher solubility than stable forms. Even though the more 
soluble polymorphs are metastable and will eventually convert to the stable form, the 
rate of such conversion is often slow enough for the metastable form to be employed in 
the formulation. From a pharmaceutical point of view the degree of conversion should 
obviously be monitored during storage of the drug product to ensure that its efficacy is 
not altered significantly. In addition, conversion to the least soluble and most stable 
polymorph may contribute to the growth of crystals in suspension formulations.3  
 
 
 
 
C(4) 
R 2 2(8) 
D
S(6) 
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Suspensions: In preparing physically stable dosage forms such as suspensions with 
aqueous vehicles, if the wrong polymorph is used, phase conversion from the metastable 
polymorph may occur, producing crystal growth and caking. Crystal growth gives rise 
to undesirable particle size distribution which can be especially problematic with 
parenteral suspensions. If caking occurs, the preparation cannot be uniformly 
suspended.  
 
Solutions: The stability of a drug in its vehicle is the first consideration in 
formulating a solution. If this information is obtained with regard to a metastable form, 
it is possible that the concentration of the drug in a solution can exceed the solubility of 
a less soluble stable form. It is with sparingly water-soluble drugs (e.g. steroids) that 
solutions, supersaturated with respect to the stable form, may undergo chance 
nucleation which results in crystallisation and precipitation. One approach to solving 
this type of problem is to formulate the product in a vehicle containing sufficient co-
solvent in order to solubilise the less soluble form.  
 
Creams: In creams, the wrong polymorph suspended in a cream base can undergo 
phase conversion. The less soluble, stable form will result in crystal growth giving 
gritty, cosmetically unacceptable creams or products in which the active ingredient is 
unevenly distributed. The polymorph least susceptible to growth in the cream base 
should be selected – this is the form least soluble in the base. The greater the solubility 
of the metastable form suspended in a cream base, the higher the risk of eventual 
nucleation of the more stable, less soluble form. If the phase conversion is particularly 
slow in a base, the more soluble metastable form can safely be incorporated to take 
advantage of the higher therapeutic activity associated with the thermodynamically 
more active metastable form.  
 
Suppositories: In suppositories, polymorphic transitions affect changes in 
melting characteristics. Suppository bases often depend on melting at body temperature 
to release the active ingredients and an increased melting point will mean reduced 
therapeutic activity.  A depressed melting point creates problems with storage and 
handling. For example, cocoa butter exists in three polymorphic forms and this causes 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction  
 
 14
great difficulty in making suppositories by the fusion method.3 Cocoa butter melted and 
brought to a relatively high temperature, say 60-70 ºC, then solidified by rapid cooling, 
will melt below 30 ºC. The rapid cooling promotes the formation of only α crystals 
which melt at too low a temperature (22 ºC) to allow normal handling. There is a slow 
transition from the metastable α form to the β' form (melting point = 28 ºC), and finally 
to the stable β form with highest melting point of 34.5 ºC. This transition is fairly slow 
and suppositories poured from over-heated cocoa butter will only exhibit a normal 
melting point after several days. Careful melting of the cocoa butter just a few degrees 
above its melting point allows the crystallisation of nuclei of the β form to remain in the 
melt, which on cooling favours additional crystallisation of the β form. 
 
Tablets: In tablets, different crystalline forms have different hardness and 
cohesion properties. When a compound exhibiting polymorphism makes up a large 
portion of a tabletting mixture, the ease with which th  powder is compressed into a 
tablet can be affected. In general, great care must be taken in the use of raw materials 
when polymorphism is a physical characteristic of a particular compound. 
 
Polymorphism and Generically Equivalent Dosage Forms 
The successful use of a polymorph of significantly greater thermodynamic activity (i.e. 
higher solubility, higher Gibbs free energy) than the stable form can result in higher 
blood levels and consequently better therapeutic effects. The amorphous form of the 
antibiotic novobiocin gives a better therapeutic response than the crystalline form 
because it is more soluble in the GIT fluids and therefore better absorbed into the 
bloodstream. Special ingredients (e.g. methylcellulose, PVP, sodium alginate) must be 
added to suspensions of novobiocin to retard or prevent its transition to the stable 
crystalline form. The antibiotic chloramphenicol palmitate exists as three crystalline 
forms (A, B and C) and one amorphous form.3 The best therapeutic effect is found in 
those preparations containing only Form B. The presence of the other forms makes the 
drug less effective and there may therefore be brand to brand variation. Other examples 
include the anhydrous form of ampicillin which is more efficiently absorbed than the 
trihydrate forms3, Form II of methylprednisolone more than Form I and amorphous 
insulin zinc complex more than the crystalline complex.17 By varying the ratio 
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amorphous:crystalline, insulin preparations having different onset and duration of 
action can be prepared. Hence, the study of polymorphism and its control is vital in the 
pharmaceutical industry when dealing with a potential new drug during preformulation 
studies. It is at this stage that the choice of the proper polymorph should be made as this 
will determine if a pharmaceutical preparation will be chemically and physically stable, 
or if a powder will tablet well or not, or if the blood level obtained will be the 
therapeutic level to give the desired pharmacological response. 
 
Polymorphic Control, Structural Elucidation and Crystal Structure Prediction 
The decisive need to control the polymorphic forms obtained is of great concern to the 
pharmaceutical industry and understandably so. The industry may suffer massive 
financial losses when it fails to manufacture the desired polymorph or an undesired form 
appears accidentally. Once a particular form has been obtained, a knowledge of the 
thermodynamics of the polymorphic system, e.g. in the form of energy vs temperature 
diagrams, is essential to provide information on the storage conditions necessary to 
prevent any unwanted transformations. The complexity of the practical control of the 
crystallisation of a desired form may vary between simply reproducing the form with 
the same protocol as used before, to the  rational design of auxiliaries that through 
selective molecular recognition may inhibit or suppress the growth of the undesired 
stable form, thus allowing the growth of the desired metastable form.10 The latter 
strategy has enjoyed very limited success thus far, but one successful example has been 
the crystallisation of the metastable form of N-(2-acetamido-4-nitrophenyl)pyrrolidine 
by the addition of a small amount (0.03%) of the designed inhibitor.18 Between these two 
extremes there are chemical and physical variations that have been used to produce 
specific polymorphs.10 These include, amongst others, examples of polymorphs that 
have been produced from solutions seeded with the desired form,19 successive chemical 
reactions,20 desolvation of solvates,21 and successive reheating and cooling strategies to 
produce a metastable form. 
 
When single-crystal X-ray techniques are not appropriate, such as when the production 
of microcrystalline particles only is possible, high-resolution powder X-ray diffraction 
may be employed to elucidate crystal structures. Indexing of the powder diffraction 
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pattern, optimisation of the molecular unit by modelling methods, generation of trial 
structures and Rietveld refinement are employed to determine the structure.22 
Optimisation of the method includes the use of synchrotron radiation for rapid data 
capture, superior treatment of overlapping reflections, more reliable indexing routines, 
and more flexible methods of obtaining trial structures. Telmisartan23 is a compound 
with two polymorphic forms, the structure of one of these having been determined from 
PXRD data. However the method does prove to have one limitation, namely that while 
molecular conformations in different polymorphs may be determined with high 
precision, the same is not true for molecular parameters such as bond lengths and 
angles.22 
 
Ideally, crystal structure prediction is the ultimate objective of supramolecular chemists 
engaged in the field of polymorphism. However, is it a very complex problem, as 
acknowledged by Caira22 in a review article. The problems arise with generating a set of 
potential polymorphs of the compound, detection of the most stable one at a given 
temperature and modelling of the nucleation kinetics to determine which phase will 
actually appear under given conditions. Advancement in this area is growing rapidly 
and challenges are met with renewed vig ur each time. For example, conformationally 
flexible molecules are especially challenging for crystal structure prediction, not to 
mention the severe challenge of polymorphic solvates, for which the correct positions 
and orientations of the drug and solvent molecules must be determined.  
 
To conclude, polymorphs of pharmaceuticals have significant consequences in terms of 
their performance, e.g. their solubilities may have an impact on their bioavailabilities, 
their melting points on solubilities, or structures on melting points. The varying 
physical properties of polymorphs thus command control over the form produced. This, 
however, can prove costly and with the inclusion of drugs into cyclodextrins, the need 
for this careful control is effectively eliminated, as ‘new chemical entities’ are formed 
and the polymorphic identity of the drug is removed. It should be noted, however, that a 
given cyclodextrin drug inclusion complex itself may exist in different crystalline forms 
as proved in 2003.24 An overview of cyclodextrins in terms of their structure, properties, 
inclusion complexes and application in the pharmaceutical industry follows. 
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1.2 CYCLODEXTRINS  
Natural Origin of Cyclodextrins 
Enzymatic degradation of starch generally results in the production of glucose, maltose, 
maltotriose and related sugars i.e. a long series of linear or branched chain malto-
oligomers, known as dextrins. Dextrins are heterogeneous, amorphous, hygroscopic 
substances, produced in large quantities for the food, textile, paper and other industries. 
They are also consumed without prior isolation in such products as e.g. beer and bread. 
This type of starch degradation is a true hydrolytic process, as the primary product 
from the splitting of the glycosidic linkage reacts with one molecule of water.25,26  
If, however, the starch is degraded by the glucosyltransferase enzyme, the primary 
product of the chain splitting undergoes an intramolecular reaction without the 
participation of a water molecule. The α-1,4-linked cyclic products are formed; they are 
known as cyclodextrins (CDs).26  
CDs are a family of three well known, industrially produced, major cyclic 
oligosaccharides, and several minor rare ones. The three major cyclodextrins (α-, β- and 
γ-CD) are crystalline, homogeneous, non-hygroscopic substances, which possess a 
torus-like macro-ring shape, built up from glucopyranose units.The α-, β- and γ-CD, 
also known as Schardinger’s α-, β- and γ-dextrins, respectively, comprise n = 6, 7 and 8 
glucopyranose units respectively26 (Figure 1.5).      
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Figure 1.5 (a) The truncated cone representation and (b) the macrocyclic ring of 
α-CD (as representative) and in parentheses in (c) a α-D-glucopyranose monomer. 
 
Brief Historical Overview 
1891  Villiers27 - first publication of a substance named ‘cellulosine’ which  
  later proved to be a cyclodextrin. 
1904-1911 Schardinger28-31 – credited with laying down fundamentals of cyclodextin 
chemistry. Schardinger referred to these compounds as dextrins. 
1936 Freudenberg et al.32 – postulated that dextrins contain cyclic α-1,4-
glycosidic linkages. 
1950s French33 and Cramer34 – were responsible for the enzymatic production 
of cyclodextrins and characterising their physical and chemical 
properties. 
(c) (b) 
Primary rim 
  Secondary rim 
(a) 
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1960s Ability to form inclusion compounds with improved characteristics, such 
as solubility and volatility of the included chemical recognised.26 
Toxicological studies of inclusion complexes proved industrial 
importance in food35, pharmaceutical, biomedical and analytical 
industries.26 
 
Structural Features of Cyclodextrins 
Cyclodextrins consist of glucose monomer units made up of  
α-D-glucopyranose having the 4C1 chair conformation.36 When linked, these monomer 
units are exceptionally rigid. However, they retain sufficient rotational flexibility 
around the α-(1,4)-linkage C1(n)-O4(n-1)-C4(n-1), (Figure 1.6).  
 
 
Figure 1.6 Numbering scheme and principal torsion angles of CD structures. 
 
The truncated cone of the cyclodextrin has a hydrophobic cavity and a hydrophilic 
exterior. The rotational flexibility of the glucopyranose monomer orientates the 
methine (C3-H and C5-H) and methylene hydrogen atoms (C6-H2) as well as the lone 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction  
 
 20
pairs of the bridging ethereal oxygen atoms O4(n) towards the interior of the CD 
cavity. The hydrophobic component of these hydrogens (methine and methylene) plus 
the additional electron density contributed by the lone pairs imposes some electrically 
positive character on the cavity.37 Each rim of the cone has hydroxyl groups attached to 
it. Each rim is named according to the number and type of hydroxyl groups located 
there. Thus, the primary rim has a single hydroxyl group (O6-H) per glucose unit while 
the secondary rim has two hydroxyl groups (O2-H and O3-H) per glucose unit. It 
follows that the primary rim is the narrower rim while the secondary rim is wider due 
to the natural tilt of the glucose units. The hydroxyl groups are there to 
promote/enhance the hydrophilicity of the cyclodextrin.38 Hydroxyl groups O2-H and 
O3-H of adjacent glucose units on the secondary rim are hydrogen bonded to each 
other. The average hydrogen bonding distances O2(n)•••O3(n-1) for α-, β- and γ-CD are 
in the range 2.98 to 2.82 Å. α-CD has the weakest hydrogen bonds (average distance 
2.98 Å) while γ-CD has the strongest (2.82 Å).  Only β-CD (2.88 Å) has a complete set 
of hydrogen bonds which involves all the O2-H and O3-H atoms of the macrocyclic 
ring. As a consequence, β-CD is the least soluble of the three parent CDs. The 
solubilities of α-, β- and γ-CD in water are 14.5, 1.85 and 23.2 g per 100 ml at 25 C˚, 
respectively (Table 1.1).38,39 
 
Table 1.1 Properties of α-, β- and γ-CDs 
Cyclodextrin Mass 
(g/mol) 
Cavity 
volume 
(Å3) 
Outer 
diameter 
(Å) 
Cavity diameter 
(Å) 
Solubility, 
g/100 ml 
in H2O 
at 20 ºC 
Inner 
rim 
Outer 
rim 
 α, (glucose)6 972 174 15.2 4.5 5.3 14.5 
 β, (glucose)7 1134 262 16.6 6.0 6.5 1.85 
 γ, (glucose)8 1296 427 17.7 7.5 8.5 23.2 
 
The principal torsion angles are the primary hydroxyl torsion angle, the glycosidic 
torsion angle and pyranoid torsion angle (Figure 1.6). 
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Principal Torsion Angles  
Primary Hydroxyl Torsion Angle 
The primary hydroxyl or O5-C5-C6-O6 torsion angle (ω) can adopt three orientations 
namely (+)-gauche, (-)-gauche or trans-conformations. The (-)-gauche orientation  
(ω = -60°) with the O6-H pointing away from the centre of the CD cavity is largely 
preferred; the (+)-gauche (ω = +60°) with the O6-H pointing toward the centre of the 
CD cavity is observed where a hydrogen bond is formed between the O6 hydroxyl 
group and an included guest, while the trans-orientation (ω = 180°) has not been 
observed for CD structures, probably due to steric interactions which might occur 
between O6-H and atoms of the adjacent glucose residue. The mean values of these 
angles for the parent molecules α-, β-, γ-CD are listed in Table 1.2.40,41a 
 
Glycosidic Torsion Angle 
The torsion angles around the C1(n)-O4(n-1)-C4(n-1) glycosidic linkage are referred to 
as the glycosidic torsion angles. They are defined as Φ = O5(n)-C1(n)-O4(n-1)-C4(n-1) 
and Ψ = C1(n)-O4(n-1)-C4(n-1)-C3(n-1). The mean values of these angles for the parent 
molecules α-, β-, γ-CD are listed in Table 1.2.41a,b 
 
Pyranoid Torsion Angles 
The two pyranoid torsion angles Θ1 (C2-C3-C4-C5) and Θ2 (C3-C4-C5-O5) can be used 
to describe the conformational relationships around the C4 atom of each glucose 
residue. The glucopyranose units generally adopt the 4C1 chair conformation with very 
small deviations from ideal, undistorted values for the glucose residue (Table 1.241a,b). 
 
Table 1.2 Mean values for principal torsion angles of CDs 
CD |ω| (°) Φ(°) Ψ(°) Θ1(°) Θ2(°) 
α 68 108 130 +52 -53 
β 64 112 128 +56 -56 
γ 68 110 130 +62 -62 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction  
 
 22
O4 Polygon 
Polygons, composed of 6, 7 or 8 glycosidic O4 atoms offer a good model for describing 
the macrocyclic structures of α-, β- and γ-CD. 
 
Figure 1.7 illustrates the various geometrical parameters of the O4 polygon. The side 
lengths (l) of the O4 polygon are the distances between O4(n) and O4(n+1), where 
O4(n+1) is the O4 atom of the next glucose unit. The radii (r) of the macrocycle are 
measured from the centre of gravity (C) of all O4 atoms to each O4 atom. The angle (a) 
is the O4(n)•••O4(n+1)•••O4(n+2) angle. 
 
The O4 polygons also offer a means to evaluate (i) the symmetry of the macrocyclic 
structure and (ii) the planarity of the macrocyclic ring.  
 
Figure 1.7 Schematic diagram of the O4 polygon for -CD.  
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Macrocyclic Symmetry 
If the macrocyclic structures of α-, β- and γ-CD showed perfect C6, C7, C8 symmetry 
then the O4•••O4•••O4 angles would be exactly 120°, 128° and 132° respectively. 
 
Coplanarity of the Glycosidic Oxygen Atoms 
This refers to the coplanarity of the O4 linker atoms of the O4 polygon. This can be 
evaluated by the deviation from planarity (d) of each O4 atom from the mean plane of all 
the O4 atoms, and the O4•••O4•••O4•••O4 torsion angles (t) (Figure 1.7). For the planar 
macrocycle the deviation of each O4 from the mean plane of the macrocycle would be 
zero and the O4•••O4•••O4•••O4 torsion angles (t) would be 0°. 
 
The mean values of the principal geometrical parameters of the O4 polygons for the 
parent molecules α-, β-, γ-CD are listed in Table 1.3.41a,c 
 
Table 1.3 The mean values of the principal geometrical parameters of the O4 
polygon 
CD r (Å) l (Å) a (°) d (Å) t (°) 
α 4.2 4.2 120 0.07 5 
β 5.0 4.3 128 0.08 5 
γ 5.9 4.5 132 0.02 2 
 
Conformational Descriptors for CDs 
Intersaccharidic Bond Angles 
The intersaccharidic bond angle (φ) is defined as φ = C1(n+1)-O4(n)-C4(n) (Figure 1.6). 
The values of φ decrease in the order φ(α-CD) > φ(β-CD) > φ(γ-CD) as the number of 
glucose residues making up the macrocycle increases (Table 1.4 ). 
 
Table 1.4 Mean values of the intersaccharidic bond angle, O2(n)···O3(n-1) 
distances and the tilt angles for α-, β- and γ-CD41b 
CD φ(°) O2(n)···O3(n-1) (Å) τ1(°) 
α 118.4 2.98 + 11.4 
β 117.7 2.88 + 9.5 
γ 115.0 2.82 + 14.5 
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Intramolecular O2(n)···O3(n-1) Hydrogen Bonds 
The structural rigidity of the CD seems to be mainly due to a ring of intramolecular 
hydrogen bonds between the secondary hydroxyl groups (labelled O2-H and O3-H) of 
adjacent glucose units which are orientated cis. These O2(n)•••O3(n-1) hydrogen bonds 
stabilise the macrocyclic conformation and limit the conformational freedom of the 
glucosidic bond. The mean O2(n)•••O3(n-1) distances become smaller on increasing the 
macrocylic ring size from six to seven to eight glucose units (Table 1.4). 
 
Tilt Angle 
The tilt angle is a measure of the inclination of the glucose residue with respect to the 
mean macrocyclic plane defined by the O4 linker atoms. Two definitions of the tilt angle 
are quoted. The tilt-angle (τ1) is defined as the angle between the mean plane through 
the six pyranoid ring atoms (labelled C1, C2, C3, C4, C5 and O5) of each glucose unit 
and the normal to the O4 mean plane. The tilt angle, τ1, is schematically illustrated in 
Figure 1.8 with the glucose residue and appropriate mean planes all viewed edge-on. 
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Figure 1.8 Schematic representation of the tilt angles τ1 and τ2 (the glucose and 
various mean planes are all viewed edge-on). 
 
The tilt angle (τ2) is defined as the angle between the mean plane through O4, C4, C1 
and O4′ atoms and the O4 mean plane. The tilt angle, τ2, is schematically illustrated in 
Figure 1.8 with the glucose residue and appropriate mean planes all viewed edge-on. In 
theory, if the glucose residues were completely undistorted from ideal conformation 
then the two definitions of the tilt angle would produce identical values. In practice, 
however, the tilt angles obtained from these two definitions differ from one another 
because the formation of the macrocycle somewhat distorts the conformation around the 
glycosidic linkages. The tilt angle (τ2) has been traditionally reported for a large 
number of crystallographic investigations of CD structures. 
 
Each glucose unit is not orthogonal to the mean O4 plane, but is inclined with the O6 
sides towards the inside or outside of the macrocycle. A positive tilt angle denotes that 
O4 mean plane 
INSIDE OUTSIDE 
Normal to O4 
mean plane 
C1, C2, C3, C4, C5, O5 
mean glocuse plane  
O4, C4, C1, O4′ 
mean plane 
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the glucose unit is inclined with the O6 side towards the inside of the macrocyclic cavity 
(Figure 1.8) while a negative tilt angle denotes that the glucose unit is inclined with the 
O6 side towards the outside of the macrocyclic cavity. For α-, β- and γ-CD, the tilt 
angles are mostly positive and the result is that the O6 end is truncated for these CDs. 
 
Guest Inclusion 
The hydrophobic cavity of the CD has the ability to include guest molecules with 
polarity lower than water, the only requirement being that the guest molecule must be 
of appropriate shape and size to fit into the cavity, even if only partially. The pyranose 
conformation is affected by the interaction of included guest molecules, although it is 
difficult to detect significant changes in bond distances, angles and torsion angles. No 
covalent bonds are formed or broken during the formation of a guest-cyclodextrin 
complex and in aqueous solution the complexes readily dissociate. Initially, it was 
thought that the main driving force for complexation was the replacement of the high 
enthalpy water molecules, located in the CD cavity, by a suitable guest (Figure 1.9).42,43 
The exchange process was therefore primarily determined by enthalpy and entropy 
changes with van der Waals forces and hydrophobic interactions regarded as secondary. 
However, Liu et al.44 claimed that the exclusion of cavity-bound water and the release of 
conformational strain are not the only factors to be considered.  In other words, the 
enthalpy and entropy changes during water exclusion from the cavity are not good 
criteria for the determination of a driving force due to the enthalpy-entropy 
compensation.44 Liu et al. also claimed that the primary forces of inclusion are therefore 
the van der Waals and hydrophobic interactions along with hydrogen bonding and 
steric effects.36, 45-53a 
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 Guest           CD    Complex 
  
 
O  - Water 
Red arrows  -  repulsive interactions 
Green arrows  -  attractive interactions 
 
Figure 1.9 Guest inclusion by cyclodextrins and expulsion of water from the CD 
cavity. 
 
 
Orientation of Guest in CD Cavity 
Size and Shape 
The primary factor determining the orientation and fit of a guest molecule in the 
cyclodextrin cavity is that the guest must be able to fit into the cavity, even if it is only 
partially included. The physical dimensions and cavity volumes of α-, β- and γ-CD are 
presented in Table 1.1. CDs are somewhat flexible hosts which can adapt to the 
topologies of the guests embedded in their cavities. The macrocyclic host adjusts its 
geometry to the topology of the guest during complex formation in a process that can 
best be envisaged to occur via an induced-fit type mechanism. 
 
Dipole Moment Alignment 
Large values of the dipole moments have been calculated for α-, β- and γ-CD using the 
X-ray structures of the three CDs. The relative strengths are in the order α-CD < β-CD 
< γ-CD, which is expected as the number of glucosyl residues in the macrocycle 
increases. The dipole moments are of the order of 10-20 Debye and are directed with the 
positive end of the dipole at the primary hydroxyl end and the negative end at the 
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secondary hydroxyl rim. In the inclusion complexes of CDs with aromatic molecules, 
the guest dipole moment has been noted to adopt an anti-parallel direction to that of the 
CD.  
 
The overall electric field of CDs is expressed strongly within the cavity of the 
macrocyle and the dipole moment of a CD is therefore thought to strongly influence the 
orientation of polar guest compounds in the CD cavity. 
 
The direction of the cyclodextrin dipole moment can be expressed as the tilting angle, 
ω, between the dipole moment vector and the axis of the cavity. If ω is sufficiently 
smaller than 90° then the dipole moment is directed from the secondary to the primary 
hydroxyl side, and this is the case for all CDs that have been studied thus far. The 
direction of the guest dipole moment can be expressed as Ω, the angle between the 
vector of the CD dipole moment and the vector of the guest dipole moment (Figure 
1.10). When these two vectors are anti-parallel the angle Ω is 180°.53b 
 
Figure 1.10 The relationship between the cyclodextrin and guest dipole moments. 
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Derivatised Cyclodextrins 
With native cyclodextrins having low solubilities, especially in the case of β-CD, 
methylation of β-CD at the C2-OH, C3-OH and C6-OH hydroxyl positions successfully 
enlarges the hydrophobic surface area of the entire cyclodextrin. An additional 2 Å is 
added to the height of the cyclodextrin with a simultaneous solubility enhancement in 
water. The overall effect is that the topology of inclusion is altered for these modified 
cyclodextrins.38 This allows the accommodation of larger guests in the cavity as well as 
in the interstitial space between CD molecules. Heptakis(2,6-di-O-methyl)-β-
cyclodextrin (DIMEB) and heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin (TRIMEB) are 
two β-CD derivatives which are modified at the C2-OH, C6-OH and C2-OH, C3-OH 
and C6-OH hydroxyl positions, respectively. As none of the O3-H hydroxyl groups is 
modified in DIMEB, it therefore retains the O2•••H-O3′ hydrogen bonds.  The average 
O2•••O3′ distances are similar to those of β-CD.54 This results in DIMEB and β-CD 
having similar conformations. The molecule of TRIMEB has none of the O2•••O3′ 
interactions that occur in DIMEB and β-CD. The conformation of TRIMEB differs 
from that of β-CD as it has only the C6-H•••O5 hydrogen bonds between adjacent 
methylglucose units which stabilise its structure.55 
 
Crystal Forms of Parent and Modified Cyclodextrins 
Crystal Forms of  α-, β- and γ-cyclodextrin 
For α-CD, there are three hydrated forms which all crystallise in the orthorhombic 
crystal system in the space group P212121. The three forms have 6, 7.57 and 11 water 
molecules per molecule of α-CD. Included in the α-CD search, an unhydrated form was 
also identified crystallising in space group P212121.40 The search of the Cambridge 
Structural Database (CSD)40 produced 18 β-cyclodextrin structures including repeat 
determinations. All of these are hydrated forms of β-cyclodextrin with the level of 
hydration ranging from 1 to 12.26 water molecules per molecule of cyclodextrin.  There 
are 10 different hydrated forms with 1, 9, 9.35, 10.41, 11, 11.19, 11.56, 11.89, 12 and 
12.26 water molecules.  All 18 forms are monoclinic, crystallising in the space group 
P21. γ-CD presented three crystal forms having different levels of hydration: 11, 14 and 
17 water molecules.40  These three forms crystallise  in the space group P21. 
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Crystal Forms of DIMEB 
There are 11 structures of the DIMEB parent recorded on the CSD, ten of which are 
hydrated forms while the remaining structure is anhydrous.  Of the reported hydrated 
forms (8) the level of hydration ranges between 1.1 and 15 water molecules per 
cyclodextrin molecule. Within the set of hydrates, five of these have unreported 
hydration values. The atomic coordinates for only five of the structures were provided 
in the CSD. These included three different hydrates and the single anhydrous form.40 
All the DIMEB parent compounds crystallise in the space group P212121 except for one 
form with two water molecules per cyclodextrin which crystallises in the space group 
P21. 
 
Crystal Forms of TRIMEB 
TRIMEB has three reported forms listed on the CSD, an anhydrate, a monohydrate and 
a trihydrate. From the calculated PXRD traces, unit cell parameters and the packing 
arrangements, the anhydrous form is the dehydrated form of the trihydrate.40   
 
Crystal Forms of TRIMEG 
There are three different structures of octakis(2,3,6-tri-O-methyl)-γ-cyclodextrin 
(TRIMEG) all of which are hydrated with 2, 4.8 and 4.5 H2O molecules per molecule of 
CD. Two of the structures crystallise in the orthorhombic crystal system in the space 
group P212121 while the third is monoclinic crystallising in the space group P21.40 
 
Crystal Forms of Peracetylated Cyclodextrins 
Hexakis(2,3,6-tri-O-acetyl)-α-cyclodextrin (TriAcACD), heptakis(2,3,6-tri-O-acetyl)-β-
cyclodextrin (TriAcBCD) and octakis(2,3,6-tri-O-acetyl)-γ-cyclodextrin (TriAcGCD) 
were investigated and characterised by Bettinetti et al.56  Thermal analysis (DSC and 
TGA), PXRD and FTIR were employed in the characterisation. From their studies it 
was concluded that recrystallisation of the peracetylated CDs from various solvent 
systems produced solvates, while hydrates and amorphous forms were obtained from 
spray drying or microwave-drying. However, the crystal structure of TriAcGCD 
containing mixed solvents was determined by Caira et al.,57 the mixtures including 
isopropanol/water and ethanol/water.40 
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Cyclodextrin Complex Packing Arrangements in the Solid State 
Single crystal X-ray analysis is a very powerful technique for studying CDs and their 
complexes in the solid state. The technique provides information regarding structural 
aspects of CDs and included guests and the nature of their interactions. Several reviews 
present comprehensive discussions of these structural aspects as determined by 
crystallographic studies.58 These structures may be classified according to their unit cell 
parameters and packing arrangements. The consequence of detailing packing 
arrangements stems from the fact that complexes with similar packing arrangements 
have similar PXRD patterns.  PXRD is an important screening technique used in the 
initial characterisation of presumed complexes.  
 
β-CD Complexes 
β-CD inclusion complexes can regularly arrange themselves in either cage type or 
channel type structures.59 Small guest molecules are usually associated with cage 
structures. These guests are easily enclosed by the CD cavity. Channel structures are 
favoured for larger guests. Cage structures are usually monomeric arrangements while 
the channel type structures are typically dimeric.   
 
Cage Type Monomeric 
Cage type structures are usually arranged in such a way that the cavity is blocked off by 
adjacent molecules leaving no contact between guests. There are four cage type 
monomeric structures (Figure 1.11): herringbone (HB), layer (LY), brickwork (BW) and 
zigzag (ZZ).  For β-CD complexes, herringbone, layer and brickwork structures usually 
crystallise in the space group P21, while the zigzag type crystallises in the space group 
P212121.40    
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      (a)                 (b) 
    
       (c)              (d) 
Figure 1.11 (a) Herringbone packing arrangement for monomeric β-CD 
complexes. (b) Layer packing arrangement with layer propagation along the b-
axis. (c) Brickwork packing showing the alternating ‘primary rim up’ – ‘primary 
rim down’ of successive CD molecules in the direction of c′. (d) Zigzag 
arrangement of the β-cyclodextrin monomers along the c-direction. 
 
 
Channel Type Monomeric (Figure 1.12) and Channel Type Dimeric (Figure 1.13) 
The helical channel type (HC) structure crystallises in the hexagonal space group P61.  
It is an unusual arrangement with an isolated cavity.40 β-CD is able to form hydrogen 
bonded dimers in order to accommodate larger or multiple guests. These dimeric units 
are held together by several O-H•••O hydrogen bonds. Similar to the monomeric unit, 
the dimeric unit is able to assemble into a number of three-dimensional motifs.  
Mavridis et al.60 identified four modifications; however, more categories have since been 
added.58,61 The four modifications are: channel (CH), intermediate (IM), screw channel 
(SC) and chessboard (CB). The space groups associated with these modifications are as 
follows: P1 and C2 with channel type, P1 with intermediate, P21 with screw channel and 
C2221 with chessboard. 
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Figure 1.12 The helical channel arrangement of β-CD monomers. 
          
          (a)                  (b)        
     
        (c)               (d) 
Figure 1.13 (a) Channel packing arrangement for P1 (left) and C2 (right) forms.  
(b) The intermediate arrangement for β-CD dimers. (c) Dimeric layers of the 
screw channel arrangement. (d)  Chessboard packing motif. 
 
Packing Arrangements of DIMEB Complexes  
DIMEB and its complexes generally crystallise in the space groups P21 and P212121.  
The packing arrangements vary from channel type head-to-tail, to modified brick type 
and modified herringbone motifs. The guest may be located in the cyclodextrin cavity 
or in the interstitial spaces.40 
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Packing Arrangements of TRIMEB Complexes  
TRIMEB and its inclusion complexes favour the space group P212121 with the 
molecules in a screw channel type structure,40 although structures with space group P21 
have been identified.62,63  The molecules are arranged in a head-to-tail manner. 
 
The Hydrogen Bonded Network of CD Structures 
Different hydrogen bonding interactions that may occur between CDs, included guests 
and the water molecules of crystallisation in the cyclodextrin inclusion complex are as 
follows: 
1. Cyclodextrin to cyclodextrin hydrogen bonds (CD-CD) 
2. Cyclodextrin to water hydrogen bonds (CD-W) 
3. Water to water hydrogen bonds (W-W) 
4. Guest to cyclodextrin hydrogen bonds (CD-G) 
5. Guest to water hydrogen bonds (G-W) 
6. Guest to guest hydrogen bonds (G-G) 
 
The β-CD molecule almost always contains a ring of intramolecular O2•••O3 hydrogen 
bonds which gives the macromolecular structure a rigid, cyclic shape. These consist of 
seven O2(n)•••O3(n-1) intra-CD bonds. Neutron diffraction studies have shown that this 
type of hydrogen bonding is of the flip-flop nature in β- and γ-cyclodextrin with both 
O2(n)-H•••O3(n-1) and O2(n)•••H-O3(n-1) hydrogen bonds being observed. The mean 
O2(n)•••O3(n-1) distance is 2.88 Å for β-CD. 
 
Isostructurality 
Two or more crystalline phases are said to be isostructural if they have similar unit cell 
dimensions, the same space group (this includes structures which are related by a metric 
transformation) and common moieties having nearly identical atomic co-ordinates.64 
Practically, isostructurality of two phases is recognized when their X-ray diffraction 
patterns match, implying similarity of unit cell dimensions. The closer the registration 
of X-ray reflections both in terms of their angular positions and relative intensities, the 
greater the degree of isostructurality. 
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When large monocrystals of CD complexes suitable for X-ray analysis cannot be 
consistently identified or their poor quality prevents structure determination, 
isostructurality is employed to determine the structures of such CD complexes.58,65 
Since microcrystalline precipitates are more readily obtained in attempts to prepare CD 
inclusion complexes, PXRD, by itself, is employed as a means of complex identification 
and characterisation.58,65  
 
A CD inclusion complex is generally a ternary system comprising host CD, guest and 
water molecules. For CD inclusion complexes, isostructurality is basically confined to 
the host CD (i.e. for example when two complexes of the same host are considered). The 
outcome of the above prerequisites is nearly identical packing arrangements and 
superimposable PXRD traces. Thus, PXRD is an important tool in determining 
isostructurality in the absence of single crystal X-ray data.   
 
Effects of CDs on Important Drug Properties in Formulation 
Effect on Drug Solubility and Dissolution 
CDs play a vital role in the formulation of poorly water-soluble drugs by improving 
apparent drug solubility and/or dissolution through inclusion complexation or solid 
dispersion. The CDs act as hydrophilic carriers for drugs with inadequate molecular 
characteristics for complexation, or as tablet dissolution enhancers for drugs with a high 
dose, with which use of a drug/CD complex is difficult, for example, paracetamol.66  
Methylated CDs are known to be the most powerful solubilisers. With the reduction of 
drug crystallinity on complexation, CDs contribute to the increased apparent drug 
solubility and dissolution rate.67,68 Furthermore, CDs, as a result of their ability to form 
inclusion complexes in dissolution medium, can enhance drug dissolution even when 
there is no complexation in the solid state.69 β-CD is well known to be a good solubiliser 
for several drugs but it is not as effective as the methylated derivative DIMEB.70 CDs 
can also act as release enhancers, for example: β-CD enhanced the release of 
theophylline from hydoxypropyl methylcellulose (HPMC) matrix by increasing the 
apparent solubility and dissolution rate of the drug.71,72 
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Biological membrane 
Effect on Drug Bioavailability 
CDs improve the bioavailability of poorly soluble drugs by enhancing the drug 
solubility, dissolution, and/or drug permeability. CDs increase the permeability of 
hydrophobic drugs by making the drug available at the surface of the biological barrier, 
e.g. skin, mucosa, or the eye cornea, from where it partitions into the membrane without 
disrupting the lipid layers of the barrier (Figure 1.14). Here it is imperative to use just 
sufficient CD to solubilise the drug in the aqueous vehicle since excess may decrease the 
drug availability.73,74,75 At low concentrations of randomly methylated β-CD (RAMEB), 
when hydrocortisone was in suspension, increasing the CD concentration increased the 
drug flux. At higher CD concentrations, when the drug was in solution, increasing the 
CD concentration decreased the flux.76 It was found that addition of polymers can 
further enhance the drug permeability from aqueous CD solutions.  
 
 
Figure 1.14 Mode of penetration enhancement by CDs (adapted from reference 
77).  
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Effect on Drug Safety 
CDs have been used to improve irritations caused by drugs.77 The enhanced drug 
effectiveness and potency caused by CD-increased drug solubility, may reduce drug 
toxicity by making the drug effective at lower doses. β-CD improved the antiviral action 
of ganciclovir on human cytomegalovirus clinical strains and the resultant increase in 
the potency reduced the drug toxicity.78 The toxicities associated with crystallisation of 
poorly water-soluble drugs in parenteral formulations can often be reduced by 
formation of soluble drug:CD complexes.  
 
Effect on Drug Stability 
CDs can enhance the stability of several labile drugs against dehydration, hydrolysis, 
oxidation, and photodecomposition and thereby increase the shelf life of drugs.79 CD-
induced enhancement of drug stability may be a result of inhibition of drug interaction 
with vehicles and/or inhibition of drug bioconversion at the absorption site.80 By 
providing a molecular shield, CD complexation enca sulates labile drug molecules at 
the molecular level and thus insulates them against various degradation processes.  
The stabilising effect of CDs depends on the nature and effect of the included functional 
group on the drug stability and the nature of the vehicle. Since the hydrolysis of drugs 
encapsulated in CDs is slower than that of free drugs,81 the stability of the drug/CD 
complex, plays a major role in determining the extent of protection.82-85 Very low 
concentrations of hydroxypropyl β-CD (HPBCD) (1% or lower), due to formation of a 
more physically unstable complex, did not protect taxol as effectively as higher CD 
concentrations.86 
 
CD Applications in Drug Delivery 
Oral Drug Delivery 
Applications of CDs in oral drug delivery include improvement of drug bioavailability 
due to increased drug solubility, improvement of rate of dissolution, and stability of the 
drug at the absorption site e.g. the gastrointestinal tract (GIT) drug-induced irritation, 
and taste masking. CD complexation was found to decrease local drug irritation and 
also modify the time of drug release during GI transit. An itraconazole oral preparation 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction  
 
 38
containing 40% (w/v) of HPBCD (with reduced drug irritation) has been 
commercialised in the United States and Europe.82 
 
CDs enhance the mucosal drug permeability by increasing the free drug availability at 
the absorptive surface.87,88 CD complexation can present improved and uniform 
absorption of low-soluble drugs with poor and unpredictable absorption and also 
enhance the drug activity on oral administration.89-91  
The relative safety, efficacy in terms of complexation, cost, and acceptance in 
pharmacopeias, are some important factors to be considered in selecting a CD for drug 
complexation. HPBCDs were shown to have a better oral safety profile than β-CD and 
other parent CDs, but only limited data are available on the oral safety of the 
methylated CDs. However, for oral administration all CDs can be considered practically 
non-toxic due to lack of CD absorption through the GIT. Hence, the relative safety 
profile of CDs is a concern when drug doses used in complexes exceed the LD50 (i.e. 
dose that kills 50% of the sample population) of CDs.79 β-CD is the most cost-effective 
compound of all CDs, whereas HPBCD is more expensive. The monograph of β-CD is 
already incorporated in various pharmacopeias and national formularies (NF).79 Hence, 
β-CD can be considered most favourable for oral use when it is effective for drug 
complexation. Modified CDs like HPBCD and DIMEB may be used when they are more 
effective and when their peculiar property is required in formulation.92,93 
 
Parenteral Drug Delivery 
Amorphous HPBCD has been studied extensively for parenteral use on account of its 
high aqueous solubility and minimal toxicity. HPBCD allows parenteral administration 
of various drugs with no significant toxicity problems. As mentioned earlier, an 
itraconazole parenteral injection containing HPBCD (40% w/v) has been 
commercialised in the United States and Europe.82,94 Applications of CDs in parenteral 
delivery are solubilisation of drugs, reduction of drug irritation at the site of 
administration, and stabilisation of drugs in the aqueous environment. Formation of a 
stable, water-soluble dexamethasone complex with sugar branched β-CDs suggested 
the potential of these CDs as excellent carriers in steroidal injectable formulations.95 
Aqueous phenytoin parenteral formulations containing HPBCD exhibited reduced drug 
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tissue irritation and precipitating tendency because their pH values were significantly 
closer to the physiological value (7.4).96 
 
Ocular Delivery 
Applications of CDs in aqueous eye drop preparations include solubilisation and 
chemical stabilisation of drugs, reduction of ocular drug irritation, and enhancement of 
ocular drug permeability. Vehicles used in ophthalmic preparations should be non-
irritating to the ocular surface to prevent fast washout of the instilled drug by reflex 
tearing and blinking. Hydrophilic CDs, such as HPBCD, have shown to be non-toxic to 
the eye and are well tolerated in aqueous eye drop formulations. An example is the 
decreased ocular irritation of a lipophilic pilocarpine prodrug by HPBCDs.79  
HPBCD also enhanced the ocular permeability of dexamethasone acetate and inhibited 
the conversion of the salt to a less permeable dexamethasone.79 Since only the free drug 
can permeate biological membranes, ophthalmic delivery of drugs can be limited by the 
dissociation of drug/CD complexes in the precorneal area due to the limited dilution in 
this area. The dissociation of drug/CD complexes depends more on the binding of 
drugs to precorneal proteins, absorption by corneal tissue, and displacement of drugs 
from CD complexes by precorneal fluid components.  
 
Nasal Drug Delivery 
CDs are useful adjuvants in nasal drug delivery. They enhance nasal drug absorption by 
increasing aqueous drug solubility and by enhancing nasal drug permeability. However, 
large interspecies differences were found in CD-enhanced nasal drug absorption. The 
safety and non-toxicity of CDs in nasal drug formulations have been demonstrated by 
the clinical data, with CDs showing no adverse effects. Merkus et al.97 demonstrated 
that CDs can be safely used to improve nasal bioavailability of drugs, especially 
peptides. DIMEB improved the nasal bioavailability of estradiol in rats and rabbits.  
 
Rectal Drug Delivery 
Applications of CDs in rectal delivery include enhancing drug absorption from a 
suppository base, increasing drug stability in the base or at the absorption site, 
providing sustained drug release, and alleviating drug-induced irritation.80,98 
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Drug release from the suppository base is important in rectal absorption because of the 
high viscosity of rectal fluids. The effect of CDs on rectal drug absorption can be 
influenced by the partition coefficient of the drug and its CD complex, magnitude of the 
complex stability constant, and nature of the suppository base (oleaginous or 
hydrophilic). Hydrophilic CDs (especially methylated and hydroxypropyl CDs) enhance 
the absorption of lipophilic drugs by improving the drug release from oleaginous 
vehicles and by increasing the drug dissolution rate in rectal fluids. Formation of 
hydrophilic CD complexes was found to inhibit the reverse diffusion of drugs into 
oleaginous vehicles by reducing the drug/vehicle interaction. Rectal absorptions of 
flurbiprofen and biphenylacetic acid were enhanced by DIMEB and HPBCD, 
respectively.77  
 
Controlled Drug Delivery 
CDs, due to their ability to complex drugs and act as functional carrier materials in 
pharmaceutical formulations, can potentially deliver efficient and precise required 
amounts of drugs to targetted sites for a necessary period of time. β-CD derivatives are 
classified as hydrophilic, hydrophobic, and ionisable derivatives. The hydrophilic 
derivatives improve the aqueous solubility and dissolution rate of poorly soluble drugs, 
while the hydrophobic derivatives retard the dissolution rate of water-soluble drugs 
from vehicles. Hence hydrophilic and hydrophobic CD derivatives are used in immediate 
and prolonged release type formulations, respectively. The ionisable CD derivatives, on 
the other hand, improve inclusion capacity, modify drug dissolution rate, and alleviate 
drug irritation.  
 
Colon-Specific Drug Delivery 
CDs are hardly hydrolysed and only slightly absorbed in the stomach and small 
intestine but are absorbed in the large intestine after fermentation into small 
saccharides by colonic microbial flora. The hydrolysing property of CDs makes them 
useful for colon drug targetting. Biphenyl acetic acid (BPAA) prodrugs for colon-
specific delivery were developed by conjugation of the drug onto one of the primary 
hydroxyl groups of α-, β-, and γ-CDs97 through an ester or amide linkage. In the case of 
ester prodrugs, the maltose and triose conjugates released the free drug after initial 
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hydrolysis of the susceptibile ester linkage, but in the case of amide prodrugs, the 
conjugates remained as such providing delayed release due to the resistance of the 
amide bond to hydrolysis. The CD-based prodrug approach was used for colon-specific 
and delayed drug delivery. For example, when tested in rats with carageenan-induced 
inflammation, the absorption of BPAA from γ-CD prodrugs was found to be from 
caecum and colon in contrast to that from the highly soluble β-CD complex, which was 
mainly from the small intestine.99 
 
Peptide and Protein Delivery 
Problems related to the practical use of therapeutic peptides and proteins are their 
chemical and enzymatic instability, poor absorption through biological membranes, 
rapid plasma clearance, unusual dose response curves, and immunogenicity. CDs, 
because of their bioadaptability in pharmaceutical use and ability to interact with 
cellular membranes, can act as potential carriers for the delivery of proteins, peptides, 
and oligonucleotide drugs.100 
β-CD improved insulin loading of alginate microspheres prepared by an emulsion-based 
process. The process proved to be important in the development of an oral insulin drug 
delivery system as the absorption of insulin from optimised microspheres was found to 
take place from the GI region.101 
 
Gene and Oligonucleotide Delivery 
The toxicity and immunogenicity associated with viral vectors led to the development 
of nonviral vectors for gene delivery. Besides the plasmid or virus-based vector systems, 
“naked” nucleotide derivatives have also been investigated for possible use as 
therapeutic agents through several routes of administration. Gene delivery 
technologists are now testing CD molecules in the hope of finding an optimal carrier for 
the delivery of therapeutic nucleic acids. However, the limitations of CDs, such as CD-
associated toxicity (e.g. DIMEB) must be considered before their clinical use.102 
 
Dermal and Transdermal Delivery 
CDs have been used to optimise local and systemic dermal drug delivery. Applications 
of CDs in transdermal drug delivery include enhancement of drug release and/or 
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permeation, drug stabilisation in formulation or at the absorptive site, elimination of 
drug-induced local irritation, sustaining of drug release from vehicle, and modification 
of drug bioconversion in the viable skin. Parent CDs (α-, β-, and γ-CDs) and various 
chemically modified CD derivatives with extended physicochemical properties and 
inclusion capacity have been used in transdermal drug delivery.80 
CDs enhance drug delivery by increasing the drug availability at the barrier surface, 
where the free drug partitions from the CD cavity into the lipophilic barrier. The free 
drug fraction at the barrier surface depends on the drug dissolution rate, relative 
magnitude of the stability constants of the CD complexes with the drug and the 
competing agent at the absorption site, and the drug absorption rate constant. In 
ointments, just as in suppositories, a drug in the CD complex may be displaced by 
ointment components, depending on the magnitude of the stability constant of the 
drug/CD complex. Hence, for optimum drug release, the vehicle or the CD complex 
chosen should be such that the complex barely dissociates but still maintains a high 
drug thermodynamic activity in the vehicle.103 The order of prednisolone release rate 
from a hydrophilic ointment was drug alone < γ-CD complex < β-CD complex < 
DIMEB complex, which was reflective of the order of the complex stability constants.80 
For absorption, the CD complex must dissociate to release free drug (the actual 
absorbable species) and the dissociation of the CD complex depends on the magnitude of 
the complex stability constant. If the complex stability constant is too high, the complex 
may not release the free drug at the absorption site and thus may decrease or inhibit 
drug absorption.103  
CDs have also been used to reduce drug degradation in topical preparations. β-CD 
maintained the stability of tixocortol 17-butyrate, 21-propionate in vaseline and 
oil/water emulsion bases even after 30 days.80 Complexation with CDs suggested a 
sensible means to enhance the physicochemical properties of drugs for transdermal 
delivery. β-CD and HPBCDs increased the skin permeability of dexamethasone and also 
improved its stability in skin by protecting it against skin metabolism.104  
 
Brain Drug Delivery or Brain Targetting 
The concept of Bodor’s chemical delivery system (CDS) (e.g. covalent coupling of drugs 
to 1-methyl-1,4-dihydronicotinic acid through an enzymatically labile linkage, which 
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increases drug lipophilicity) was applied for targetting drugs such as steroids, antitumor 
agents, and calcium channel antagonists to the brain.105 However, presence of the 
lipophilic moiety makes prodrugs of CDSs poorly water-soluble. HPBCD, due to its 
ability to solubilise drugs and also to enhance the chemical stability of dihydronicotinic 
acid in aqueous solution solved the solubility problems of the CDS.105 Formulation 
development of CDSs is based on the need for appropriate dosage form, stability, 
solubility, and dissolution characteristics. Brewster and Loftsson106 discussed the use of 
chemically modified, especially water-soluble, CD derivatives such as HPBCD in the 
formulation development of CDSs. HPBCD contributed to the development and 
preclinical testing of several CDSs by providing a stable and water-soluble dosage form 
suitable for parenteral administration. Use of CDs in the formulation of CDSs can be 
confirmed by the significantly improved solubility, stability, and pharmacological 
activity of CDSs of thyrotropin-releasing hormone analogues on complexation with 
HPBCD.105 
 
CD Applications in the Design of Novel Delivery Systems 
Liposomes 
In drug delivery, the concept of entrapping CD-drug complexes into liposomes 
combines the advantages of both CDs (such as increasing the solubility of drugs) and 
liposomes (such as targetting of drugs) into a single system and thus avoids the 
problems associated with each system.107 Liposomes entrap hydrophilic drugs in the 
aqueous phase and hydrophobic drugs in the lipid bilayers and retain drugs en route to 
their destination. The fact that some lipophilic drugs may interfere with bilayer 
formation and stability limits the range and amount of valuable drugs that can be 
associated with liposomes. By forming water-soluble complexes, CDs would allow 
insoluble drugs to accommodate in the aqueous phase of vesicles and thus potentially 
increase drug-to-lipid mass ratio levels, enlarge the range of insoluble drugs amenable 
for encapsulation (i.e. membrane-destabilising agents), allow drug targetting, and 
reduce drug toxicity. Problems associated with intravenous administration of CD 
complexes such as their rapid removal into urine and toxicity to kidneys, especially after 
chronic use, can be avoided by their entrapment in liposomes.108,109 
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Microspheres 
In the presence of a high percentage of highly soluble hydrophilic excipients, 
complexation may not improve the drug dissolution rate from microspheres. Nifedipine 
release from chitosan microspheres was impeded on complexation with HPBCD in spite 
of the enhanced drug-loading efficiency. Since CD molecules rarely diffuse out of the 
microspheres, even with a low stability constant, the complex must first release the free 
drug that can permeate out of the microspheres. Therefore the observed slow nifedipine 
release from the microspheres was reported to be due to lesser drug availability from 
the complex and also due to formation of hydrophilic chitosan/CD matrix layer around 
the lipophilic drug that further decreases the drug matrix permeability.110 Sustained 
hydrocortisone release with no enhancement of its dissolution rate was observed from 
chitosan microspheres containing its HPBCD complex. The sustained hydrocortisone 
release was reported to be due to formation of a layer adjacent to the interface by the 
slowly-dissolving drug during the dissolution process that makes the microsphere 
surface increasingly hydrophobic.111 
 
Microcapsules 
β-CD microcapsules, because of their ability to retard the release of water-soluble drugs 
through semipermeable membranes, can act as release modulators to provide efficiently 
controlled release of drugs. Terephthaloyl chloride (TC) crosslinked β-CD 
microcapsules were found to complex p-nitrophenol rapidly and the amount complexed 
increased as the size of the microcapsules decreased.112 TC crosslinked β-CD 
microcapsules retarded the diffusion of propranolol hydrochloride through dialysis 
membrane.112 Double microcapsules, prepared by encapsulating methylene blue with 
different amounts of β-CD microcapsules inside a crosslinked human serum albumin 
(HSA), showed decreasing release rate of methylene blue with increasing amount of β-
CD microcapsules.112 Dissociation of methylene blue complex with β-CD microcapsules 
was found to serve as an additional mechanism in controlling the release kinetics of 
HSA double microcapsules. In the case of HSA microcapsules with parent β-CD, the 
hydrating property of the CD, by promoting the diffusion of water into the 
microcapsules, caused an increased release rate of methylene blue compared with those 
without the CD. However, in the case of HSA double microcapsules (i.e. with β-CD 
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microcapsules), the hydrophobic groups introduced during crosslinking suppressed the 
CD hydration and provided controlled release without enhancing the diffusion of water 
that can impair the complexation of methylene blue.112 
 
Nanoparticles 
Nanoparticles are stable systems suitably designed for targetted drug delivery and to 
enhance the efficacy and bioavailability of poorly soluble drugs. However, the safety and 
efficacy of nanoparticles are limited by their very low drug loading and limited 
entrapment efficiency that may lead to excessive administration of polymeric 
material.113,114 Two applications of CDs have been found very promising in the design of 
nanoparticles: one is increasing the loading capacity of nanoparticles and the other is 
spontaneous formation of either nanocapsules or nanospheres by nanoprecipitation of 
amphiphilic CD diesters. Both of these proved to be useful due to the great interest in 
nanoparticles in oral and parenteral drug administration. CDs increased the loading 
capacity of poly(isobutylcyanoacrylate) nanoparticles. The increased loading capacity 
was reported to be a result of increased drug concentration in the polymerisation 
medium on addition of the drug:CD complex and increased number of hydrophobic sites 
in the nanosphere structure on association of large amounts of CDs to the 
nanoparticles.109 HPBCD increased saquinavir loading into poly(alkylcyanoacrylate) 
nanoparticles by providing a soluble drug reservoir in polymerisation medium that 
feeds the nanoparticle-formation process. A dynamic equilibrium was observed between 
the complex, the dissociated species, and the forming polymeric particle.109,115,116 It was 
indicated that during nanoparticle formation the free drug becomes progressively 
incorporated into the polymer network, driven by the drug partition coefficient between 
the polymer and polymerisation medium. 
Thus, the most noteworthy uses of CDs in the pharmaceutical industry include: 
- Increasing aqueous solubility, dissolution rates, release rates and 
bioavailability of various water-insoluble drugs 
- Improving chemical stability of unstable drugs by providing increased 
protection from photodegradation, hydrolysis, decomposition, oxidation, 
racemisation and isomerisation 
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- Suppressing volatile and unpleasant odours or tastes associated with the 
drug  
- Avoiding incompatibility problems with other drugs or excipients in a 
formulation 
- Reducing local irritance and haemolysis caused by a drug. 
In conclusion, cyclodextrin complexes of pharmaceuticals have significant consequences 
with regard to their physical performance and worldwide about thirty different 
pharmaceutical products containing CDs have reached the market thus far.117,118 The 
enhanced physical properties of such complexes can be costly initially but in the long 
run patient benefit can prevail over these expenses. The supramolecular modification of 
drugs covers a wide range of activities of which polymorphism and cyclodextrin 
inclusion have already added much value to the discussion. An additional, yet innovative 
approach to modifying drugs is by co-crystallisation strategies.  An overview of co-
crystallisation and its potential application in the pharmaceutical industry follows. 
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1.3 PHARMACEUTICAL CO-CRYSTALS 
Introduction 
Crystalline material obtains its major physical properties from its molecular 
arrangement within the solid, and altering the placement and/or interactions between 
these molecules can have a direct impact on the properties of the particular solid.119,120 
Solid-state chemists employ a variety of different strategies when attempting to modify 
the chemical and physical solid-state properties of active pharmaceutical ingredients 
(APIs), namely, the formation of salts, polymorphs, solvates, and co-crystals, as 
illustrated in Figure 1.15.119  
 
Figure 1.15 Physical state properties of APIs (adapted from reference 119).  
 
These days many of the medicines on the market are administered as salts since salt 
formation is one of the principal solid-state approaches used to alter the physical 
properties of APIs.119 The API must, however, include a suitable (basic or acidic) 
ionisable site, which can be a major drawback with this approach. Co-crystals present a 
different pathway, where any API regardless of acidic, basic, or ionisable groups, could 
possibly be co-crystallised.119 This feature helps complement existing methods by re-
introducing molecules that had limited pharmaceutical profiles based on their non-
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ionisable functional groups. Additionally, the number of potential non-toxic co-crystal 
formers (or co-formers) that can be incorporated into a co-crystalline reaction is very 
large.121 
 
A co-crystal is a multicomponent assembly of compounds held together by freely 
reversible, noncovalent interactions. It is believed to be the consequence of a molecular 
recognition event between different molecular species122,123 and further clarification of 
the definition is that co-crystals are “made from reactants that are solids at ambient 
temperature”.124  
 
Crystal Engineering and Design of Pharmaceutical Co-crystals 
The most frequently studied functional groups in crystal engineering are carboxylic 
acid moieties. They present an essential building block in the formation of 
intermolecular interactions. In supramolecular chemistry a more appropriate term given 
to this building block is a ‘supramolecular synthon’. The carboxylic acid group exists in 
most prescription drugs and its complementary hydrogen bond donor and acceptor sites 
make supramolecular homosynthon I favourable (Figure 1.16). However, 
supramolecular heterosynthon II is favoured over I and supramolecular heterosynthon 
IV is favoured over supramolecular homosynthons I and III. Supramolecular 
heterosynthons are energetically more favoured and their formation is the most 
consistent and robust route to designing co-crystals.121,124,125 
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Figure 1.16 Examples of supramolecular homosynthons and heterosynthons. 
 
Generally, for superior co-crystallisation research, theme functional group compatibility 
(supramolecular synthons), as illustrated in Figure 1.16, serve as an established primary 
step. The API is evaluated according to number and arrangement of hydrogen bond 
donors and acceptors,124 salt forming ability (where difference between conjugate acid 
and conjugate base is at least ≥ 3 pKa units, ‘rule of three’),124 conformational flexibility, 
and solubility requirements.125-128 APIs that are rigid, highly symmetrical, have strong 
non-bonded interactions, and have low molecular weight are more likely to co-
crystallise with additional components (co-formers or counter-molecules). Suitable co-
formers are frequently selected based on hydrogen bonding rules,126 probable molecular 
recognition events,121 and toxicological profiles. Prediction of a co-crystallisation 
reaction is not yet possible,128 and thus reactions must be carried out experimentally 
under varied conditions with different techniques to produce co-crystals.119 
 
Co-crystal Characterisation 
A number of different characterisation techniques can be used to help distinguish 
between co-crystals and salts, and it should be noted that in some cases differentiation 
between the two may be somewhat difficult. Single crystal X-ray diffraction is the 
preferred characterisation technique; however, suitable X-ray quality crystals cannot 
always be produced.119 Thus, various solid-state, spectroscopic techniques such as 
I 
II 
III IV 
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Raman, infrared, and solid-state NMR spectroscopy are used when attempting to 
characterise potentially new co-crystalline materials,129,130 especially when the locations 
of hydrogen atoms are indistinct. 
Infrared spectroscopy can also be a very powerful tool in detecting co-crystal formation, 
especially when a carboxylic acid is used as a co-former and/or when a neutral O–H•••N 
hydrogen bond is formed between an acid and a base. Distinct differences, within the IR 
spectra, can be observed between a neutral carboxylic acid moiety and a carboxylate 
anion.122,124 A neutral carboxylic group (-COOH) displays a strong C=O stretching 
band around 1700 cm-1 and a weaker C–O stretch around 1200 cm-1, while a carboxylate 
anion (-COO¯) displays both asymmetric CO2 stretch (1650-1540 cm-1) and symmetric 
CO2 stretch (1450-1360 cm-1). If a neutral intermolecular O–H•••N hydrogen bond were 
to form between the components, then two broad stretches around 2450 and 1950 cm-1 
would be observed.124 Observations about the state of the carboxylic moiety (neutral or 
ionic) can also be confirmed through measuring the C–O and C=O bond distances from 
single-crystal X-ray data. A typical C=O bond distance is around 1.2 Å, while the C–O 
bond distance is around 1.3 Å; however, if deprotonation has occurred (as in –COO-) 
then the resonance stabilised C–O bond distances will be practically identical.119 
 
Preparation of Co-crystals 
Briefly, co-crystals are usually synthesised by slow evaporation from a solution that 
contains stoichiometric amounts of the components, by sublimation, growth from melt, 
slurries, neat grinding and solvent drop-grinding.123 A detailed understanding of the 
supramolecular chemistry of the functional groups present in a given molecule is a 
prerequisite for designing a co-crystal since it facilitates selection of appropriate co-
crystal formers. With multiple functional groups, the hierarchy of possible 
supramolecular synthons is not easily addressed.124 Furthermore, the role of the solvent 
in nucleation of crystals and/or co-crystals can be critical in obtaining a particular co-
crystal from solution.124 A more detailed description of the preparative methods for co-
crystallisation and analysis of co-crystals is presented in Chapter 2. 
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Relevance of Pharmaceutical Co-crystals 
Co-crystallisation will profoundly affect physical properties such as solubility, stability, 
dissolution rate, and bioavailability of the API. Co-crystallisation proposes several 
opportunities without making or breaking covalent bonds by modifying chemical and 
physical properties of APIs.125 Co-crystals in the context of the pharmaceutical industry 
are not limited to form and formulation; they may also be used to isolate or purify an 
API during processing and the co-former could be discarded prior to formulation. 
Additionally co-crystallisation with homochiral co-crystal formers might be used to 
separate enantiomers as well.125 A detailed discussion of the physicochemical properties 
such as melting point, stability, solubility, dissolution, bioavailability, scale-up, 
polymorphism, intellectual property and lifecycle management of co-crystals follows, 
with special emphasis on the pharmaceutical industry. 
 
Physicochemical Properties of Co-crystals 
Melting Point 
To determine the melting point of a compound is standard practice as a means of 
characterisation or purity assessment. In the pharmaceutical sciences, the melting point 
is also important due to its relationship with aqueous solubility and vapour pressure.131 
The melting point, in fact, has been directly correlated with the Logarithm of 
solubility.132 Being able to establish the melting point of a particular API before it is 
synthesised would be very beneficial in order to modify its aqueous solubility. However, 
correlations relating chemical structure directly to melting point data remain vague.133 
Given the number of factors contributing to the melting point of a crystalline solid, 
including the molecular arrangement within the crystal, molecular symmetry, 
intermolecular interactions, and conformational degrees of freedom for a molecule, one 
clearly observes the difficulties in attempting to draw comparisons from molecular 
structure to crystalline lattice energy to melting point. When observing multi-
component systems such as co-crystals, the situation becomes more complex because 
each component has its own characteristic properties and those can influence the 
environment (and intermolecular interactions) around its neighbours.132  
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The API AMG517 (an analgesic) co-crystallises with 10 co-formers and the melting 
points of the resulting co-crystals were compared.134 Each of the co-crystals displayed a 
melting point that fell between the melting point of AMG517 and that of the co-former. 
A plot generated using the melting points of the co-crystals and co-formers displayed a 
direct proportionality between the two (r=0.7849). Hence, the variability of the melting 
point of the co-crystal can be attributed to the variability of the co-former’s melting 
point. These data thus showed that within the set of AMG517 co-crystals the melting 
point can be altered according to which co-former is chosen; for example, if a higher 
melting co-crystal is desired, then a higher melting co-former should be selected. 
 
High melting points even though desirable at times, may result in poor solubility 
characteristics. Alternatively, low melting points can hinder processing, drying, and 
stability characteristics. 
 
Stability 
Stability is a key factor studied during the development of a new chemical entity. 
Several types of stability need to be considered depending on the structure and 
characteristics of the molecule. Chemical and physical stability data are generally 
obtained under accelerated stability conditions to determine developability and shelf 
life.135 Water uptake is included from a handling and packaging point of view. The 
amount of water present can also lead to form changes or even degradation and so the 
effect of water uptake should be investigated early in the process.136 Thermal stress 
studies are also incorporated, and extra work may be expected for hydrates or thermally 
labile materials. In the case of co-crystals and salts, solution stability may be a factor 
due to dissociation of the material, resulting in precipitation of the less soluble parent 
compound or a less soluble form (such as a hydrate in aqueous media).137 
 
Relative Humidity Stress  
Relative humidity (RH) variation is a vital concern when developing any drug 
compound.136,138 X-ray powder diffraction (PXRD) data collected on a solid at the end of 
a moisture balance experiment provides information on the final form, but not 
necessarily on any form conversions that may have transpired during the experiment. 
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Moisture uptake throughout the course of the experiment may justify longer exposure 
at a specific relative humidity using a relative humidity chamber and subsequent 
analysis of the sample after equilibration. 
An example for water sorption/desorption data was found for co-crystals where a 1:1 
indomethacin/saccharin co-crystal showed about <0.05% water uptake at 95% RH.139 
No solid-state transformation was suggested, although PXRD data of the sample after 
the moisture balance experiment were not reported. Hence, relative humidity may not 
be a major concern for this co-crystal; however, longer exposure to these relative 
humidities may produce more significant effects.  
 
Thermal Stress  
High temperature stress is a common condition used to determine chemical and physical 
stability based on accelerated stability conditions.135 Paracetamol co-crystals of 4,4’-
bipyridine, 1,4-dioxane, N-methylmorpholine, morpholine, N,N-dimethylpiperazine, and 
piperazine were analysed by DSC.140 The paracetamol/4,4’-bipyridine sample was the 
only co-crystal that did not lose the co-former upon heating and by coincidence 
exhibited a melting endotherm corresponding to the monoclinic form of paracetamol. 
Heating studies provide information on elevated temperature transitions and can 
provide support regarding possible long-term stability problems and guidance on 
drying steps.  
 
Chemical Stability  
Chemical stability is generally studied to minimise any chemical degradation that may 
occur during the developmental stages of a new compound and during formulation. The 
comparison of a co-crystal with the parent API can provide important information for 
development. A 1:1 carbamazepine:saccharin co-crystal was compared with 
carbamazepine (Form III) in a chemical stability study using temperature (5, 40, and 60 
°C at ambient humidity) and elevated RH conditions (25 °C/60% RH and 40 °C/75% 
RH) over two months.141 Degradation was not observed for either material at the 
elevated temperatures; however, both materials showed similar degradation patterns 
under the second set of conditions. Hence, it was proved that the co-crystal was just as 
stable as the marketed carbamazepine form under the set conditions.119 
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Solution Stability  
The definition of solution stability is the ability of the co-crystal components to stay in 
solution and not readily crystallise. A range of vehicles including water, simulated 
gastric fluid (SGF), simulated intestinal fluid (SIF), formulation vehicles, and buffered 
solutions may be employed.  Solubility or dissolution experiments may be included to 
obtain a more complete picture of the behaviour of the co-crystal and the solid form 
remaining at the end of the experiment. Because dissociation of a co-crystal can occur, 
solution stability is a key consideration for development. In the study of caffeine co-
crystals,142 the 2:1 caffeine/oxalic acid co-crystal was found to be stable at all relative 
humidities up to 98% RH for 7 weeks. The material was then slurried in water at 
ambient temperature for two days,142 and no change in physical form was observed, 
demonstrating the stability of the material.   
 
Solubility 
Increasing the solubility of a poorly soluble compound is beyond a doubt one of the 
main motives for studying co-crystals. There are a number of considerations when 
discussing solubility data of which the first is equilibrium versus kinetic solubility 
measurements. Kinetic solubility values are approximate values usually based on one 
measurement at one time point.  For equilibrium solubility, a number of time points and 
measurements are recorded to ensure that the solution has reached equilibrium, as 
evidenced by a plateau in the concentration data. This is called powder dissolution.129 
Powder dissolution rates can also be dependent on particle size. Another consideration 
is form changes duri g the experiment. When form changes occur, the solubility data 
obtained may not be relevant to the starting compound in the experiment. Form 
changes can be suggested by solubility data collected at various time points by a 
precipitous drop in concentration indicating crystallisation of a less soluble form 
(Figure 1.16).119 Suggested form changes can be confirmed by analysis of the solid form 
remaining at the end of the experiment.  
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Figure 1.16 Schematic of a solubility curve due to a form change and 
precipitation of a less stable form (curve A); at equilibrium, the curve will level 
out to the solubility of the less soluble form. Curve B represents the less soluble 
form. 
 
 
Intrinsic Dissolution 
Intrinsic dissolution measures the rate of dissolution without the effect of particle size. 
A compressed disc or pellet is used and solution concentration is measured over time to 
determine the dissolution rate. The disc remains intact during the experiment, so 
compression pressures may be critical for poorly compressible powders.119 No form 
change should occur during compression of the disc. PXRD data can be obtained on the 
initial disc and the remaining disc after completion of the experiment to determine any 
major form changes that may affect the dissolution data. Data for the glutaric acid co-
crystal of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide143a were 
collected in water over 90 min and showed that the co-crystal dissolution was about 18 
times faster than that of the parent compound. PXRD of the solid left behind showed 
mainly the glutaric acid co-crystal, with minor peaks for the parent material, indicating 
that the results were not distorted by any form changes during the dissolution test.  
 
Bioavailability 
Bioavailability is a measure of the rate and extent of the active drug that reaches 
systemic circulation.143b The bioavailability of APIs in animals such as rodents, rabbits, 
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dogs, pigs, and primates is an important parameter to consider when preparing new 
forms of a compound. During early drug development, small studies (4-6 animals) to 
determine pharmacokinetic data are undertaken. The same animals are generally used 
for all forms/formulations, with a washout period of about a week. This gives a direct 
comparison within the same animals for all the materials in the study.119 
Both the parent material and the co-crystal will give a direct assessment of 
bioavailability improvements due to the co-crystal. The amount of drug in the blood is 
measured periodically after oral administration of the original form and after 
administration of the co-crystal.119 It is important to note that the materials used in the 
study need to be formulated in the same way if a direct comparison is desired. Most 
dosing is done orally and formulation possibilities include powder in a capsule, powder 
and excipient in a capsule, or liquid formulations (solutions or suspensions). It is 
important to differentiate between solutions and suspensions since dissolution of the 
solid in a solution could significantly enhance bioavailability. Absolute bioavailability 
includes not only the co-crystal formulation, but an IV formulation as well to determine 
maximum exposure based on the IV data and a comparison with the oral formulation.119 
In a bioequivalence study, a 1:1 AMG 517/sorbic acid co-crystal134,144 was compared to 
the parent free base administered in a rat model. A significant increase in bioavailability 
was observed for the co-crystal. It was found that a 30 mg/kg dose of the co-crystal 
resulted in comparable exposure to a 500 mg/kg dose of the free base.  
 Scale-up 
For pharmaceutical co-crystals to move from small scale screening to large scale high 
co-crystal purity and yields, adequate scaling-up processes must be employed. With 
slow evaporation and grinding being the two most common techniques for co-crystal 
production, limitations with regard to scaling up are inevitable.145 
A carbamazepine/saccharin co-crystal was produced on a 30 kg scale through solution 
crystallisation.141 The components were dissolved in a mixture of ethanol and methanol 
(~3:1) and refluxed at 70 °C for 1 h. The temperature was then lowered, and the 
precipitate was filtered, dried, and characterised as the 1:1 co-crystal of carbamazepine 
and saccharin. Notably, no seeding was required under the reaction conditions selected, 
to produce the desired co-crystalline form in high purity. 
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A carbamazepine/nicotinamide co-crystal scale-up study outlined three criteria to be 
examined during the crystallisation methodology: (a) to determine an appropriate 
solvent system; (b) to identify the pathway, through multicomponent solid-liquid phase 
equilibrium diagrams, to produce the desired form; (c) to determine a mechanism to 
induce nucleation and control the desaturation kinetics of the process. Through a 
seeding strategy in ethanol, the co-crystal was successfully produced on a 1 L scale in 
ethanol with yields in excess of 90%. 
Ternary phase diagrams should also be considered when scaling up co-crystals from 
solution because information about the relationship between equilibria of the solid 
phases and solvent choices is then accessible. The solubilities of the individual 
components must be determined and mapped since the phase region where the most 
thermodynamically stable co-crystal is located will be altered based on whether or not 
the components possess similar solubilities in a given solvent.119 Thus, evaluation and 
optimisation of scaleable co-crystals is essential if the pharmaceutical industry sees a 
viable future for such products.  
 
Co-crystal Polymorphism 
Since polymorphic compounds can possess very different physical and chemical 
properties, polymorphic co-crystals can possess varying physicochemical properties 
between forms. For example, a conformational polymorphic pair of 1:1 co-crystals was 
observed when a chloroform solution of caffeine and glutaric acid was allowed to slowly 
evaporate.146 Crystals of two different morphologies, rods (Form I) and blocks (Form 
II), crystallised concomitantly. As revealed by X-ray studies, differences arose in the 
torsion angles involving the methylene carbons on the acid component. Each of the 
forms could be produced individually through mechanical grinding. In the absence of 
solvent or when a fairly nonpolar solvent was used, Form I was produced; however, 
when a more polar solvent was employed, Form II resulted. Form II was found to be 
more stable with respect to humidity, as Form I displayed partial conversion to Form II 
after 1 day at 43% RH, with full conversion to Form II after 1 day at 75% RH. This 
example clearly shows the differences in stability that polymorphic co-crystalline forms 
can possess. 
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Intellectual Property (IP) and Lifecycle Management 
Finally, patents are a key element of drug development, especially when covering solid 
forms. Pharmaceutical patents include composition of matter (molecular structure, solid 
form, or formulation), method of use (medical indication), and manufacturing 
processes.119 The three criteria: novelty, utility, and non-obviousness, must be met for 
an invention to qualify for patent coverage. To date, there are no known co-crystal 
products on the market. 
Co-crystals can also play a role in lifecycle management.119 Lifecycle management can 
involve drug product improvements along with new solid forms. Early in the 
development process, chemical structures are patented and additional IP protection can 
be obtained by patenting different solid forms throughout development. If an approved 
drug product contains a new patented solid form, especially where the solid form offers 
a commercial advantage over the original form, the solid form patent might provide 
meaningful IP protection after the expiration of the original patent. However, a solid 
form that was not found by the innovator, but was found and patented by a competitor, 
could significantly alter this strategy. Co-crystal screens for potential blockbuster drugs 
could end up being very large in order to protect, not only the co-crystals found, but 
also any polymorphs, hydrates, solvates, or other solid forms of the individual co-
crystals.119 
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1.4 MOTIVATION AND OBJECTIVES OF THE STUDY 
Two pharmacologically active steroids, 2-methoxyestradiol (2ME) and 2-
methoxyestradiol-bis-sulfamate (2MES), as well as the antiretroviral, nevirapine (NV), 
were investigated in this study (Figure 1.17).  
 
 
 
 
 
 
 
 
  (a)       (b) 
 
 
               (c) 
 
Figure 1.17 Pharmacologically active molecules used in this study: (a) 2-
methoxyestradiol, (b) 2-methoxyestradiol-bis-sulfamate and (c) nevirapine. 
 
2-Methoxyestradiol (2ME) belongs to the family of drugs called angiogenesis 
inhibitors and is derived from estrogen, although it binds poorly to known estrogen 
receptors. The chemical name for 2ME is (17β)-2-methoxyestra-1,3,5(10)-triene-3,17-
diol. Estradiol, the major endogenous estrogen, metabolises to 2ME via enzymes in 
vascular cells and furthermore circulates at measurable levels in humans.147-9 2ME 
prevents the formation of new blood vessels that tumours need in order to grow 
(angiogenesis) and has undergone Phase 1 clinical trials against breast cancers.147-9 
Preclinical models suggest that 2ME could also be effective against inflammatory 
diseases such as rheumatoid arthritis while also displaying vasodilator activity.148 
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Several studies have been conducted showing 2ME to be a microtubule-inhibitor and 
effective against prostate cancer in rodents.148 2ME is available as a capsule (Panzem®) 
formulation and NanoCrystal® dispersion (NCD) formulation. In the Phase II trial of 
the NCD formulation it was found that 2ME was well tolerated and had better 
bioavailability than the capsule formulation.148 However, anti-tumour activity was 
modest, with therapeutic benefit exceeding one year in selected subjects (dose 1000 mg 
4 times a day).148 Studies have indicated that 2ME also inhibits the proliferation of 
vascular smooth muscle and inhibits injury-induced neointima formation in vivo.149 It 
has vasculoprotective effects in rat models of drug-induced hypertension and pulmonary 
hypertension and reduces the oxidation of low-density lipoprotein in vitro which raised 
questions about the anti-atherosclerotic effects of 2ME.149 
 
Investigation of its anti-atherosclerotic effects149 led to the conclusion that 2ME reduces 
atherosclerotic lesion formation in vivo and this finding led to several implications: 
1) 2ME may partially mediate the anti-atherosclerotic effect of estradiol in mouse 
models;  
2) the anti-atherogenic activity of an estradiol metabolite lacking estrogen receptor 
activating capacity may argue that clinical trials on cardiovascular effects of hormone 
replacement therapy should use estradiol rather than other estrogens; and  
3) 2ME may also hold promise for cardiovascular disease prevention.149 
Furthermore, it was discovered that sulfamoylation significantly enhances the anti-
cancer activity of estrogen derivatives, which led to the synthesis of 2MES,149,150 a 
sulfamoylated derivative of 2ME and consequently, inclusion of this compound in this 
study. 
2-Methoxyestradiol-3,17-O,O-bis-sulfamate (2MES) is a sulfamoylated derivative of 
2ME with enhanced activity and improved pharmacokinetic properties and a promising 
candidate for early clinical trials.151 After a single oral administration (10 mg/kg) of 
2MES, significant concentrations of this compound were still detectable at 24 h.150 In 
contrast, no 2ME or metabolites of 2ME were detected in plasma at any time after a 10 
mg/kg oral dose. Thus, the bioavailability of 2ME is very low, whereas for 2MES it was 
85 %.151 No significant metabolites of 2MES were detected in plasma after oral or 
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intravenous dosing, showing that 2MES is resistant to metabolism.150 In a tumour 
efficacy model, oral administration of 2MES at 20 mg/kg/day for 28 days almost 
completely inhibited tumour growth. Inhibition of tumour growth was maintained for a 
further 28 days after the cessation of dosing, and at this dose 2ME did not inhibit 
tumour growth.150 Display of such significant pharmacological potential of 2ME and the 
advanced activity of its derivative, 2MES, were bound to provoke the interest of the 
formulating chemist.   
 
Neither 2ME nor 2MES is recorded in the CSD,40 hence single crystal X-ray structural 
elucidation was considered essential for the commencement of the study. Polymorphic 
behaviour in steroids is quite common (about 66% of steroids show polymorphic 
behaviour), hence elucidating other forms of both 2ME and 2MES could be of much 
commercial interest since any modification of the crystal structures could alter 
physicochemical properties as well as biological activity considerably. 2ME is sparingly 
soluble in aqueous media at pH 1 to 8 with an experimental value of 0.0048 g/L (25 ºC) 
across the pH ranges. The solubility of 2MES was not in evidence in the literature and 
for comparative reasons one of the first objectives was to determine its solubility 
relative to that of 2ME.  
 
With 2ME currently in clinical trials as a treatment for different cancers and with trials 
being carried out relating to an oral version of 2ME to treat primary tumours, the oral 
version of 2ME seems to be poorly suited to entering the bloodstream and reaching the 
actual tumour site.151 This stated, it is the physicochemical property of solubility that 
represents the limiting factor for the oral administration of 2ME (0.0048g/L water at 
pH 7 and 25°C).  Hence, the formation of complexes of selected cyclodextrins (CDs) 
with 2ME may extend the applications of 2ME. CDs are able to enhance the stability, 
aqueous solubility, dissolution and ultimately, the bioavailability of drugs.152 To date, 
there is no record of any attempts to complex 2ME with CDs. However, many attempts 
were made to complex other steroidal molecules with CDs. Thus far, the structure of 
only one steroidal cyclodextrin inclusion complex, that containing rocuronium bromide 
as guest,143a has been elucidated using single crystal X-ray analysis.40 Significant 
solubility improvement of 2ME by CD inclusion would be of great interest to 
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researchers. Thus, investigation of the interaction between 2ME and a wide variety of 
CDs was considered a worthy topic for research.  
 
Nevirapine, condemned as “the drug from hell” by AIDS dissidents while heralded as a 
"godsend" by many health professionals, is used to eliminate the deadly HIV virus.153 
HIV is an acronym for the Human Immunodeficiency Virus, a retrovirus that causes 
AIDS (acquired immunodeficiency syndrome) by infecting helper T cells of the immune 
system. HIV uses the enzyme reverse transcriptase to incorporate its own genetic 
material into host cells, which then allows it to reproduce freely. Nevirapine, a member 
of the dipyridodiazepinone class of anti-HIV drugs with the systematic name 11-
cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one 
(Figure 1.17), manufactured by Boehringer Ingelheim, one of a class of drugs known as 
non-nucleoside reverse transcriptase inhibitors (NNRTIs),154 prevents this enzyme from 
functioning. This results in a reduced amount of virus in the body and an increase in the 
CD4 cell (T cell) count, improving the host's immune function, and thereby reducing 
the risk of new and opportunistic infections, and death.  
 
In 2002, nevirapine was at the centre of a court case and a major political debacle where 
South African health professionals and AIDS activists were jointly lobbying their 
government, protesting in the streets and finally taking the matter to court.153 The 
court case arose due to government not providing adequate access to the HIV treatment 
programme thereby contravening the ‘right to health’ and access to modern medicine.  
The people of South Africa won the case and government was forced to provide 
treatment to all with HIV and AIDS.  
Nevirapine has been widely used in adults as one of a combination of drugs to treat 
established HIV infection. It has a special role in the prevention of mother-to-child 
transmission of HIV, as it is effective when given alone as a single dose to the mother at 
the beginning of labour and as one dose administered to the baby within 72 hours of 
birth.155 Nevirapine given to HIV-positive pregnant women rapidly crosses the placenta 
into the foetus with its effects lasting through the first week of life. The timing of its 
delivery to the mother during labour is important as up to two-thirds of infants born 
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with HIV are infected in the birth canal.155 Thus, nevirapine as a ‘risk’ or ‘necessity’ is 
every medical practitioner’s nightmare and this applies to numerous other APIs in the 
pharmaceutical industry. 
Clinical trials have confirmed the efficacy of nevirapine in preventing mother-to-child 
transmission of HIV. No trials are available comparing nevirapine with placebo. The 
Ugandan HIVNET 012 study involving 626 women showed that nevirapine was able to 
reduce mother-to-child transmission by 47 %, with only 8.1 % of infants exposed to 
nevirapine acquiring HIV at birth.156 Almost all the babies were breast-fed, resulting in 
ongoing exposure to HIV. Despite this, the benefits of nevirapine were maintained with 
a 42 % reduction in transmission at the age of 12 months.156  
In the South African Intrapartum Nevirapine Trial (SAINT), 1306 mother/infant pairs 
were randomised to either nevirapine during labour and post-delivery, or multiple doses 
of AZT/3TC during labour and for one week after delivery to mother and baby. In both 
treatment arms, about 40 % of infants were breast-fed. Eight weeks after birth, there 
was no significant difference observed between the rate of HIV infection or death across 
the two treatment arms, with a rate of 14.3 % in the simpler nevirapine arm and 12.5 % 
in the more involved and expensive dual therapy arm.157 For pregnant women already 
receiving highly active antiretroviral therapy, there appeared to be no additional 
advantage of adding nevirapine to an existing regimen.157  
Nevirapine was approved by the FDA in 1996 for use in combination with nucleoside 
analogues in adults with HIV infection. Approval was based on studies showing that the 
combination of nevirapine with zidovudine plus didanosine was more effective in 
increasing CD4 T-lymphocyte counts and decreasing HIV viral load than a regimen of 
zidovudine plus didanosine alone. Approval for pediatric use was granted in 1998. The 
FDA has granted generic versions of nevirapine "tentative approval" status for purchase 
and use only as part of the President's Emergency Plan for AIDS Relief (PEPFAR) in 
resource-limited countries. Nevirapine is available in tablets and oral suspension. The 
adult dose is 200 mg daily for 14 days, then 200 mg twice daily; nevirapine should not 
be initiated in women with CD4 >250 cells/μL or men with CD4 >400 cells/μL, unless 
the benefit clearly outweighs the risk. The paediatric dose (age 15 days to adolescence) 
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is 150 mg/m2 daily for the first 14 days, then 150 mg/m2 twice daily. The maximum 
total daily dose is 400 mg.  
For the purpose of this study, our interest in this drug stems from its unique chemical 
structure, which differs significantly from other commercially available NNRTIs.158 
Specifically, from a crystal engineering viewpoint, the presence of the amide function 
CO–NH in the nevirapine molecule presents a unique candidate for co-crystallisation 
experimentation as reviewed earlier in the chapter. 
 
For the co-crystallisation experiments, the following 12 compounds were chosen for 
this study as suitable co-formers with nevirapine viz. saccharin, nicotinamide, 
isonicotinamide, succinic acid, tartaric acid (racemic, D and L), citric acid, oxalic acid, 
stearic acid, L-aspartic acid and maleic acid. These potential co-formers were chosen 
based on the presence of their carboxylic acid moieties and/or because they appear on 
the GRAS (generally regarded as safe) list.  Nevirapine, as noted by its structure, was 
uniquely identified for successful attempts at co-crystallisation. It should be noted that 
during co-crystallisation experimentation, several nevirapine solvates were identified 
and shared with the University of North-West for publication purposes (see page iv). 
 
Objectives 
The primary objectives of the study described in this thesis were: 
1. The preparation of 2-methoxyestradiol and 2-methoxyestradiol-bis-sulfamate 
polymorphs using several methods discussed in chapter 2. The characterisation 
of these products by TGA, DSC, HSM and PXRD.   
2. The preparation of 2-methoxyestradiol cyclodextrin inclusion complexes using 
methods discussed in chapter 2. The characterisation of these products by TGA, 
DSC, HSM and PXRD.   
3. The attempted preparation of a limited series of nevirapine co-crystals as ‘proof 
of concept’ using methods discussed in chapter 2 and their characterisation by 
TGA, DSC, HSM and PXRD.   
4. The investigation of the detailed solid-state features of the polymorphs, 
cyclodextrin inclusion complexes and co-crystals using single crystal X-ray 
diffraction.    
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Introduction  
 
 65
5. Furthermore, measurement of the solubilities and/or dissolution profiles of the 
various targetted products was considered an important objective to assess the 
possible pharmaceutically-relevant consequences of supramolecular modification. 
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Chapter 2  p r e s e n t s  t h e  e x p e r i m e n t a l  m e t h o d o l o g y  o f  t h e  s t u d y .  I t  
d e s c r i b e s  a l l  ma t e r i a l s  and  m e t h o d s  u s e d  t o  p r e p a r e  p o l y m or p h s ,  
c y c l o d e x t r i n  i n c l u s i o n  c o m p l e x e s  a n d  c o - c r y s t a l s .  F u r t h e r m o r e ,  t h e  
c h a p t e r  p r o v i d e s  a n  o v e r v i e w  o f  m e t h o d s  ( b o t h  l a b o r a t o r y  a n d  
c o m p u t a t i o n a l )  em p l o y e d  t o  i d e n t i f y  a n d  a n a l y s e  p o l ym o r p h s ,  
c y c l o d e x t r i n  i n c l u s i o n  c o m p l ex e s  a nd  c o - c r y s t a l s .   
 
2 .1  COMPOUNDS STUDIED 
Guest  Compounds  
2-Methoxyestradiol (2ME) was a gift from Shimoda-Biotech (Port Elizabeth, South 
Africa) and 2-Methoxyestradiol-bis-sulfamate (2MES) was synthesized by Dr Gareth 
Arnott (University of Cape Town). Nevirapine (anhydrous) was originally purchased 
from Cipla (Mumbai, India, batch number 1001003). However, for the purposes of this 
study we received it as a gift from North-West University (Potchefstroom, South 
Africa). All three compounds were used as received. 
 
Host  Cyc lodext r in  Compounds  
Alpha-cyclodextrin (α-CD), beta-cyclodextrin (β-CD), gamma-cyclodextrin (γ-CD), 
hexakis(2,3,6-tri-O-methyl)-α-CD (TRIMEA), hydroxypropyl-β-CD (HPBCD), 
randomly methylated β-cyclodextrin (RAMEB), heptakis-(2,6-di-O-methyl)-β-CD 
(DIMEB), heptakis(2,3,6-tri-O-methyl)-β-CD (TRIMEB), heptakis(2,3,6-tri-O-acetyl)-
β-CD (TriAcBCD), heptakis (2,3,6-tri-O-ethyl)-β-CD (TriEtBCD) and octakis(2,3,6-tri-
O-acetyl)-γ-CD (TriAcGCD) were obtained from Cyclolab (Budapest, Hungary) and 
were used as received. 
 
Co-crystal Former Compounds 
Sacchar in ,  n i co t inamide ,  i s on i co t inamide ,  s t e a r i c  a c id ,  L -a spar t i c  
a c id ,  oxa l i c  a c id  and  ma l e i c  a c id  were  ob ta ined  f rom S igma-Aldr i ch  
Chemie Gmbh (Steinheim, Germany). Succ in i c  a c id  and  D- ta r t a r i c  a c id  were  
o b t a i n e d  f r o m  B . D . H .  L a b o r a t ory  Chemica l s  D iv i s i on  (Poo l e ,  
Eng land ) .  C i t r i c  a c id ,  r a c emic  and  L - t a r t a r i c  a c i d  w e r e  o b t a i n e d  
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f rom SAARCHEM  (Pty) Ltd (Krugersdorp, Gauteng, South Africa).  All compounds 
were used as received. 
 
2.2 PROCEDURES FOLLOWED TO GROW POLYMORPHS 
To obtain polymorphic forms of a compound the following methods were employed, as 
suggested by Guillory:1 
 
Sublimation:   a direct change of state from solid to gas1 and back to solid. 
Method I - A small quantity (10-20 mg) of the compound was placed in a petri dish 
that was covered with a watch glass. The petri dish was heated gently on a hot plate 
and the watch glass was observed to determine if crystals were growing on it.1 
Method II- The vacuum sublimation method employed a horizontal vacuum 
sublimation apparatus. The latter is a piece of laboratory glassware consisting of a 
cylindrical, flat-bottomed flask for the sample and a water-cooled finger-type condenser. 
The condenser has an outer short skirt with an outer joint to fit over the neck of the 
flask. Above the joint there is a side-hose connector for attachment to the vacuum 
source. The solid was placed in the flask which was then heated under vacuum. Under 
this reduced pressure the solid volatilised and condensed as a purified compound on the 
cooled finger-type condenser surface, leaving the non-volatile residue impurities behind. 
Once heating had ceased and the vacuum was released, the sublimed compound was 
collected from the cooled surface. 
 
Crystallisation from a Single Solvent 
A known mass of the compound was dissolved in a known volume of solvent. Heating 
temperatures were set below the melting point of the ingredient with the lowest melt 
and 10 oC below the boiling point of the solvent. The solvent was added dropwise into 
the vial fitted with a magnetic stirrer while on a hot plate until the powders were 
completely dissolved. Solutions of the material being crystallised were filtered via a 0.45 
μm syringe filter to remove most nuclei and transferred to a clean vial and then closed 
with Parafilm containing a few holes. The solution was then left undisturbed for a 
reasonable period of time to allow for evaporation to occur.  
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Evaporation from a Binary Mixture of Solvents 
Multi-component solvent evaporation methods depend on the difference in the 
solubility of the solute in various solvents. Here, a second solvent in which the solute is 
sparingly soluble was added to a saturated solution of the compound in a ‘good’ solvent. 
Often a solvent system was selected in which the solute was more soluble in the 
component with the higher vapor pressure. As the solution evaporated, the volume of 
the solution was reduced and, because the solvents evaporated at different rates, the 
composition of the solvent mixture changed. 
 
Vapour Diffusion 
A solution of the solute in a ‘good’ solvent was placed in a small, open container that 
was stored in a desiccator containing a small amount of a miscible, volatile non-solvent. 
The desiccator was then tightly closed. As solvent equilibrium was reached, the non-
solvent diffused through the vapor phase into the solution, and saturation or 
supersaturation was achieved. The solubility of the compound in a precipitant used in a 
two-solvent crystallisation method such as vapour diffusion should be as low as possible 
(much less than 1 mg/ml), and the precipitant (the solvent in which the compound is 
poorly soluble) should be miscible with the solvent and the saturated solution. 
  
Thermal Treatment 
When using differential scanning calorimetry as an analysis technique, one can observe 
an endothermic peak corresponding to a phase transition, followed by a second 
endothermic peak corresponding to melting. Sometimes there is an exothermic peak 
between the two endotherms, representing a crystallisation step. These endothermic 
and/or exothermic peaks are associated with a series of thermal events, such as guest 
release, phase transformation, recrystallisation, melting and decomposition.  Thus, the 
onset temperatures and enthalpy changes (area under the peak ∝ΔH) of these thermal 
events can be determined and new polymorphs may be isolated. 
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Crystallisation from the Melt  
The cooling of melts of polymorphic substances often yields the least stable 
modification, which subsequently rearranges into the stable modification in stages. 
Since the metastable form will have the lower melting point, it follows that supercooling 
is necessary to crystallise it from the melt. After melting, the system was supercooled 
below the melting point of the metastable form, while at the same time the 
crystallisation of the more stable form or forms was achieved. Quench-cooling  a melt  
resulted in formation of an amorphous solid that on subsequent heating underwent a 
glass transition followed by crystallisation. 
 
Thermal Desolvation of Crystalline Solvates  
The term “desolvated solvates” has been applied to compounds that were originally 
crystallised as solvates but from which the solvent has been removed (generally by 
vaporisation induced by heat or vacuum). Often, these “desolvated solvates” retain the 
crystal structure of  the original solvate form and exhibit relatively small changes in 
lattice parameters. For this reason, these types have been referred to as 
pseudopolymorphic solvates. However, in instances where the solvent serves to stabilise 
the crystal structure, the process of desolvation may produce a change in lattice 
parameters, resulting in the formation of either a new crystal form or an amorphous 
form. These solvates have been referred to as polymorphic solvates. Byrn2 had 
characterised the desolvation of polymorphic solvates as occurring in four steps: 
(a) molecular loosening, (b) breaking of the host-solvent hydrogen bonds (or other 
associations), (c) solid solution formation, and (d) separation of the product phase.     
The process of desolvating pseudopolymorphic solvates is simpler, involving only the 
two steps of: (a) molecular loosening and (b) breaking of host-solvent hydrogen bonds 
or associations. 
 
Grinding 
Polymorphic transformations can be achieved with both manual grinding (mortar and 
pestle) and mechanical grinding. Polymorphic transformations in the solid state require 
three steps: (a) molecular loosening (nucleation by separation from the lattice), (b) solid 
solution formation, and (c) separation of the product (crystallisation of the new phase). 
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Depending on the material and the conditions employed, grinding can result in 
conversion to an amorphous substance and with the exercise of care, different 
polymorphic forms could be obtained.2 
 
Solvent-drop Grinding  
Polymorphic transformation may also be initiated by adding small amounts of a suitable 
solvent to either manually or mechanically ground mixtures. As a further modification, 
each mixture was placed at various relative humidity (RH) conditions which in turn 
could facilitate polymorphic transformation. Samples were checked on a weekly basis 
using PXRD to see whether any changes had occurred. 
 
Dicarboxylic Acids as Templates in Solution 
The use of templates in  solution may also facilitate polymorphic transformation of the 
compound. A known amount of the template is placed in a suitable solvent and stirred 
for a half hour at ~50 C. The solution should be supersaturated before the addition of 
the compound which is stirred again for a few hours. The solution is then filtered and 
the solvent is allowed to slowly evaporate at ambient temperatures. Terephthalic acid 
was used in this study with basic solvents (alcohols). 
 
Methods Used to Obtain Hydrated Forms of a Compound 
Pharmaceutical solids may come into contact with water during processing steps such 
as crystallisation, lyophilisation, wet granulation, aqueous film-coating, or spray-drying. 
Moreover, they may be exposed to water during storage in an atmosphere containing 
water vapour, or in a dosage form consisting of materials that contain water (e.g. 
excipients) and are capable of transferring it to other ingredients. Water may be 
adsorbed onto the solid surface and/or may be absorbed in the bulk solid structure. 
When water is incorporated into the crystal of the compound in stoichiometric 
proportions, the molecular adduct or adducts formed are referred to as hydrates.3 
Hydrates can be prepared by re-crystallisation from water or from mixed aqueous 
solvents. They could also result, in some instances, from exposure of crystal solvates to 
an atmosphere containing water vapour. Finally, hydrates may also be obtained by 
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exposure to high relative humidity conditions. For example, dexmedetomidine 
hydrochloride exposed to 100 % relative humidity converted to a monohydrate.4  
 
Methods Used to Obtain Solvated Forms of a Compound 
When organic solvents are employed in the purification of new drug substances by re-
crystallisation, it is often observed that the isolated crystals include solvent molecules, 
either entrapped within voids in the crystal or interacting via hydrogen bonding or van 
der Waals forces with molecules constituting the crystal. A crystal with large empty 
channels or cavities is not stable because of packing demands. The size and chemical 
environment of the cavity or channel determine what kind of solvent molecule can be 
included in the structure and what kind of interaction occurs between solvent and host 
structure. Depending on the nature of molecular packing arrangements, it may happen 
that the inclusion of solvent is necessary to build a stable crystal structure. The 
techniques used to obtain solvates were generally similar to the methods used to obtain 
polymorphs, i.e. crystallisation from a single solvent, from mixed solvents, or by vapour 
diffusion. Sometimes, it is also possible to exchange one solvent within the crystal 
structure for another. 
 
Methods Used to Obtain Amorphous Forms of a Compound  
Solids can exist in crystalline or amorphous form. Crystalline materials have defined 
structures, stoichiometric compositions, and melting points and are characterised by 
their chemical, thermal, electrical, optical, and mechanical properties.5 By contrast, 
amorphous materials have no long-range order, so their structure can be viewed as 
being similar to that of a frozen liquid but without the thermal fluctuations observed in 
the liquid phase. While crystalline solids offer the advantages of chemical and 
thermodynamic stability, amorphous solids are occasionally preferred because they 
undergo dissolution at a faster rate. Rapid dissolution is desirable in the case of solids, 
which must be dissolved prior to parenteral administration. Faster dissolution is also 
important for poorly soluble compounds administered orally, since there is often a 
correlation between dissolution rate and bioavailability. In fact, there are instances in 
which only the amorphous form has adequate bioavailability. Several methods employed 
in attempts to produce amorphs are described below. 
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Solidification of the Melt 
Amorphous solids are often created by rapidly cooling a liquid so that crystallisation 
nuclei can neither be created nor grow sufficiently, whereupon the liquid then remains 
in the fluid state well below the normal freezing point. Here the rate of cooling is high 
relative to the rate of crystallisation, whereupon the liquid state can persist well below 
the normal freezing point. As cooling continues there is a rise in the rate of increase in 
viscosity of the supercooled liquid per unit drop in temperature. The initially mobile 
fluid turns into a syrup, then into a visco-elastic state, and finally into a brittle glass. A 
glass is, therefore, a supercooled liquid, characterised by an extremely high viscosity. 
Mechanically, if not structurally, glasses can be regarded as solids. 
 
Reduction of Particle Size 
Reduction of particle size of crystalline materials to the microcrystalline level can yield 
a material incapable of exhibiting an X-ray powder diffraction pattern. The milling 
disrupts the crystal structure and imparts excess free energy and entropy associated 
with amorphous substances. Particle size reduction can be achieved using a variety of 
methods. Sometimes it is helpful to carry out the particle size reduction at reduced 
temperatures, such as 4 °C or at liquid nitrogen temperature, -196 °C. In other 
instances, grinding with an excipient was employed as a means of obtaining amorphous 
materials. Cyclodextrins were used for this purpose. 
 
Removal of Solvent From a Solvate or Hydrate 
Solids can sometimes be rendered amorphous by the simple method of allowing solvent 
molecules of crystallisation to evaporate at modest temperatures. If the solvent merely 
occupies channels in the crystal structure, the structure often remains intact on heating, 
and may improve certain properties such as flowability and uniformity of particle size,6 
but when the solvent is strongly bonded to molecules of the host, the structure will 
frequently  collapse when the solvent is removed and one obtains an amorphous powder. 
 
All of the above methods were employed to try to isolate new forms of both 2ME and 
2MES. Full details of the preparation of individual polymorphs and solvates actually 
found in this study are given in the appropriate chapter. 
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2 .3  PROCEDURES FOR PREPARING CYCLODEXTRIN 
COMPLEXES 
 
To obtain cyclodextrin complexes of a compound the following methods were 
employed: 
 
Complex Preparation by Co-precipitation   
The complex was prepared by stirring an aqueous solution of CD (warm or cold) with 
the guest molecule using a fixed host:guest ratio. The calculated amounts of host and 
guest molecules were agitated intensely at a set temperature to achieve the common 
saturated solution of both the host and guest. The CD inclusion complex was 
crystallised from this homogenous solution upon slow evaporation, slow cooling, 
freezing or elevating the temperature.  
 
Complex Preparation by Kneading 
The cyclodextrin was placed in a mortar with a few drops of water and ground to a 
paste.  An equimolar amount of the guest was added slowly with simultaneous 
kneading. The process required between 45 min to one hour.  During this time the paste 
was kept moist by the dropwise addition of water. Here less water was used than in the 
co-precipitation method; however, excess water was removed from the paste-like 
product by drying in an air stream.7,8  
 
Full details of the preparation of individual complexes are given in the appropriate 
chapter. 
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2.4 PROCEDURES USED TO PREPARE CO-CRYSTALS 
To obtain co-crystals the following methods were employed:9 
 
Slow Evaporation  
Stoichiometric amounts of the components (co-crystal formers) were dissolved in a 
known volume of solvent system (either single solvent or binary mixture).  All 
temperatures were kept below the melting point of the lowest melting component and 
10 oC below the estimated boiling point of the solvent system.  Samples were dissolved 
separately in the respective solvent systems,  stirred with a magnetic stirrer while on a 
hot plate until the powders were completely dissolved.  The two solutions were then 
mixed together in the vial with the lesser amount of solvent, stirred, extracted via 
syringe and filtered from the syringe through a 0.45 μm micro-filter into a clean vial. 
The vial was closed with Parafilm and perforated to allow the solvent to evaporate.  
 
Sublimation   
A small quantity (10-20 mg) of the respective co-crystal formers in stoichiometric 
amounts was placed in a petri dish that was covered with a watch glass. The petri dish 
was heated gently on a hot plate and the watch glass was observed to determine if co-
crystals were growing on it.1  
 
Grinding 
Co-crystal formation can be achieved with both manual grinding (mortar and pestle) 
and mechanical grinding of a physical mixture of the co-crystal formers. Depending on 
the material and the conditions employed, grinding can result in the formation of a co-
crystal.  
 
Solvent-drop Grinding 
Addition of a small amount of suitable solvent to the ground mixture to accelerate co-
crystallisation appears to be a particularly promising preparation method. Trask et al.10 
reported that grinding of cyclohexane-1,3-cis-5-cis-tricarboxylic acid and 4,4′-bipyridine 
in the dry state does not afford a co-crystal whereas grinding the two components with 
few a drops of MeOH facilitates complete conversion within minutes. Solvent-drop 
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grinding avoids excessive use of crystallisation solvent and hence it can be regarded as a 
“green” process. Solvent-drop grinding could also prove useful for polymorph control9 
and selective polymorph transformation.10 
Full details of the preparation of individual co-crystals are given in the appropriate 
chapter. 
 
2.5 PROCEDURE USED TO DETERMINE SOLUBILITY PROFILE OF A 
COMPOUND 
The solubility profile of a compound can be determined both experimentally and 
theoretically. Theoretically, the simplest equation to date is a modification of the 
general solubility equation which uses the melting point (MP) of the compound and the 
octanol-water partition coefficient (Kow).11  
 
The equation log Ssolid = 0.5 – 0.01(MP – 25) – log Kow is used to calculate the 
theoretical aqueous solubility of an organic compound.11 
 
However, experimentally, the following procedure was used: a saturated solution was 
obtained either by stirring excess powdered solute with solvent for several hours at the 
required temperature until equilibrium had been attained, or by warming the solvent 
with an excess of the solute and allowing the mixture to cool to the required 
temperature. It was essential that some undissolved solid should be present at the 
completion of this stage in order to ensure that the solution was saturated.12 
 
The following requirements were observed in all solubility determinations: 
1. The solute and the solvent must be pure. 
2. A saturated solution must be obtained before any solution is removed for 
analysis. 
3. The method  of separating a sample of saturated solution from undissolved 
solute must be satisfactory. 
4. The method of analysing the solution must be reliable. 
5. Temperature must be adequately controlled. 
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A sample of the saturated solution was obtained for analysis by separating it from the 
undissolved solid. Filtration was used, but precautions were taken to ensure that it was 
carried out at the temperature of the solubility determination, in order to prevent any 
change in the equilibrium between dissolved and undissolved solute.12 The filtration 
process could have been simplified by the introduction of membrane filters that could be 
used in conjunction with conventional syringes fitted with suitable inline adapters. 
However, this was not employed in the present study. 
 
Full details of the determination of the solubility of individual compounds are given in 
the appropriate chapters. 
 
2.6 PROCEDURE USED TO DETERMINE DISSOLUTION PROFILE OF A 
COMPOUND 
 
Dissolution studies were conducted using the rotating basket method as described in 
the BP 2005.13 Gelatin capsules containing 5-10 mg of the formulation were made. Tests 
were carried out in the Vankel VK 700 (220 V) dissolution apparatus and with the 
Vankel VK 650 A Heater/Circulator Benchsaver® series used  to regulate temperature 
at 37 ºC. 900 ml flasks filled with distilled water were used and a stirring speed of 100 
rpm was applied. The capsules were enclosed in stainless steel baskets to prevent 
floating. A 3 h run was conducted and at pre-specified times (15 minute intervals) 5 ml 
samples were withdrawn and filtered for analysis, with 5 ml of the distilled water being 
replaced to maintain a constant volume. The assay was by UV spectrophotometry at an 
appropriate wavelength for the active ingredient. 
 
The powders placed in the capsules were kneaded prior to encapsulation for ~5 minutes 
to obtain uniform and predictable dissolution of the drug. The particle size range of the 
powders was  between  65 and 200 μm. Powders were not sieved prior to encapsulation 
due to high costs and limited resources of ingredients.  
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2.7 ANALYTICAL METHODS USED IN THIS STUDY  
Hot Stage Microscopy (HSM) 
A Linkam TP92 temperature control unit linked to a Linkam TH MS600 hot stage was 
used  to heat crystals at a controlled  rate. Visual characterisation was rendered by a 
real-time Sony Digital Hyper HAD colour video camera fitted to a Nikon SMZ-10 
stereoscopic microscope. Images that were recorded were analysed by the Soft Imaging 
system, analySIS.14 HSM used under these conditions proved quite useful, allowing one 
to distinguish new solid phases such as polymorphs, cyclodextrin complexes and co-
crystals. HSM complements TGA and DSC analysis by visually recording the thermal 
events during the heating and cooling process.  For example, guest loss is usually 
indicated by the appearance of bubbles when the sample is immersed in an inert medium 
(e.g. silicone oil), and polymorphic transition is typically shown by colour or opacity 
changes in crystals.   
 
Thermogravimetric Analysis (TGA) 
Thermogravimetry (TG) measures the mass loss of a sample as a function of time or 
temperature. It is used to establish the stoichiometry of inclusion compounds and to 
study the decomposition of desolvated materials. 
TG analyses for all compounds were performed on a Mettler Toledo TGA/SDTA851e 
instrument under N2 gas purging at a flow rate of 30 mL/min. The Mettler TG 
instrument was calibrated using indium (mp = 156.6 ºC) and aluminium (mp = 660.3 ºC) 
in an automated process in which temperature calibration, tau lag calibration and sensor 
calibration were performed simultaneously. The cystals were rapidly dried on a filter 
paper to remove surface solvent. The weighed samples were placed in an open porcelain 
pan. The programmed TG analyses were carried out over a temperature range 30 ºC to 
400 ºC at the predetermined linear heating rate of 10 K/min. This technique was 
primarily used to determine the stoichiometry of the compounds from the percentage 
weight loss. The samples were continuously purged by a stream of dry nitrogen gas at a 
flow rate of 30 mL/min.  
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Differential Scanning Calorimetry (DSC) 
DSC measurements were performed using a Perkin-Elmer PC-7 series thermal analysis 
system at a scanning rate of 10 K/min under N2 gas purge with a flow rate of 30 
mL/min. The temperature range over which the traces were recorded was 30 – 400 ºC. 
Sample masses were in the range 2-5 mg. Samples were removed from mother liquor, 
dried on filter paper and crushed to an appropriate particle size and sealed in a crimped, 
vented aluminium pan. A sealed and empty pan was used as a reference. The DSC 
analyser was calibrated by measuring the onset temperatures of the melting of indium 
(156.6 ºC) and zinc (419.5 ºC) while the heat flow was calibrated from the enthalpy of 
melting of indium (28.62 J/g). Endothermic and exothermic peaks appearing in the DSC 
traces were analysed in terms of their onset temperatures, temperature range of the 
peak (determined from the first derivative of the trace) and the enthalpy of the peak 
(measured in J/g). The various endothermic and exothermic peaks observed in the DSC 
trace were interpreted in conjunction with HSM and TGA to be associated with solvent 
loss, phase changes in the sample and decomposition. The decomposition of 
cyclodextrin inclusion complexes is a complicated and multi-stage process and is 
characterised by a number of thermal events observed with DSC. 
 
UV Spectrophotometry (UV) 
UV spectra were recorded on a BECKMAN DU® 640 series UV/visible 
spectrophotometer over a wavelength range of 190– 450 nm at a scanning rate of 1200 
nm/min. All samples were dissolved in distilled water. The samples were placed in 2 
mm quartz cuvettes and the concentrations were suitably adjusted such that all 
absorbance readings were measurable between zero and one absorbance unit. 
Calibration curves for the various drugs were constructed using readings taken at the   
λmax value of the appropriate drug. The aborbance of a solution of an inclusion complex 
with an accurately known concentration was determined. The percentage weight of the 
drug in the inclusion complex could then be determined. Together with the percentage 
weight of water in the inclusion complex, obtained from TGA, the stoichiometry of the 
inclusion complex was eventually expressed in terms of the cyclodextrin : drug : water 
ratio. Assays for the solubility tests and dissolution tests were performed using UV 
spectrophotometry at an appropriate wavelength for the active ingredient.  
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FTIR Spectroscopy (FTIR) 
IR spectra were obtained using a Perkin-Elmer 100 FTIR instrument fitted with 
UATR and controlled with Spectrum ® software for sample analysis. Samples were run 
as crystalline or amorphous powders over the range 400-4000 cm-1 (unless otherwise 
stated). Percentage transmittance was recorded against frequency. For the CD 
complexes obtained by kneading, shifts in certain characteristic bands of the appropriate 
drug molecule were indicative of interaction between CD and drug. 
 
Crystal Structure Determination  
In each case single crystals, typically between 0.2  and 0.5 mm in all dimensions, of good 
quality were selected for their ability to extinguish plane-polarised light uniformly.  
Crystals were mounted on a nylon loop and coated with paratone N oil to prevent the 
loss of included solvent and to provide a rigid mount during low temperature data-
collection.  The nylon loop was mounted on a goniometer head.   
Two single crystal X-ray diffractometers were employed in this study: a Nonius Kappa 
CCD (Charge Coupled Device) Single Crystal X-ray Diffractometer and a Bruker 
KAPPA APEX II DUO diffractometer.      
 
Data-collection   
Crystal intensity data were collected on a Nonius Kappa CCD (Charge Coupled Device) 
Single Crystal X-ray Diffractometer, using graphite-monochromated MoKα radiation (λ 
= 0.71069 Å) generated by a Nonius FR590 generator operated at 50 kV and 30 mA.  
Unit cell determinations were carried out both at ambient temperature (294 ± 2 K) as 
well as low temperature (113 ± 2  K). This check was performed to ensure there were 
no significant changes in the unit cell dimensions that might indicate phase 
transformations induced by cooling. All full intensity data-sets were measured at 113 ± 
2 K.  The low temperatures were maintained by cooling the crystals with a constant 
stream of N2 gas at a flow rate of 20 ml/min with the aid of a Cryostream cooler 
(Oxford Cryosystems, UK).  Data were corrected for Lorentz-polarisation effects; unit 
cell refinement and data-reduction were performed using the programs DENZO and 
SCALEPACK.15  All data were subjected to absorption correction using the multi-scan 
method (program SADABS16).   
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The Bruker KAPPA APEX II DUO diffractometer used graphite-monochromated Mo-
Kα radiation (λ = 0.71069 Å). The unit cells of the crystals were determined at low 
temperature (100 ± 2 K) after their removal from mother liquor. The data collections 
were carried out in the above temperature range using Cryostream coolers (Oxford 
Cryosystems, UK). Data reduction was performed using the program SAINT.17 
 
For both instruments the space group determinations were carried out by examining 
the systematic absences and matching the observed conditions to a known space 
group.18  These assignments were confirmed by running the data through the program 
XPREP.19  SHELXS-9720 input files were generated with XPREP. 
 
Structure Solution and Refinement   
The structures presented in this thesis were solved using different structure solution 
programs and a variety of methods depending on the size of the structure, quality of the 
data and nature of the problem. SHELXS-9720 was used to solve smaller structures, 
such as those of the polymorphs and co-crystal compounds. This program was, 
however, not adequate for the CD complexes due to the poor diffraction that crystals of 
these compounds exhibit, as well as the complexity of their larger structures. CD 
structures were solved by isomorphous replacement in cases where isostructural 
complexes existed, using the published coordinates of the respective cyclodextrin non-
hydrogen atoms. An alternative to this method was to use SHELXD,20 a program 
specifically designed for solving larger structures ab initio. All structures were refined 
on F2 using full-matrix least-squares in the program SHELXL-97.20 Both SHELXS-
9720 and SHELXL-9720 were accessed via the X-SEED21 interface. More detail on 
SHELXD20 and SHELXL-9720 follows below.  
 
SHELXD   
SHELXD20 is used for the ab initio solution of structures from native data when a 
solution is not likely with SHELXS-97.20  SHELXD is based on the dual-space strategy 
first introduced in the program Shake and Bake.22-26  The dual-space approach alternates 
between real and reciprocal space.  In reciprocal space, phases are expanded in 
SHELXD from the 40 % most reliable using the tangent formula devised by Karle and 
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Hauptman in 1956.27,28  The real space cycles are required to impose the strong 
constraint that it is expected to find N sites with approximately equal scattering power.  
SHELXD makes extensive use of the Patterson function to provide better than random 
starting phases for the dual-space recycling.  It is only limited by the requirement of 
atomic resolution 1.2 Å.  
 
SHELXH-9720  
Refinement in SHELXH-97 for larger structures involves minimisation of the 
function  222  co FFw  using the full-matrix least-squares technique.  The agreement 
between the observed (Fo) and calculated (Fc) structure factors is expressed by the 
residual index R1, where R1 is low for a satisfactory model and where  
R1 =     oco FFF .   
Refinement against F2 tends to magnify the deviations of the Goodness-of-Fit, S 
(defined later), from unity compared with refinement against F and therefore these 
values are not directly comparable to structures refined against F.   
The weighting scheme (w) in wR2 =     2122222     oco FwFFw  and the 
parameters a and b were refined for each structure using the following expressions:  
w =     bPaPFo  2221   and P =    320 22 co FF ,max .  The terms a and b are 
chosen in the above weighting scheme to yield constant distributions of     222 co FFw  
with sin and   21maxo FF .  S (Goodness-of-Fit) is defined by the expression 
S =     21222    pnFFw co , where n is the number of reflections and p is the 
total number of parameters refined.  For a well-behaved structure S should be close to 
unity, and the over-determination ratio should be of the order pn  ≈ 10. 
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Additional Resources 
The Cambridge Structural Database (CSD)29 was used to obtain coordinate data for the 
fragments used to solve the structures reported in this thesis.  Molecular parameters 
and geometrical data with their associated e.s.d.s and non-bonding distances were 
calculated using the program PLATON.30  WinGX31 was used as an interface for 
PLATON.  Molecular diagrams were created with POV-Ray for Windows.32  Molecular 
packing, stereo and CPK diagrams were produced using the program Weblab 
ViewerPro Version 3.5.33  Diagrams showing anisotropic thermal ellipsoids were drawn 
with the aid of Ortep-3 for Windows.34  LAYER was used for the graphic display of 
intensity data as simulated precession photographs.35 Table 2.1 lists the final 
crystallographic data files pertinent to the compounds studies. They are stored on a 
CD-rom appended to the thesis. 
 
Table 2.1.  File types found in Appendix. 
File extensions/formats Contents 
.HKL Reflection data 
.RES SHELX co-ordinate data 
.CIF Crystallographic information file 
.FCF Structure factor tables 
.LIS Platon output 
.XL SHELX output file 
.SUP Tabulated supplementary data 
 
X-ray Powder Diffraction (PXRD) 
PXRD was used to determine characteristic ‘fingerprint’ traces of crystalline materials. 
This technique can uniquely identify materials thus allowing for the identification of 
new species of polymorphs, cyclodextrin complexes and co-crystals. This technique is 
especially useful in the absence of good quality crystals for single crystal structure 
determination. Polymorphism can be detected due to different packing arrangements 
that polymorphs exhibit. CD complexes also usually have very different PXRD traces 
from those of the parent CDs due to their different packing arrangements. 
Complexation is proven if the trace is different from that of the drug and host, as well as 
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a physical mixture of the latter two, or if it corresponds to that of a known complex of 
the particular CD, the latter indicating isotructurality. 
 
Powder patterns of ground samples were recorded on a Philips PW1050/25 vertical 
goniometer with Ni-filtered CuKα radiation (λ = 1.5418 Å) produced at 40 kV and 25 
mA. Samples were packed in aluminium or glass sample holders and step scans of 0.1º 
2θ, with 2 s counting times, in the range 5-40º 2θ were employed. In cases where sample 
material was limited, PXRD patterns were recorded using a Huber Imaging Plate 
Guinier Camera 670. All samples were manually ground and packed into Lindemann 
capillaries with an internal diameter of 1 mm and a glass thickness of 0.01 mm. The 
capillaries were obtained from Hilgenberg, Germany. Nickel-filtered CuKα radiation (λ 
= 1.5418 Å), produced at 40 kV and 20 mA by a Philips PW1120/00 generator fitted 
with Huber long fine-focus tube PW2273/20 and a Huber Guinier Monochromator 
Series 611/15, were employed. For high temperature PXRD the Huber High 
Temperature Controller HTC 9643 unit was used with capillary rotation device 670.2. 
A 2θ range of 4 to 100.0º was used with step a size of 0.005º 2θ. 
 
For each successfully determined single crystal structure LAZY PULVERIX36 was 
used to generate a computed PXRD trace. These were compared with experimental 
traces to establish whether any phase transformations had taken place upon grinding 
the material in the course of preparation of samples for analysis. More importantly, 
when a match between the experimental PXRD trace and the computed PXRD pattern 
was obtained, it could be concluded that the structure of the bulk material was correctly 
represented by that of the crystal selected for full single crystal X-ray analysis. 
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Chapter 3 presents the study of polymorphism of the steroids 2-methoxyestradiol 
(2ME) and 2-methoxyestradiol-bis-sulfamate (2MES). The chapter firstly describes the 
characterisation of synthetic samples of 2ME and 2MES and secondly, illustrates the successful 
preparation and physicochemical characterisation of the different forms of 2ME and 2MES in 
the solid state. After polymorphism experimentation it was evident that there are three definitive 
forms of 2ME. Form I was recrystallised from a single solvent (diethyl ether) and matched the 
original starting material. Form II, an amorph, was identified by melt studies and Form III is 
a chloroform solvate. Only one form of 2MES (Form I) was obtained by recrystallisation from a 
single solvent (amyl alcohol) and this form matched the original starting material, a 
hemihydrate. Furthermore, the dissolution characteristics of Form I and Form II of 2ME and 
Form I of 2MES using the BP dissolution method are illustrated and from the results it is 
evident that the two steroids have significantly different dissolution profiles.   
 
3.1 INTRODUCTION  
A steroid is a terpenoid lipid characterised by its sterane core and additional functional 
groups. The core is a carbon structure of four fused rings: three cyclohexane rings and 
one cyclopentane ring (Figure 3.1). The steroids vary by the functional groups attached 
to these rings and the oxidation state of the rings. 
 
Figure 3.1 IUPAC recommended ring lettering (left) and atom numbering (right) 
of the steroid skeleton.1,2 
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Hundreds of distinct steroids are found in plants, animals, and fungi. All steroids are 
made in cells either from the sterols lanosterol (animals and fungi) or cycloartenol 
(plants). Both lanosterol and cycloartenol are derived from the cyclisation of the 
triterpene squalene.3 Sterols are special forms of steroids, with a hydroxyl group 
attached to atom C-3 and a skeleton derived from cholestane,1 with cholesterol being 
one of the best known sterols. Steroid classification can be based upon their taxonomy 
and function (Table 3.1) and chemical composition (Table 3.2). 
Table 3.1 Taxonomical and Functional Classification of Steroids 
Taxonomical and Functional Classification of Steroids 
Animal 
steroids 
Insect 
steroids 
Ecdysteroids  Ecdysterone   
Vertebrate 
steroids  
 
Steroid 
hormones 
Sex steroids Produce sex 
differences or 
support 
reproduction 
Androgens, 
estrogens, and 
progestagens 
Cortico-
steroids 
Glucocorticoids 
and 
mineralocorticoids 
Glucocorticoids 
regulate 
metabolism and  
immune 
function, 
mineralocorti-
coids help 
maintain blood 
volume and 
control renal 
excretion of 
electrolytes 
Anabolic 
steroids 
Interact with 
androgen 
receptors 
Increase muscle 
and bone 
synthesis 
Cholesterol Modulates the fluidity of cell membranes and is the 
principal constituent of the plaques implicated in 
atherosclerosis.  
Plant 
steroids  
 
Phytosterols  
 
Steroid 
alcohols 
Phytochemicals 
Brassino-
steroids 
Involved in plant processes such as cell expansion and cell elongation 
Fungus 
steroids 
Ergosterols  Provitamin 
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Table 3.2 Chemical Composition Classification of Steroids 
Class Example Number of carbon atoms 
Cholestanes Cholesterol 27 
Cholanes Cholic acid 24 
Pregnanes Progesterone 21 
Androstanes Testosterone 19 
Estranes Estradiol 18 
Gonane (or steroid nucleus) is the hypothetical parent (17-carbon tetracyclic) hydrocarbon molecule 
without any alkyl sidechains.3 
 
2-Methoxyestradiol (2ME): 
The sequential biochemical hydroxylation and methylation of the natural hormone 
estradiol gives rise to the endogenous mammalian metabolite 2ME (Figure 3.2a). In 
Chapter 1, 2ME is reviewed as a natural metabolite of estrogen inhibiting the cellular 
machinery involved in replicating cancer cells. In addition, 2ME prevents the growth of 
new blood vessels required to nourish tumours.  
 
 
 
(a)      (b) 
Figure 3.2 Chemical structures of (a) 2ME and (b) 2MES. 
 
The mechanism of action of 2ME involves disruption of cellular microtubules leading to 
mitotic arrest and initiation of apoptosis. Preclinical studies revealed that it is orally 
active, inexpensive to produce and, in general effective without toxicity, hence, further  
studies on second-generation derivatives with superior properties, including better oral 
availability and different chemosensitivity profiles have been initiated.4,5,6 Several of the 
new compounds synthesised involve structural modifications in ring A or ring B of 
2ME. Rao et al.7 looked at structural modifications of 2ME and found that structures in 
Figure 3.3 produced better biological potency than 2ME. The results also suggest that 
these new derivatives and 2ME share the same intracellular target, tubulin. 
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 (a)    (b)    (c) 
 Figure 3.3 Structural modification of 2ME.7 
  
Earlier testing of 2ME variants for inhibition of tubulin polymerisation and inhibition of 
endothelial cell proliferation seems to indicate that free hydroxyl groups at the 3- and 
17-positions are required for potent biological activity. Furthermore, 17-hydroxy 
analogues are more active than 17-oxo counterparts, thus supporting the generalisation 
for the free 17-OH group being required for potent activity. However, an exception to 
this is 2-methoxyestrone-3-O-sulfamate which was shown by Purohit et al.8 to be 10 
times as active as 2ME against human breast cancer cells. 
Other structural modifications on 2ME carried out by Cushman et al.9,10 have focused 
primarily on variations at the 2- and 6-positions of the parent compound. The authors 
concluded that the optimum 2-substituent for cytotoxic activity appears to be an 
unbranched chain containing three atoms chosen from the second row of the periodic 
table, with activity increasing with increased electron density adjacent to the aromatic 
ring. The introduction of additional unsaturation in ring D for compounds a and b 
(Figure 3.3) gives the most interesting results and leads to a modest to dramatic 
increase in cytotoxicities relative to 2ME. Whether these structural modifications lead 
to an increased binding affinity towards tubulin or perhaps a decreased rate of metabolic 
inactivation remains to be investigated.11 
 
Structural modification of 2ME is vast and ongoing and structure-activity relationships 
are fundamental in determining potency of activity of these compounds. Furthermore, 
any slight supramolecular modification (viz. different forms and packing arrangements) 
of 2ME may significantly affect physicochemical as well as structure–activity 
relationships of the compound.  
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2-Methoxyestradiol-3,17-O,O-bis-sulfamate (2MES):  
In the search for new anti-cancer therapies with improved side-effect profiles, it has 
become increasingly important to also evaluate the in vitro cancer cell specificity of 
potential drugs. 2ME has decreased stability when compared to derivative molecules 
and attempts at improving 2ME bioavailability have been conducted, most successfully 
by sulfamoylation of the original molecule.12 These sulfamoylated analogues cause 
increased cytotoxic and cytostatic activity, plasma half-life and bioavailability, whilst 
replicating the original anti-proliferative effects of 2ME. 
One of the most successful sulfamoylated analogues of 2ME is 2-methoxyestradiol-bis-
sulfamate (2MES).13 The molecule was created by the addition of sulfamate groups on 
carbons 3 and 17 (Figure 3.2b) and was originally developed as a steroid sulfatase 
inhibitor. 2MES has improved oral bioavailability, high resistance to degradation and a 
significantly decreased IC50 value (concentration of drug that inhibits cell growth by 
50%) when compared to 2ME.13,14,15 It irreversibly inhibits cancer cell proliferation and 
tumour growth in estrogen receptor positive and negative cells as well as multiple drug 
resistant (MDR) cell lines.14 The molecule is not yet commercially available and samples 
have to be synthesised individually. Figure 3.4 shows the typical morphological changes 
in 2MES-exposed cells which indicate cellular stress when compared to vehicle control 
samples. 
 
 
Figure 3.4 Transmission electron microscopy of cellular ultrastructure revealed 
slight morphological changes in 2MES-exposed cells (right) indicative of cellular 
stress when compared to vehicle control samples (left).12 
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A few properties of 2ME and 2MES are listed in Table 3.3. 2ME is sparingly soluble in 
aqueous media at pH 1 to 8 with an experimental value of 0.0048 g/L (25 ºC) across the 
pH ranges.16 At the commencement of this study, the solubility of 2MES was unknown 
and therefore one of the objectives was to determine its solubility relative to that of 
2ME. 
 
Table 3.3 Properties of 2ME and 2MES 
 2ME 2MES 
Molecular formula C19H26O3 C19H28N2O7S2 
Molecular weight 302.41 g/mol 460.55 g/mol 
Melting point 186-187 ºC 174-175 ºC 
 
Identification of Synthesised Samples of 2ME and 2MES  
Microanalysis  
The sample of 2ME used was a gift from Shimoda-Biotech (Port Elizabeth, South 
Africa). Dr Gareth Arnott (University of Cape Town) was commissioned to synthesise 
the 2MES using the 2ME as starting material. A 10 g batch was prepared and its 
structure confirmed by 1H-NMR analysis. The results of C, H and C, H, N, S 
microanalysis for 2ME and 2MES hemihydrate respectively are listed in Table 3.4. The 
experimental values agree with their respective calculated values within experimental 
error thus showing a high degree of purity in their preparation.  
 
Table 3.4 Microanalysis for 2ME (C19H26O3) and 2MES (C19H28N2O7S2•(H2O)0.5) 
synthesised material  
Steroid Experimental (n=3) Calculated  
 %C %H %N %S %C %H %N %S 
2ME 75.33 8.61 - - 75.46 8.66 - - 
2MES 48.76 6.17 5.88 13.84 48.60 6.22 5.97 13.66 
 
Henceforth, the synthesised starting materials 2ME and 2MES will be referred to as 
Form I in both instances. Many experiments using different techniques with a wide 
variety of recrystallisation solvents, were performed in order to isolate new forms of 
2ME and 2MES. Some representative results are listed in Table 3.5 and a full listing 
appears in Appendix 1 on the attached CD-rom. 
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Table 3.5 Representative recrystallisation outcomes for 2ME and 2MES 
Method 1i: Slow evaporation (59 solvents) 
Solvent Concentration 
(mg/ml) 
2ME 2MES 
Dimethylformamide 5 Form I No crystal 
Water (deionised) 5 No crystal Form I 
Acetone 5 Form I Form I 
Methylene chloride  5 Form I Form I 
Chloroform   5 Form III Form I 
Benzene 5 Form I No crystal 
Method 2ii: Sublimation  
 Hot plate (watch-
glass) 
Vacuum method 
2ME Form I Form I 
2MES Form I Form I 
Method 3ii: No grinding, neat grinding and solvent-drop grinding at various RH analysed 
every week for 7 weeks (19 solvents) 
Solvent  Mass  2ME 2MES 
No grinding 5 mg Form I Form I 
RH – 43%  Form I Form I 
RH – 98%  Form I Form I 
Neat grinding  5 mg Form I Form I 
RH – 43%  Form I Form I 
RH – 98%  Form I Form I 
Dimethyl sulfoxide 5 mg/3-4 drops Form I Form I 
RH – 43%   Form I Form I 
RH – 98%  Form I Form I 
Method 4iii: Solvent : water (95%:5%) mixtures (35 combinations with varying ratios) 
Solvent  Concentration 
(mg/ml) 
2ME 2MES 
Acetic acid 
(glacial)  
5 No crystal No crystal 
1-Propanol   5 Form I No crystal 
Methanol  5 Form I Form I 
Acetonitrile  5 Form I Form I 
Ethyl acetate 5 Form I No crystal 
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Method 5iii: Binary mixtures  (165 combinations with varying ratios) 
1º solvent  
(50%) 
2º solvent 
(50%) 
2ME 2MES 
2-propanol     
 Petroleum ether Form I No crystal 
 Hexane Form I No crystal 
 Carbon tetrachloride Form I No crystal 
Method 6iii: Vapour diffusion  
Non-Solvent Solvent 2ME 2MES 
Diethyl ether Acetone  Form I No crystal 
Diethyl ether Isopropyl Amine Form I No crystal 
Methanol Diethyl ether Form I Form I 
Method 7iv: Thermal methods  
 2ME 2MES 
Crystallisation from the melt Form II  Form I 
Method 8iii: Dicarboxylic acid (terephthalic acid) as template in solution (11 solvents 
with varying ratios) 
Ratio (Drug: 
template) 
Solvent 2ME 2MES 
1:2 Methanol  Form I No crystal  
2:1 DMF Form I No crystal 
2:1 Cyclohexanol Form I No crystal 
2:1 Glycerol Form I No crystal 
i Products obtained by method 1 were analysed by single crystal X-ray diffraction and HSM. Small 
crystals or powder masses were analysed using PXRD.  
ii Products obtained by methods 2 and 3 were analysed by PXRD 
iii Products obtained by methods 4, 5, 6 and 8 were analysed by HSM and single crystal X-ray diffraction 
iv Products obtained by method 7 were analysed by HSM and DSC 
NOTE: Vapour diffusion was employed to grow bigger crystals when crystals from slow evaporation 
were too small for diffraction purposes  
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3.3 2-METHOXYESTRADIOL FORMS  
 
Sample preparation 
Form I: Recrystallisation of 2ME from Diethyl Ether 
A saturated solution of the raw material was prepared by adding the required amount of 
drug to the respective neat solvent (diethyl ether) with heating to a few degrees below 
the boiling point of the solvent and continuous stirring. The saturated solution was 
then filtered (0.45 μm) and allowed to crystallise at ~20 ºC. Crystals were kept under 
mother liquor prior to analysis. Large crystals of 2ME with rectangular to cubic 
morphology were isolated.  
 
Form II: 2ME Amorphous 
The thermal characteristics of Form I were measured using a differential scanning 
calorimetry (DSC) instrument. The sample was heated from 30 to 190 ºC at 10 K/min, 
cooled to 30 ºC and reheated from 30 to 250 ºC at 10 K/min. DSC measures 
temperature and enthalpy (heat) associated with transitions in materials. A glassy mass 
(2ME amorphous) was found upon cooling of the melt. 
 
Form III: 2ME Chloroform Solvate 
A saturated solution of the raw material was prepared by adding the required amount of 
drug to  chloroform with continuous stirring at ~20 ºC  (no heating was required due to 
the low boiling point of the solvent viz. 60-61 ºC). The saturated solution was then 
filtered (0.45 μm) and allowed to crystallise at ~20 ºC. Crystals were kept under mother 
liquor prior to analysis. Unstable, plate-like crystals were obtained. 
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Thermal Analyses 
Hot Stage Microscopy 
HSM was used to analyse the thermal behaviour of the various crystals upon heating at 
a constant rate of 10 K/min with photographs of Form I, II and III crystals presented 
below (Figure 3.5). The analysis was performed with the sample immersed in silicone oil 
to assess the presence of included solvent as would be indicated by bubble formation. 
The photographs of the three forms were recorded at (a) start of analysis, (b) onset of 
opacity, (c) the first sign of melting, (d) completion of melt and the onset of 
decomposition. 
 
Form I remained relatively stable throughout the heating process with no change until 
185 °C. The crystal then melted and at 200 °C, the crystal started to decompose. 
 
Form II (amorphous phase) became opaque at 112 °C whereby transition to a 
crystalline form occurred. The crystalline form was identified as Form I since the next 
phase change occurred within the same melting range as Form I (185 °C). 
Decomposition of the crystal occurred at 200 °C. 
 
Form III was identified as an unstable solvated crystal since it became opaque at 65 °C 
indicating loss of the chloroform solvent. The crystal collapsed and the resulting 
powder then melted within a similar range as that for Form I. Decomposition once 
again occurred at ~ 200 °C. 
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Figure 3.5 HSM photographs of Forms I, II and III of 2ME.  
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Differential Scanning Calorimetry and Thermogravimetric Analysis 
TGA analyses for both Form I and Form II of 2ME [not shown] indicated negligible 
mass losses in the range 30-200 °C, thus confirming that they were not solvates. TGA 
and DSC analyses of Form III proved to be quite challenging since the solvate 
desolvated immediately after removal from mother liquor; however, TGA was 
eventually recorded (Figure 3.6) which established the stoichiometry of Form III. 
There was a 44.6 ± 0.1 % mass loss (n=2) which established the stoichiometry as 1:2 for 
2ME : chloroform (theoretical mass loss = 44.12 %) .  
 
 
Figure 3.6 TGA trace of Form III.  
 
DSC analysis for Form I was performed in the 30-210 °C temperature range and proved 
to correlate well with HSM findings. The DSC trace for Form I shown in Figure 3.7 
exhibited a single endotherm (173.5-192.1 °C) representing fusion.  
 
The DSC trace for Form II in Figure 3.7 (quenched melt) was as expected from the 
HSM analysis. Initially, the trace plateaued very closely to the baseline; then, between 
92.4 and 120.1 °C we see a distinct exotherm which identifies the transition from glassy 
(amorphous) phase to crystalline phase (Form I) of 2ME. This result correlates well 
with the HSM analysis where the Form II mass opacified at this stage, indicating phase 
change.      
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Figure 3.7 DSC traces of Form I and Form II.  
 
 
Experimental PXRD Patterns 
Experimental PXRD patterns of Forms I, II (amorphous form), III (before and after 
desolvation) are presented in Figure 3.8. The powder patterns of Form I, II and III 
differ significantly showing that these can serve as references for their identification. 
Form I has four intense peaks (2θ values 15.4º, 16.1º, 17.1º and 21.7º) and four weaker 
peaks (10.9°, 14.2°, 21.0° and 27.9°) which matched the original 2ME material and 
Form III desolvated. The trace for Form II had no peaks, indicating a glassy mass as 
was seen in HSM at 20 °C. The material following desolvation of Form III displayed 
the same PXRD pattern as Form I indicating that Form III reverts to the most stable 
form established thus far. It has, however, been reported that desolvation of solvates 
may improve flowability and particle size17 of the original compound. 
The experimental pattern for Form III was quite difficult to obtain since each PXRD 
run produced the Form I pattern. We account for the transformation to Form I as 
being due to rapid solvent loss during the preparation and analysis of the sample. 
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Furthermore, obtaining a PXRD pattern for Form III proved challenging since crystals 
were quite large and had to be ground for sample preparation. Grinding of the sample 
led to rapid desolvation and transformation to Form I. Eventually, after careful 
manipulation of the Form III removed from the mother liquor and immersed in silicone 
oil (without grinding), a reproducible Form III PXRD pattern was achieved.  
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Figure 3.8 PXRD pattern of Forms I (original and recrystallised), II (amorphous),  
and III (before and after desolvation). 
 
X-ray Crystallographic Analysis of Form I and Form III  
Data-collection 
Diffraction intensities were collected on a Nonius Kappa CCD diffractometer using 
graphite-monochromated MoK radiation at low temperature (-160 °C for Form I and 
-100 °C for Form III). Unit cell determinations were performed at both room 
temperature (21 °C) and low temperatures to ensure that no phase changes were 
effected on cooling the crystals. The program XPREP18 was used to determine the 
space groups of Forms I and III. For Form I Laue symmetry 2/m was confirmed for 
the collected intensity data, thus indicating the monoclinic system. The reflection 
conditions were hkl: none; h0l: none; 0k0: k=2n indicating the space groups P21 (non-
centrosymmetric) and P21/m (centrosymmetric). Since 2ME is a chiral molecule the 
former space group was the correct choice. The |E2-1| value of 0.838 confirmed this 
choice. For Form III Laue symmetry1 was confirmed for the collected intensity data, 
thus indicating the triclinic system and therefore the space group P1 (non-
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centrosymmetric) and P1 (centrosymmetric) were implied. Since the 2ME molecule is 
chiral, P1 was chosen. Intensity statistics provided by XPREP18 showed |E2-1| = 0.735 
indicating a non-centrosymmetric space group and the structure was successfully solved 
and refined in the space group P1. No disorder was observed for either structure and the 
final residual factors R1 for observed data [Fo >4σ(Fo)] were  0.0366 and 0.0297 for 
Forms I and III respectively. 
 
The unit cell determinations at room temperature and low temperature for Form I are 
presented in Table 3.6. The close similarity between the data for Form I at room 
temperature and low temperature indicates that no phase change took place on cooling 
the crystal. In the case of Form III, attempts to measure the unit cell at room 
temperature failed because the crystal spontaneously desolvated. 
 
Table 3.6 Unit cell parameters for Form I 
 Form I (21 °C*) Form I (-160 °C) 
Space group  P21  
a (Å) 6.243 6.2540(2) 
b (Å) 11.313 11.2919(3) 
c (Å) 11.567 11.5524(4) 
α (º) 90.17 90 
β (º) 97.21 97.356(1) 
γ (º) 89.91 90 
Volume (Å3) 810.43 809.11(4) 
*For room temperature unit cell data, no e.s.d.s are reported since relatively few intensity frames were 
collected 
 
Structure Solution and Refinement 
SHELXS-9719 was used for the structure solution of Forms I and III. The asymmetric 
unit of Form I comprised one 2ME molecule while that of Form III consisted of one 
2ME molecule and two chloroform (CHCl3) molecules. Direct methods revealed the 
positions of all the non-hydrogen atoms and allowed their placement. The 2ME 
molecules were included in the models with their correct known absolute configuration. 
All non-hydrogen atoms were then refined isotropically on F2 with SHELXL-9720 and 
subsequently with anisotropic thermal parameters. Hydrogen atoms were located in the 
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difference electron density maps and were then placed in fixed geometric positions using 
a riding model. They refined isotropically with thermal parameters equal to 1.2 times 
those of their parent atoms in the case of phenyl hydrogens and 1.5 times those of the 
parent atom for the methyl hydrogen atoms.  The hydroxyl hydrogen atoms were 
assigned a common variable isotropic temperature factor and were placed using the 
hydrogen bond search model. For Form I, the absence of heavy atoms led to a Flack 
parameter value that did not indicate absolute structure unequivocally. The Friedel 
opposites were therefore merged (MERG 4 in SHELXL-9720). Least-squares weights 
were employed in the final cycles of the refinement.   
 
Refinement data for low-temperature structure determinations of Form I and Form III 
are presented in Table 3.7 
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Table 3.7 Crystal and refinement data for Form I and Form III  
Parameter Form I Form III 
Molecular Formula C19H26O3 C19H26O3•2(CHCl3) 
Formula Weight/g mol-1 302.41 541.17 
Crystal System Monoclinic Triclinic 
Space group P21 P1 
a (Å) 6.2540(2) 6.3150(2) 
b (Å) 11.2919(3) 9.3352(3) 
c (Å) 11.5524(4) 11.1622(5) 
α (º) 90 104.386(2) 
β (º) 97.356(1) 95.464(2) 
γ (º) 90 107.774(2) 
Volume (Å3) 809.11(4) 596.44(4) 
Z 2 1 
Densitycalc / g cm-3 1.241 1.507 
 (MoK) / mm-1 0.082 0.742 
F(000)  328 280 
Crystal size / mm3 0.15 x 0.18 x 0.22 0.18 x 0.26 x 0.28 
Temperature (K) 113(2) 173(2) 
Range scanned  /  1.00 ≤  ≤ 26.02 3.99 ≤  ≤ 27.88 
Index ranges  h: -7, 7  k: -13, 13  l: -14, 14 h: -7, 8  k: -12, 12  l: -14, 14 
 scan angle /  1.0 1.0 
 scan angle range, frames 327, 327 363, 363 
 scan angle /  1.0 1.0 
 scan angle range, frames 134, 134 562, 562 
Dx / mm  30 30 
Total no. of reflections collected 3106 17779 
No. of unique reflections 1655 5185 
No. of reflections with I  2(I) 1373 4697 
No. of L.S. parameters 203 278 
Rint, Rσ 0.026, 0.049 0.035, 0.039 
Flack parameter 0(1) 0.03(4) 
S 1.010 1.030 
R1 [Fo >4σ(Fo)] 0.0366 0.0297 
No. of reflections omitted 3 26 
wR2 (all reflections) 0.0842 0.0721 
Weighting scheme a = 0.0487, b = 0 a = 0.0391, b = 0.1123 
( / )mean  < 0.001 < 0.001 
 excursions / eÅ-3  0.182, -0.219 0.353, -0.438 
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Description of the Structures 
With few exceptions, steroids generally crystallise in the monoclinic and orthorhombic 
crystal systems.21 Since the naturally-occurring steroids and their synthetic derivatives 
contain asymmetric centres, they must crystallise in space groups which lack inversion 
centres and mirror planes.21 Furthermore, the majority of steroids crystallise in the 
monoclinic space group P21 or the orthorhombic space group P212121. Thermal-ellipsoid 
plots of the asymmetric units of Form I and Form III are presented in Figures 3.9 and 
3.10.  
 
Figure 3.9 The asymmetric unit in Form I with thermal ellipsoids drawn at the 
50% probability level. 
 
Figure 3.10 The asymmetric unit in Form III with thermal ellipsoids drawn at the 
50% probability level. 
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Figures 3.9 and 3.10 illustrate that the 2ME molecule appears to adopt remarkably 
similar conformations in Forms I and Form III. A graphical overlay of the two 
molecules (Figure 3.11) illustrates that the two 2ME molecules are nearly perfectly 
superimposable. A detailed geometrical analysis of the respective molecules follows to 
present a more detailed comparison of their structures.  
 
 
Figure 3.11 Overlay of 2ME in Forms I (blue) and Form III (pink). 
 
Geometrical Analysis of 2ME in Form I and Form III  
Table 3.8 presents selected, representative bond distances and torsion angles of the 
2ME molecule in Form I and Form III for comparison as well as the distances and 
angles for all the strong intermolecular hydrogen bonds in both forms. In addition, the 
differences between corresponding molecular parameters for 2ME in Forms I and III 
are listed in Table 3.8. A full set of the molecular parameters is available in Appendix 4 
on the CD-ROM provided. 
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Table 3.8 Common selected geometrical parameters for the 2ME molecule in 
Form I and Form III 
Parameter Form I  Form III  |Δ| 
Selected bond 
distances (Å) 
   
O19-C17         1.431(3)      1.436(2)      0.005  
C13-C18         1.540(3)      1.535(3)      0.005  
O20-C2          1.391(3)      1.386(2)      0.005  
O20-C21         1.432(3)      1.432(3)      0.000 
O22-C3          1.366(3)      1.368(2)      0.002  
C1-C10         1.408(3)      1.407(3)      0.001  
C8-C9          1.546(3)      1.546(3)      0.000 
C13-C14         1.541(3)      1.537(3) 0.004  
Selected torsion 
angles (º) 
   
C21-O20-C2-C1  -20.6(3) -12.4(3) 8.2 
C9-C10-C5-C6 3.2(3) -0.2(3) 3.0 
C13-C14-C15-C16 -34.1(2) -36.5(2) 2.4 
C14-C15-C16-C17 7.7(2) 11.8(2) 4.1 
C15-C16-C17-C13 21.3(2) 17.1(2) 4.2 
C16-C17-C13-C14 -41.3(2) -38.9(2) 2.4 
C17-C13-C14-C15 46.7(2) 46.9(2) 0.2 
D-H•••A (Å)    
O19-H19•••O20i       2.810(3)      2.899(2)      0.089 
O22-H22•••O19ii      2.671(3)      2.669(2)      0.002 
D-H•••A (º)    
O19-H19•••O20i 154 154(2) 0 
O22-H22•••O19ii      171 177 6 
Symmetry operators for both forms: (i) x,y,1+z and (ii) -1+x,y,-1+z 
 
This geometrical comparison confirms what is illustrated in Figure 3.11, namely that 
the steroid molecules in both crystal forms have very similar geometrical features. 
Corresponding bond lengths are equal within experimental error, with torsion angles 
differing to some extent. The notable consistency of the steroid molecules in each form 
is indicative of the rigidity and stability of this conformer and therefore the following 
closer, detailed examination of its structure is necessary. 
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Overall Description of the 2ME Molecule in Form I and Form III   
The basic steroid nucleus consists of three fused six-membered rings (A, B, C) (Figures 
3.9 and 3.10) and one cyclopentane ring (ring D). Ring A is aromatic and rings B and C 
are cyclohexane rings. The standard steroid numbering and ring nomenclature are 
indicated (Figure 3.9). The asymmetric carbon atoms in 2ME are C8, C9, C13, C14 and 
C17.  As regards the conformations of the respective rings in the 2ME molecule, ring A 
is planar (since it is aromatic), ring B adopts a half-chair conformation, ring C a chair 
conformation and ring D an envelope conformation with flap at C13. The A-end21 is 
generally referred to as the head and the D-end21 is generally referred to as the tail of 
the steroid. More specifically, the head-tail designation usually refers to C3 and C17 
respectively or to substituents at these positions. Table 3.9 lists the endocyclic torsion 
angles in rings B, C and D that define their precise conformations.  
Table 3.9 Endocyclic torsion angles (º) in rings B, C and D of Form I and Form III 
Ring Form I Form III 
Ring B   
C5-C6-C7-C8 44.1(3) 37.1(2) 
C6-C7-C8-C9 -64.5(2) -64.0(2) 
C7-C8-C9-C10 52.4(2) 57.6(2) 
C8-C9-C10-C5 -22.9(3) -26.6(2) 
C9-C10-C5-C6 3.2(3) -0.2(3) 
C10-C5-C6-C7 -13.6(3) -4.7(3) 
Ring C   
C8-C9-C11-C12 53.7(3) 51.3(2) 
C9-C11-C12-C13 -54.8(3) -54.8(2) 
C11-C12-C13-C14 55.8(2) 58.1(2) 
C12-C13-C14-C8 -59.8(3) -61.5(2) 
C13-C14-C8-C9 59.0(2) 57.5(2) 
C14-C8-C9-C11 -54.5(2) -51.1(2) 
Ring D   
C13-C14-C15-C16 -34.1(2) -36.5(2) 
C14-C15-C16-C17 7.7(2) 11.8(2) 
C15-C16-C17-C13 21.3(2) 17.1(2) 
C16-C17-C13-C14 -41.3(2) -38.9(2) 
C17-C13-C14-C15 46.7(2) 46.9(2) 
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Hydrogen Bonding Motifs and Crystal Packing in Form I and Form III 
The hydrogen bonding motif for Form I is shown in Figure 3.12a. In the structure 
there are two intermolecular hydrogen bonds which create a ring with graph set 
analysis descriptor R2 2(9), as indicated.22  The 2ME molecules associate as non-
centrosymmetric, hydrogen bonded dimers, the unique H-bonds being O19-H19•••O20 
(x,y,1+z) and C16-H16A•••O22 (x,y,1+z).  The cyclic H-bonded pattern contains a total 
of nine atoms, two of them being donors and two being acceptors, and is therefore 
designated as R2 2(9). These hydrogen bonds stabilise the layered intermolecular 
arrangement vertically.  Furthermore, the H-bonds O22 - H22•••O19 (-1+x,y,-1+z) and 
O19-H19•••O20 (x,y,1+z)  stabilise the intermolecular arrangement horizontally.  
 
 
Figure 3.12 (a) Hydrogen bonding motif of Form I. Symmetry operators shown in 
light blue and hydrogen bonds in aqua. (Note: vertical and horizontal applies to 
the figure as drawn). 
R2 2(9) 
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Figure 3.12b is a stereoview of the extended packing within a layer of 2ME molecules. 
The ‘dimer’ of Figure 3.12a is seen to propagate in a polymeric fashion producing 
inifinite ribbons in the vertical direction. These ribbons are linked horizontally by 
O-H•••O hydrogen bonds. 
 
 
Figure 3.12 (b) Stereoview of hydrogen bonding in Form I. Hydrogen bonds in 
aqua. 
 
 
Figure 3.13a shows the O-H•••O hydrogen bonds of Form III excluding the chloroform 
molecules for the purpose of clarity. The two intermolecular bonds seen are exactly the 
same as those illustrated in Form I. These two bonds viz. O22-H22•••O19  
(-1+x,y,-1+z) and O19-H19•••O20 (x,y,1+z) contribute to the formation of continuous 
ribbons of 2ME molecules related by translation along the x-direction.  
 
 
 
 
 
 
z 
o x 
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Figure 3.13b shows the hydrogen bonding motif of Form III inclusive of four hydrogen 
bonds (one of the two chloroform molecules is now included in the illustration). Two of 
these intermolecular hydrogen bonds (C-H•••O) give rise to the ring motif with graph 
set descriptor R 21 (5) shown. The 2ME molecule bonds with a chloroform molecule via 
the hydrogen bonds C23-H23•••O20 and C23-H23•••O22. The two bonds contain a 
total of five atoms, one of them being a donor and two atoms being acceptors, and the 
motif is hence designated as R 21 (5).  
 
 
Figure 3.13 (a) Hydrogen bonding motif of Form III omitting chloroform 
molecules. Symmetry operators shown in light blue and hydrogen bonds in aqua. 
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Figure 3.13 (b) Hydrogen bonding motif of Form III including one of the 
crystallographically independent CHCl3 molecules. Symmetry operators shown in 
light blue and hydrogen bonds in aqua. 
 
 
Figure 3.13c is a stereoview of the crystal packing in Form III. The hydrogen bonded 
2ME molecules form a layer, upon which the CHCl3 molecules are themselves layered. 
One of the CHCl3 molecules engages in hydrogen bonding (C-H•••O) to the 2ME layer, 
as indicated, while the other is involved in a C-H•••π interaction with the A-ring of the 
2ME molecule.  
 
       
Figure 3.13 (c) Stereoview of hydrogen bonding in Form III. Hydrogen bonds 
shown in aqua. 
R 21 (5) 
a 
o z 
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Hydrogen Bonding Interactions in Form I and Form III  
Table 3.10 lists all the intermolecular hydrogen bonds for both Form I and Form III as 
calculated by PLATON.23 All hydrogen bonds are formed with head-to-tail (A ring to D 
ring) arrangement. Noticeably, Form I has an additional hydrogen bond between 2ME 
molecules. Analogous hydrogen bonds made within Forms I and III are  
O22-H22•••O19 (-1+x,y,-1+z) and O19-H19•••O20 (x,y,1+z). In addition, Form I 
features a C16-H16A•••O22 bond which is the second hydrogen bond to O22.  In fact 
each of the three O-atoms in both forms engages in two hydrogen bonds. Atom H23 of 
one of the two CHCl3 molecules in the asymmetric unit engages in bifurcated C-H•••O 
hydrogen bonding with O20 and O22. The second chloroform molecule engages in the 
C-H•••π interaction described above. These interactions are clearly shown in Figure 
3.13c.  
 
Table 3.10 Hydrogen bonding interactions for Form I and Form III  
Hydrogen bond H•••A (Å) D•••A (Å) D-H•••A (º) Symmetry 
codes 
Form I      
O19-H19•••O20 2.03 2.810(3) 154 x,y,1+z 
O22-H22•••O19 1.84 2.671(3) 171 -1+x,y,-1+z 
C16-H16A•••O22 2.53 3.454(3) 154 x,y,1+z 
Form III      
O19 - H19•••O20 2.12(2) 2.899(2) 154(2) x,y,1+z 
O22 - H22•••O19 1.83 2.669(2) 177 -1+x,y,-1+z 
C23 - H23•••O20 2.57 3.467(3) 149  
C23 - H23•••O22 2.43 3.256(3) 139  
C24 - H24•••Cg(A) 2.73 3.621(3) 148  
 
Chloroform molecules are located between the assemblies of the 2ME molecules as 
shown in Figure 3.14.  No guest-guest interactions are observed within the layers. 
Figure 3.15 illustrates a space-filling diagram along [001], indicating that each 
chloroform molecule appears to be slightly hidden by 2ME molecules, by implication, 
presenting  a very closely packed layered arrangement. 
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Figure 3.14 Space-filling illustration of Form III along [100]. 
 
  
 
Figure 3.15 Space-filling illustration of Form III along [001]. 
 
The program SECTION24 was used to examine the topology of guest (chloroform) 
inclusion in the Form III crystal. This program draws atoms with their van der Waals 
radii at desired intervals along a selected crystal axis, thus revealing features of the 
packing such as channels or isolated sites which may accommodate guest molecules. In 
Figure 3.16a and 3.16b the unit cell is sectioned at two representative values of x. Guest 
chloroform molecules are shown in blue and they clearly occupy layers that exist 
o 
x 
y 
o 
z
y 
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between layers of host 2ME molecules (grey). The layers run parallel to the xz-plane 
and the CHCl3 molecules occur in pairs, separated by small intervals along z. Such 
layers provide obvious paths for diffusion of CHCl3 molecules out of crystals of Form 
III and their presence explains the rapid desolvation observed for this solvate even at 
room temperature. 
 
   
     (a)           (b) 
Figure 3.16 Sections through Form III illustrating guest in blue between layers of 
2ME molecules represented by grey areas, viewed along [100] with the unit cell 
sectioned at representative levels (a) 0 Å and (b) 3.4 Å from 0,0,0. Chloroform 
molecules are omitted in the upper diagrams. 
 
Calculated PXRD Patterns 
Following the structural refinements, the single crystal X-ray data were used to 
compute simulated PXRD patterns with the program Lazy-Pulverix.25 The peaks of the 
computed versus experimental patterns (Figure 3.17) for each of Form I and III 
matched in their respective numbers and 2θ positions. The relative intensity 
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distribution of the peaks of the experimental pattern is similar to that of the computed 
pattern in each case indicating the lack of preferred orientation in the analysed sample. 
The close agreement of experimental and computed patterns is also an indication of the 
correctness of the single X-ray crystal structural models. The slight shifts of the 
experimental patterns with respect to the computed patterns to lower 2θ are due to the 
temperature differences at which the respective traces were obtained. For each of  
Form I and Form III, correspondence between the experimental and calculated PXRD 
patterns also indicates that the bulk materials represent pure phases. 
0
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Figure 3.17 Calculated vs experimental PXRD patterns for Form I and Form 
III of 2ME. 
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3.3. 2-METHOXYESTRADIOL-bis-SULFAMATE HEMIHYDRATE  
Characterisation of Synthesized Sample of 2MES (Form I) 
Microanalysis and Thermogravimetric Analysis 
The result of CHNS microanalysis for Form I was established before commencement of 
recrystallisation experiments (Table 3.4). Furthermore, initial thermogravimetric 
analysis (TGA) of Form I (not shown since analogous to Figure 3.19) presented a 2.1 ± 
0.2 % (n=3) mass loss in the temperature range 30-175 ºC, which established the 
MES:H2O ratio as 2:1 (theoretical mass loss = 1.92 %).  
 
Sample Preparation 
Form I: Recrystallisation of 2MES Hemihydrate  
A saturated solution of the raw material was prepared by adding the required amount of 
drug to amyl alcohol with heating to a few degrees below the boiling point of the 
solvent with continuous stirring. The saturated solution was then filtered (0.45 μm) and 
allowed to crystallise at ~20 ºC. Crystals were kept under mother liquor prior to 
analysis. Large plate-like crystals of 2MES hemihydrate were harvested. 
 
Thermal Analyses 
Hot Stage Microscopy 
HSM photographs of Form I are presented below (Figure 3.18). Thermal behaviour of 
Form I was observed upon heating at a constant rate of 10 K/min. The analysis was 
performed with crystals immersed in silicone oil to assess the presence of included 
solvent as commonly indicated by bubble formation. The photographs of Form I were 
recorded at (a) the start of the analysis, (b) the first indication of bubbling due to 
dehydration (range ~90 - 160 ºC, (c) the first sign of melting (~175 ºC) and (d) the onset 
of decomposition of the anhydrous phase (indicated by colour change of the colourless 
crystal to brown) and the subsequent appearance of bubbling as a result of 
decomposition.  
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Figure 3.18 HSM photographs of Form I recorded at various temperatures. 
  
Differential Scanning Calorimetry and Thermogravimetric Analysis 
The TGA trace (Figure 3.19) for the recrystallised sample of Form I presented a 2.2 ± 
0.2 % (n=3) mass loss (theoretical mass loss = 1.92 %) in the temperature range 30-
175ºC, establishing the MES:H2O ratio as 2:1 which matched the original starting 
material. It is evident from Figures 3.18, 3.19 and 3.20 that the compound 
spontaneously degrades upon reaching the melting point. Consequently, loss of solvent 
is indicated from 30-175ºC and thereafter the second mass loss step commences upon 
degradation and therefore cannot be accounted for as solvent loss. Furthermore, very 
significant degradation of 2MES occurs beyond 175 ºC (indicated by the third step). To 
maintain the purity of the compound during experimentation, Form I had to be stored 
under special conditions avoiding light and maintaining a temperature of 25 °C owing 
to possible photodegradation. [To test the storage conditions of Form I, it was noted 
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that upon exposing 2MES to constant light for prolonged periods it started to discolour 
(turned brown) indicating degradation].  
 
Figure 3.19 TGA trace of Form I.  
 
The DSC trace (Figure 3.20) for Form I indicates an endotherm between 170 ºC and 
179 ºC, peaking at 175 ºC with immediate exothermic effect following. This correlates 
well with HSM analysis. Form I was further analysed immediately after melting had 
occurred by subjecting the melted sample to quenched cooling to detect whether any 
further polymorphic forms would arise. Degradation of Form I was again confirmed by 
the absence of an expected glass transition in the DSC trace of the quenched melt 
(Figure 3.20). 
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Figure 3.20 DSC trace of Form I and quenched melt.  
 
Experimental PXRD Pattern  
The PXRD patterns for Form I (those of both the originally synthesised material and 
material recrystallised from amyl alcohol) are shown in Figure 3.21. These patterns are 
practically indistinguishable and serve as references for this phase. The pattern is quite 
distinct, with five strong peaks appearing at 2θ values 7.9, 12.9, 15.9, 18.9 and 20.1°.  
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Figure 3.21 Experimental PXRD patterns of Form I.   
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X-ray Crystallographic Analysis of Form I of 2MES 
Data-collection 
Multiple data-collections and structure refinements were performed to overcome a 
crystal twinning problem. Crystal twinning occurs when two separate crystals share 
some of the same crystal lattice points in a symmetrical manner. The result is an 
intergrowth of two separate crystals in a variety of specific configurations. A twin 
boundary or composition surface separates the two crystals. Twinning can originate in 
three ways: as growth twins, transformation twins and glide or deformation twins. 
Form I was classified as a growth twinned crystal which may be a contact twin or 
penetration twinned crystal and hence X-ray diffraction results from apparently single 
crystals were quite misleading. On testing several different crystals on the 
diffractometer, a monoclinic unit cell was persistently indicated. Full data-collection 
followed and a structural model was obtained in the monoclinic space group P21.  
However, this did not refine satisfactorily. Further careful examination of the reciprocal 
lattice revealed the twinning described above with either rotation, reflection, or glide 
deformation occurring. The relationship of the twinned crystal and its counterpart may 
be expressed in terms of a symmetry operation needed to bring it about, the most 
common type of which is formed by rotation of 180º about a zone axis, leading to 
pseudo-twofold symmetry. For the least troublesome crystal specimen investigated, it 
was found that the reciprocal lattices of the twin components were rotated by ~3º 
relative to one another. However, it was not possible to measure accurately the 
reflection intensities from the major component only, though attempts were made to do 
so. Eventually, a very thin lamina section was selected and this showed no indication of 
twinning, yielding an orthorhombic unit cell. Selection of this specimen, with one very 
small dimension (~0.08 mm), did however compromise the ability to correct the final 
intensities adequately for absorption error, as described further below. 
 
Diffraction intensities were collected on a Bruker Apex Duo diffractometer using 
graphite-monochromated MoK radiation at room temperature (21 °C) and low 
temperature (-160 °C). Unit cell determinations were performed at both these 
temperatures (Table 3.11) to ensure that no phase change occurred on cooling the 
crystal.   
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Table 3.11 Unit cell parameters for Form I  
 Form I  
21 °C* 
Form I 
 -160 °C 
Space group  P212121 (orthorhombic) 
a (Å) 9.52 9.499(1) 
b (Å) 10.62 10.585(2)  
c (Å) 43.75 43.643(6) 
α (º) 90 90 
β (º) 90 90 
γ (º) 90 90 
Volume (Å3) 4424 4388.1(1) 
*For room temperature unit cell data, no e.s.d.s are reported since relatively few intensity frames were 
collected. 
 
From Table 3.11, it is evident that no phase change occurred on cooling the crystal to 
-160 ºC, the temperature of the final data-collection. The program XPREP18 was used 
to determine the space group of Form I. Laue symmetry mmm was confirmed for the 
collected intensity data, thus indicating the orthorhombic system. The space group 
P212121 (No. 19) was deduced from the reflection conditions h00: h=2n; 0k0: k=2n; 00l: 
l=2n. Inspection of the reciprocal lattice layers with LAYER26 confirmed these 
reflection conditions. Intensity statistics provided by XPREP18 yielded |E2-1| = 0.687, 
consistent with the non-centrosymmetric space group.   
 
Structure Solution and Refinement 
The asymmetric unit of Form I comprised two 2MES molecules and one water 
molecule. SHELXS-9719 was used for the structure solution. The E-map resulting from 
routine direct methods computations revealed the positions of all the non-hydrogen 
atoms and allowed their placement. The 2MES molecules were included in the model 
with their correct known absolute configuration. All non-hydrogen atoms were initially 
refined isotropically on F2 with SHELXL-9720 and subsequently anisotropically. 
Hydrogen atoms on the 2MES molecules were located in difference electron density 
maps and were placed in fixed geometric positions using a riding model. They refined 
isotropically with thermal parameters equal to 1.2 and 1.3 times those of their parent 
atoms. The hydroxyl hydrogen atoms were assigned a common variable isotropic 
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temperature factor and were placed using the hydrogen bond search model. Suitable 
positions of the hydrogen atoms on the water molecule, consistent with reasonable 
hydrogen bonding, were identified and these H atoms were added to the model with 
appropriate O-H distance restraints. The Flack parameter value did not indicate 
absolute structure unequivocally. The Friedel opposites were therefore merged (MERG 
4 in SHELXL-9720). Least-squares weights were employed in the final cycles of the 
refinement.  
 
Atoms O29A and C3B were refined isotropically since attempted anisotropic refinement 
resulted in least-squares matrix singularities. The highest residual peak not allocated 
had density 2.52 eÅ-3 which was quite significant, appearing at 0.99 Å from S27B. This 
peak was attributed to residual absorption error as it had no chemical significance. It 
was noted earlier that to avoid the problem of crystal twinning, a thin lamina of Form I 
was necessarily selected for the X-ray analysis. Although the transmission range for the 
specimen selected for data-collection was moderate (Tmin =0.929, Tmax=0.976) and the 
intensity data were corrected for absorption (program SADABS),27 nonetheless the 
large  peak of  2.52 eÅ-3 in the vicinity of atom S27B remained. This, furthermore 
contributed to the high final residual factor R1 [F◦ >4σ(F◦)] of 0.1030. The deepest hole 
of -1.22 eÅ-3 appeared at 0.71 Å from S27A. Twenty-one distance restraints were 
applied to the model to maintain reasonable geometries while the standard deviation 
used for restrained bond lengths was σ = 0.005 Å for two of these and 0.01 Å for the 
additional 19 restraints. Crystal and refinement data for the low temperature X-ray 
analysis are presented in Table 3.12. 
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Table 3.12 Crystal and refinement data for Form I  
Parameter Form I  
Molecular Formula C19H28N2O7S2•(H2O)0.5 
Formula Weight/g mol-1 469.56 
Crystal System Orthorhombic 
Space group P212121 
a (Å) 9.499(1) 
b (Å) 10.585(2)  
c (Å) 43.643(6) 
α (º) 90 
β (º) 90 
γ (º) 90 
Volume (Å3) 4388.1(1) 
Z 8 
Densitycalc / g cm-3 1.424 
 (MoK) / mm-1 0.289 
F(000)  1992 
Crystal size / mm3 0.083 x 0.179 x 0.26 
Temperature (K) 173(2) 
Range scanned  /  1.9 ≤  ≤  25.2 
Index ranges  h: -11, 11             k: -12, 12             l: -51, 51 
 scan angle /  0.5 
 scan angle /  0.5 
Dx / mm  51 
Total no. of reflections collected 29060 
No. of unique reflections 4441 
No. of reflections with I  2(I) 4076 
No. of L.S. parameters 574 
Rint, Rσ 0.049, 0.0313 
Flack parameter 0(1) 
S 1.106 
R1 [F◦ >4σ(F◦)] 0.1030 
No. of reflections omitted 1 
wR2 (all reflections) 0.2428 
Weighting scheme a = 0.0578,  b =56.446 
( / )mean  < 0.001 
 excursions / eÅ-3  2.52, -1.22 
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Description of Form I  
The thermal-ellipsoid plot of the asymmetric unit of Form I is presented in Figure 3.22.   
 
 
Figure 3.22 The asymmetric unit in Form I with thermal ellipsoids drawn at the 
50% probability level. 
 
In Figure 3.23, a graphical overlay of molecules A and B of the asymmetric unit in the 
crystal of 2MES hemihydrate is presented. This illustrates that there is a remarkable 
similarity between the two molecules. Figure 3.24,  a graphical overlay of 2MES and 
2ME (Form I), illustrates that there is a remarkable similarity between the two 
molecules with respect to the common rigid steroid backbone, i.e. rings A, B, C and D. 
These figures illustrate nearly perfectly superimposable molecules. A detailed 
geometrical analysis of the respective molecules follows to present a more detailed 
comparison of their structures.  
 
Molecule A 
Molecule B 
Water 
molecule  
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Figure 3.23 Overlay of the crystallographically independent molecules A (purple) 
and B (green) in the asymmetric unit of Form I of 2MES. 
 
 
 
Figure 3.24 Overlay of 2MES (green – molecule B chosen arbitrarily) and 2ME 
(Form I) (blue). 
 
Geometrical Analysis of 2MES in Form I  
Table 3.13 presents selected, representative bond distances and torsion angles of the 
2MES-A and 2MES-B molecules of Form I for comparison. The differences between 
corresponding molecular parameters are also listed in Table 3.13. A full set of the 
molecular parameters is available in Appendix 4 on the CD-ROM provided. 
 
This evaluation validates what Figure 3.23 attempts to show, namely that the 
independent steroid molecules are geometrically almost indistinguishable. The notable 
consistency of the steroid molecules in each form is suggestive of the rigidity and 
stability of this conformer. A closer, comprehensive inspection of its structure follows. 
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Table 3.13 Common representative geometrical parameters for Form I (2MES-A 
and 2MES-B molecules) 
Parameter 2MES-A  2MES-B  |Δ| 
Selected bond 
distances (Å) 
   
O19-C17         1.479(2) 1.446(1) 0.033 
C13-C18         1.527(2) 1.543(2) 0.016 
O20-C2          1.355(1) 1.380(1) 0.025 
O20-C21         1.434(1) 1.432(1) 0.002 
O22-C3          1.406(1) 1.416(1) 0.010 
C1-C10         1.409(1) 1.401(1) 0.008 
C8-C9          1.526(2) 1.560(1) 0.034 
C13-C14         1.541(2) 1.532(2) 0.009 
O19-S27 1.582(1)   1.515(1) 0.067 
S27-O29 1.429(1) 1.390(1)    0.102 
S27-O28 1.415(9)   1.447(1) 0.032 
S27-N30 1.587(1)   1.579(1)     0.008 
O22-S23 1.617(7) 1.626(7) 0.009 
S23-O24 1.421(7)   1.424(8) 0.003 
S23-O25 1.409(8) 1.434(8) 0.025 
S23-N26 1.577(9) 1.583(1) 0.006 
Selected torsion 
angles (º) 
   
C21-O20-C2-C1  -2.5(1) -0.7(1) 1.8 
C9-C10-C5-C6 4.5(2) 3.0(1) 1.5 
C13-C14-C15-C16 -35.4(1) -32.8(1) 2.6 
C14-C15-C16-C17 7.2(1) 5.7(1) 1.5 
C15-C16-C17-C13 23.6(1) 23.2(1) 0.4 
C16-C17-C13-C14 -43.8(1) -42.1(1) 1.7 
C17-C13-C14-C15 48.9(1) 44.9(1) 4.0 
C17-O19-S27-O28 63.3(1) 58.0(1) 5.3 
C17-O19-S27-O29 -171.9(9) -179.0(1) 7.1 
C17-O19-S27-N30 -52.5(1) -59.4(1) 6.9 
O24-S23-O22-C3 34.5(7) -34.2(7) 0.3 
O25-S23-O22-C3   163.1(7) -162.1(6) 1.0 
N26-S23-O22-C3 -81.6(7) 82.3(7) 0.7 
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Next, we discuss the similarity between 2ME in Form I and 2MES-B (arbitrarily 
chosen) in Form I as illustrated in Figure 3.24. The consistency of the rigid steroidal 
backbone, i.e. rings A, B, C and D, is presented in Table 3.14. The only selected torsion 
angle with a very significant difference was C21-O20-C2-C1 with a |Δ| = 19.9 º. 
 
Table 3.14 Common representative geometrical parameters for 2ME in Form I 
and 2MES-B in Form I 
Parameter 2ME  
(Form I)  
2MES-B (Form I)  |Δ| 
Selected bond 
distances (Å) 
   
O19-C17         1.431(3)      1.446(1) 0.015 
C13-C18         1.540(3)      1.543(2) 0.003 
O20-C2          1.391(3)      1.380(1) 0.011 
O20-C21         1.432(3)      1.432(1) 0.000 
O22-C3          1.366(3)      1.416(1) 0.050 
C1-C10         1.408(3)      1.401(1) 0.007 
C8-C9          1.546(3)      1.560(1) 0.014 
C13-C14         1.541(3)      1.532(2) 0.009 
Selected torsion 
angles (º) 
   
C21-O20-C2-C1  -20.6(3) -0.7(1) 19.9 
C9-C10-C5-C6 3.2(3) 3.0(1) 0.2 
C13-C14-C15-C16 -34.1(2) -32.8(1) 1.3 
C14-C15-C16-C17 7.7(2) 5.7(1) 2.0 
C15-C16-C17-C13 21.3(2) 23.2(1) 1.9 
C16-C17-C13-C14 -41.3(2) -42.1(1) 0.8 
C17-C13-C14-C15 46.7(2) 44.9(1) 1.8 
 
Overall Description of Form I 
The molecular structures of 2MES-A and 2MES-B are chemically identical and the 
same remarks that applied to the parent steroid 2ME as far as ring conformations are 
concerned apply to the 2MES molecules. In particular, the D-ring again adopts an 
envelope conformation with a flap at C13. Relevant endocyclic torsion angles for 2MES-
A and 2MES-B are listed in Table 3.15. 
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Table 3.15 Endocyclic torsion angles (º) in rings B, C and D of 2MES-A and 
2MES-B in Form I 
Ring 2MES-A 2MES-B 
Ring B   
C5-C6-C7-C8 49.9(1) 47.2(1) 
C6-C7-C8-C9 -67.3(1) -69.1(1) 
C7-C8-C9-C10 50.2(1) 54.4(1) 
C8-C9-C10-C5 -19.7(1) -22.4(1) 
C9-C10-C5-C6 4.6(2) 3.0(1) 
C10-C5-C6-C7 -19.6(2) -14.7(1) 
Ring C   
C8-C9-C11-C12 56.3(1) 51.3(1) 
C9-C11-C12-C13 -55.7(1) -54.0(1) 
C11-C12-C13-C14 56.0(1) 57.6(1) 
C12-C13-C14-C8 -60.0(1) -61.4(1) 
C13-C14-C8-C9 61.7(1) 56.1(1) 
C14-C8-C9-C11 -58.5(1) -51.0(1) 
Ring D   
C13-C14-C15-C16 -35.4(1) -32.8(1) 
C14-C15-C16-C17 7.2(1) 5.7(1) 
C15-C16-C17-C13 23.6(1) 23.2(1) 
C16-C17-C13-C14 -43.8(1) -42.1(1) 
C17-C13-C14-C15 48.9(1) 44.9(1) 
 
The A and D ends of the 2MES molecule have a sulfamate group attached to C3 and to 
C17 respectively. The sulfamate groups render the 2MES molecule more soluble in 
aqueous media than the parent 2ME steroid molecule. These –SO2NH2 groups are 
located at the equatorial positions on their respective D-rings in molecules A and B. 
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Hydrogen Bonding Motifs in Form I 
The hydrogen bonding motif in Form I is illustrated in Figure 3.25. We see a dimeric  
H-bonded motif of the 2MES molecules in the asymmetric unit. There are two 
intermolecular hydrogen bonds that generate a ring which has a graph set analysis 
descriptor R2 2(8), as indicated.22 The unique H-bonds are N26A-H26B•••O25B and 
N26B-H26D•••O24A. The cyclic H-bonded pattern contains a total of eight atoms, two 
of them being donors and two being acceptors, and is therefore designated as R2 2(8). A 
second ring (intramolecular) with graph set descriptor S 11 (5) occurs including 5 atoms 
with one acceptor and one donor. This bond stabilises the sulfamate conformation at the 
D-end of molecule A. 
 
Figure 3.25 Dimeric hydrogen-bonded motif in the 2MES hemihydrate crystal.  
 
 
 
 
 
 
 
 
R2 2(8) 
S 11 (5) 
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Hydrogen Bonding Interactions in Form I  
Table 3.16 lists all the hydrogen bonds for Form I as calculated by PLATON.23 Of the 
sixteen hydrogen bonds, one is intramolecular (highlighted in bold) and 15 are 
intermolecular bonds. 
 
Table 3.16 Hydrogen bonding interactions in Form I  
Hydrogen bond H•••A (Å) D•••A (Å) D-H•••A 
(º) 
Symmetry codes 
O1-H11•••O29B 2.07(5) 3.036(2) 168(4) -x,-1/2+y,3/2-z 
O1-H12•••O29A 2.23(7) 3.143(2) 153(8) -1/2+x,3/2-y,2-z 
N26A-H26A•••O20A 2.05(9) 2.956(1) 167(1)   -1/2+x,3/2-y,2-z 
N26A-H26A•••O22A 2.55(1) 3.009(1) 111(9) -1/2+x,3/2-y,2-z 
N26A-H26B•••O25B 2.17(1) 2.980(1) 148(9)  
N26B-H26C•••O20B 2.04(7) 2.874(1) 151(1) 1/2+x,5/2-y,2-z 
N26B-H26C•••O22B 2.56(1) 3.004(1) 110(9) 1/2+x,5/2-y,2-z 
N26B-H26D•••O24A 2.05(1) 2.968(1) 177(1)  
N30A-H30B•••O29B 2.34(7) 3.129(1) 143(7) -1/2-x,2-y,1/2+z 
N30B-H30C•••O29A 2.23(6) 3.023(2) 143(5) 1/2-x,2-y,-1/2+z 
N30B-H30D•••O1 1.83(4) 2.756(2) 170(6)  
C4B-H4B•••O24B 2.54 3.434(1) 158 1/2+x,5/2-y,2-z 
C12A-H12A•••O28B 2.42 3.359(2) 158 1/2+x,3/2-y,2-z 
C17A-H17A•••O29A 2.59 3.013(2) 105  
C21A-H21B•••O25B 2.40 3.303(1) 153 1+x,y,z 
C21B-H21E•••O24A 2.42 3.320(1)   152 -1+x,y,z 
 
Twelve host-host intermolecular hydrogen bonds exist of which eight are N-H•••O 
interactions and four are C-H•••O interactions. The average distance for the N-H•••O 
and C-H•••O interactions are 2.99 (N•••O) and 3.35 Å (C•••O) respectively while the 
average angles are 144 and 155º, respectively. There are three host-guest 
(2MES•••water) hydrogen bonds, including two O-H•••O and one N-H•••O bond. 
Figure 3.26 illustrates the hydrogen bond interactions for the 2MES hemihydrate 
which bind three 2MES molecules within the cell.  Positions for hydrogen atoms on the 
water molecule were manually generated to account for reasonable H-bonding. The 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3: Crystal Forms of 2-Methoxyestradiol and its bis-Sulfamate 
 
 144
water molecule clearly plays a pivotal role in the crystal, linking the different 2MES 
molecules through hydrogen bonding to their hydrophilic sulfamate groups. 
   
 
Figure 3.26 The role of the water molecule in the crystal of 2MES hemihydrate. 
Symmetry operators shown in light blue and hydrogen bonds in aqua. 
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Crystal Packing in Form I  
Figure 3.27 presents crystal packing diagrams for Form I viewed along the crystal a- 
and b-axes. 2MES molecules pack head-to-head (A-ring to A-ring) and tail-to-tail  
(D-ring to D-ring) in a herring-bone style. An individual 2MES molecule bonds with an 
adjacent 2MES molecule on either end through bridging hydrogen bonds with the 
water molecule. Water molecules are located in isolated sites in the crystal of Form I, 
which accounts for the thermal stability of this hemihydrate. 
  
 
Figure 3.27 Packing in Form I of 2MES projected down [100] and [010].  
 
 
Calculated PXRD Pattern 
The level of agreement between the computed and experimental patterns of Form I 
(Figure 3.28) is very reasonable. This is an indication of the correctness of the single 
crystal structural model. As usually occurs, the calculated peak positions lie at slightly 
higher 2θ values than their experimental counterparts. This arises because of the 
o 
z
y 
o z
x 
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shrinkage of the unit cell of the single crystal at the low temperature of the data-
collection (-160 ºC). 
Variable temperature PXRD patterns were recorded for Form I. No indication of form 
change over the temperature range 21 ºC to -160 ºC was observed. The experimental 
pattern also suggests clear representation of 2MES hemihydrate within the bulk of the 
sample.  
 
0
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Form I experimental
 
Figure 3.28 Calculated and experimental PXRD patterns for Form I of 2MES 
 
 
3.4 SOLUBILITY AND DISSOLUTION OF 2ME CRYSTALLINE (FORM I), 
2ME AMORPHOUS (FORM II) AND 2MES HEMIHYDRATE  (FORM I) 
 
The aqueous solubility of 2MES hemihydrate was determined experimentally using the 
following procedure: A saturated solution of 2MES hemihydrate was obtained by 
stirring excess powdered solute with solvent (distilled water) in a small glass container 
for 7 days at 25 °C until equilibrium was attained. Equilibrium attainment was 
determined by several samplings of the solubility experiment and their assay for 2MES 
by UV spectrophotometry since no prior information was available. This was achieved 
by sampling the 2MES concentration every 8 hours during the 7 days of agitation until 
the last three sample points were equal, indicating equilibrium. While conducting this 
exercise it was important not to replace the solvent removed during sampling since this 
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would drive the system away from equilibrium. It was essential that some undissolved 
solid be present at the completion of this stage in order to ensure that the solution was 
saturated.28 Since 2MES hemihydrate presented a photo-labile system, protection from 
light was achieved by covering the glass container with an opaque material such as 
aluminium foil.  
 
A sample of the saturated solution was obtained for analysis by separating it from the 
undissolved solid. Filtration through a 0.45 μm membrane filter was used and 
precautions were taken to ensure that it was carried out at the temperature of the 
solubility determination in order to prevent any change in the equilibrium between 
dissolved and undissolved solute.28 The concentration of 2MES hemihydrate in the 
saturated solution was determined by UV spectrophotometry at 199 nm. A standard 
curve of concentration of 2MES hemihydrate versus absorbance was plotted. The 
concentration of 2MES hemihydrate was subsequently determined from the calibration 
curve y = 0.0246x – 0.1762 (R2 = 0.8848) where y=0 and x=0.0005.   
 
As reported earlier in Chapter 3, the solubility of 2ME in water is 0.005g/L at a pH of 7 
and 25 ºC. The solubility of 2MES hemihydrate was determined and it was found to 
have a solubility of 0.010 ± 0.002 g/L (25 ºC) at pH 7 in water, hence twice the 
solubility of 2ME. 
 
In vitro dissolution studies of 2ME, amorphous 2ME and 2MES hemihydrate were 
conducted using the rotating basket method (at 37 ºC) as described in Chapter 2. The 
dissolution profiles for 2ME, amorphous 2ME and 2MES hemihydrate are shown in 
Figure 3.29. The assays were measured by UV spectrophotometry at 198 nm for 2ME 
and amorphous 2ME and at 199 nm for 2MES hemihydrate in distilled water. A 
standard curve of concentration of 2ME and 2MES in distilled water versus absorbance 
was plotted.  
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Figure 3.29 Dissolution of 2ME, amorphous 2ME and 2MES hemihydrate at 37 ºC 
in distilled water. 
 
The British Pharmacopoeia (BP)29 requires that 70% dissolution must be met by each of 
the capsules tested (or by all but one of the total number of units if a retest is performed) 
and that the percentage is in terms of the stated amount. Taking account of permissible 
assay ranges and content uniformity, this pharmacopoeial dissolution requirement is 
considered to offer an acceptable degree of assurance of 'total dissolution'. The choice of 
a time is somewhat arbitrary, but 45 min is considered satisfactory for the majority of 
conventional-release (non-modified-release) products.  
 
Figure 3.29 indicates that none of the three phases investigated passed the BP 
dissolution test. However, we see a significant increase in dissolution of both 2MES 
hemihydrate and amorphous 2ME compared to 2ME. We find that at 15 min, the 
percentage concentrations of 2MES hemihydrate, amorphous 2ME and 2ME are 45, 32, 
and 25 %, respectively.  There is a further ~10 % increase in dissolution for all three 
profiles by 150 min. Amorphous 2ME indicated a further ~10 % increase in dissolution 
by the end of the 3 h run. In fact, there is a steady increase in the amorphous 2ME 
profile from time zero to 3 h.  
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The amorphous solid state possesses several advantages in comparison to the crystalline 
state, allowing enhanced forms of drugs to be produced. Many drugs when generated as 
an amorphous form will exhibit better solubility and wettability since the amorphous 
state is thermodynamically the form with the highest solubility. Consequently, 
amorphous forms will exhibit a greater solubility in a solvent than any crystalline form 
of the same compound. The increased solubility of amorphous actives can lead to 
dramatically increased intrinsic dissolution rates when compared to crystalline forms. 
Also, for a drug to dissolve, its surface has to be wetted by the surrounding fluid. 
Amorphous forms possess a chemically randomised surface which expresses equal 
amounts of hydrophobic and hydrophilic interactions which can lead to improved 
wettability expressed by a lower contact angle of the drug particle surface with a liquid. 
A lower contact angle represents a higher degree of hydrophilicity, with consequently 
faster surface wetting and faster dissolution. 
 
To illustrate statistically the variation in dissolution profiles30 we applied the ANOVA 
statistical test. The Two-Way analysis of variance (ANOVA test) was used to determine 
how dissolution was affected by two factors simultaneously. The percentage dissolved 
was the dependent variable and time was the repeated factor. Statistically significant 
differences (P<0.0001) in the dissolution rates of 2MES hemihydrate, amorphous 2ME 
and crystalline 2ME were observed in the analysis.  
 
3.5 CONCLUSION 
Three forms (Form I, II, and III) of 2ME and one form of 2MES (Form I) were 
isolated and characterised by thermal and X-ray diffraction methods. For 2ME, Form II 
was identified as an amorphous form and Form III was identified as a chloroform 
solvate. For 2MES, Form I was identified as a hemihydrate. 
 
The melting point of 2ME Form I, 185 °C, was found to correspond to the previously 
reported melting point [186-187 ºC] for 2ME.16,31 Similarly, the melting point of Form 
I of 2MES, 175 °C, was found to correspond to the previously reported melting point 
[174-175 ºC] for 2MES.16   
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For 2ME, Form I crystallises in the monoclinic space group P21 with a = 6.2540(2) Å, b 
= 11.2919(3) Å, c = 11.5524(4) Å, β = 97.356(1)º with two molecules per unit cell. Form 
III crystallises in the triclinic space group P1 with a = 6.3150(2) Å, b = 9.3352(3) Å,  
c = 11.1622(5) Å, α = 104.386(2)º, β = 95.464(2)º, γ =  107.774(2)º with one formula 
unit   2ME•2CHCl3 per unit cell.  
For 2MES, Form I crystallises in the orthorhombic space group P212121 with  
a = 9.499(1) Å, b = 10.585(2) Å, c = 43.643(6) Å with eight 2MES molecules and four 
water molecules per unit cell. 
 
The basic steroid structure, determined by X-ray analysis, was superimposable for 2ME 
Form I, Form III and 2MES Form I with minimal conformational differences existing, 
illustrating the rigidity of the steroid backbone. 
 
Experimental PXRD patterns were found to be consistent with computed patterns 
based on single crystal X-ray diffraction data, allowing these to serve as reliable 
references for identification of the respective phases. 
 
From dissolution studies conducted in aqueous medium at 37 ºC, 2MES hemihydrate 
was determined as having twice the solubility of 2ME. The dissolution rate profiles of 
amorphous 2ME and 2MES hemihydrate were significantly higher than that of 2ME. 
 
Given the generally poor solubility and dissolution rate profile of 2ME, it was 
considered that forming inclusion compounds between 2ME and cyclodextrins might 
improve these properties. An account of this approach is the subject of the following 
chapter. 
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Chapter 4 
2-METHOXYESTRADIOL 
CYCLODEXTRIN INCLUSION 
COMPLEXES 
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Chapter 4 highlights the results of the cyclodextrin inclusion experimentation of 2ME 
with selected CDs. It emphasises the successful preparation of the 2ME/CD complexes and 
provides a physicochemical characterisation of the complexes in the solid state. Furthermore, the 
chapter compares the solubility and dissolution profiles of 2ME and its derivative 2-
methoxyestradiol-bis-sulfamate hemihydrate (2MES) with 2ME/CD physical mixtures and 
2ME/CD complexes using the BP dissolution method. Results will indicate a markedly 
improved solubility and dissolution profile of 2ME when mixed and complexed with selected 
CDs.  
 
4.8  INTRODUCTION 
 
Cyclodextrin (CD) molecules have non-polar cavities (Figure 4.1), which provide 
hydrophobic matrices, enabling them to form inclusion complexes with many 
hydrophobic guest molecules. In contrast, the outer part of the CD molecule is 
hydrophilic, which renders the CD soluble in water. In addition, the three-dimensional 
form and size of CDs provide an important physical design (namely a truncated cone 
with hydrophobic cavity and hydrophilic exterior) for complex formation with 
hydrophobic compounds or functional groups (Figure 4.2). Hence, specific CDs (α-, β- 
and γ-CD and their derivatives) are required for complexation of specific guest 
molecules with specific physical detail. The dynamic force of inclusion complex 
formation is the entropic effect of the displacement of water molecules from the 
hydrophobic environment of the CD cavity, combined with the fact that the water 
causes a strain on the CD ring. This strain is released following complexation, 
producing a more stable and lower energy state. Thus, since inclusion complexes are 
quite stable, they can be separated from the medium by crystallisation.1  
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Figure 4.1 Macrocyclic ring of (a) α-CD, (b) β-CD and (c) γ-CD. 
 
 
Inclusion of drug molecules into CD cavities results in the improvement of the 
physicochemical properties of the drug. Such improvements include: increasing the 
stability of labile guest molecules against oxidation, visible or ultraviolet light or heat, 
taste modification by masking flavours or bad odours, and the controlled release of 
drugs and flavours. The aforementioned functions make most CDs suitable for use in 
pharmaceuticals, cosmetics and food.1 
 
In our motivation we suggest complexing 2ME with CDs due to its limiting solubility 
profile (0.005 g in 1 L of water at pH 7 and 25°C). With clinical trials underway for 
2ME as therapy to alleviate various cancers2 and with other trials related to the oral 
Figure 4.2 Schematic diagram illustrating physical dimensions of (a) -CD,  
(b) -CD and (c) -CD molecules. 
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version of 2ME, supramolecular modification of the compound to enhance the solubility 
profile is of great significance. Hence, this study investigates the formation of complexes 
of selected CDs with 2ME, with the intention of improving the applications of 2ME, 
since CDs are able to enhance the stability, aqueous solubility, dissolution and 
ultimately, the bioavailability of drugs.3 
 
To date, there is no obvious record of any attempts to complex 2ME with cyclodextrins. 
However, several attempts were made to complex other steroidal molecules with 
cyclodextrins. As mentioned earlier (Chapter 1) thus far the structure of a CD complex 
of only one steroidal compound, namely rocuronium bromide,4 has been elucidated 
using single crystal X-ray analysis. 
 
Natural Cyclodextrins and their Derivatives: The principal advantages of natural 
CDs as drug carriers are that they have well-defined chemical structures, providing 
many potential sites for chemical modification or conjugation. These modifications in 
turn provide CDs of differing cavity sizes, toxicity levels, pharmacological activity and 
water solubility.  
Derivatives have been produced from the natural CDs, through chemical modification.  
Most of the derivatives have a different hydrophobic cavity volume from that of the 
parent CDs, which plays a role in accommodating larger guest molecules and thereby 
could enhance solubility and chemical activity of the guest drug.1 
The following parent and derivatised CDs were investigated in this study: 
α-cyclodextrin     -    α-CD  
β-cyclodextrin     -    β-CD  
γ-cyclodextrin     -    γ-CD 
Hexakis(2,3,6-tri-O-methyl)-α-CD -    TRIMEA  
Randomly methylated β-CD  -    RAMEB 
Hydroxypropyl-β-CD   -    HPBCD 
Heptakis(2,6-di-O-methyl)-β-CD   -    DIMEB 
Heptakis(2,3,6-tri-O-methyl)-β-CD  -    TRIMEB 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: 2-Methoxyestradiol Cyclodextrin Inclusion Complexes 
 
 157
Heptakis(2,3,6-tri-O-acetyl)-β-CD -    TRIAcBCD 
Octakis(2,3,6-tri-O-acetyl)-γ-CD  -    TRIAcGCD 
Heptakis(2,3,6- tri-O-ethyl)-β-CD  -    TRIEtBCD 
 
All the above CDs included in this study were tested for possible complex formation 
with 2ME and at the end of this chapter we consider dissolution studies of 2ME/CD 
mixtures or prepared complexes. To identify whether a mixture or complex is fit for 
human oral consumption we reviewed oral toxicity data. If data suggested oral toxicity 
for a particular CD, dissolution testing of the 2ME/CD combination was not 
considered. 
 
Review of Oral Toxicity of Selected CDs 
Alpha-cyclodextrin (α-CD): Owing to its small cavity volume and diameter, α-CD 
generally forms complexes with low molecular weight guest molecules, which have 
aliphatic side groups. In assessing the possible toxicity of α-CD, there was only 2-3 % 
absorption, following oral administration to rats.1   
 
In contrast, the median lethal dose (LD50) which is the oral dose at which 50% of 
subjects will die, was more than 10 000 mg/kg in the rat, while the LD50 (IV) was found 
to be between 500 and 750 mg/kg, which is considerably less than the former.1 Hence, 
it is concluded that the oral dose of α-CD is comparatively safer than the IV dose of α-
CD. However, it should be noted that α-CD is poorly metabolised by salivary and 
pancreatic enzymes. 
 
Alpha-cyclodextrin Derivative: 
Hexakis(2,3,6-tri-O-methyl)-α-CD (TRIMEA): It was established that the TRIMEA 
host may not be applicable as a drug delivery system1 due to smaller cavity volume than 
α-CD.5 Thus, dissolution studies of TRIMEA as a host were not conducted in this 
study. In contrast, its parent compound α-CD is of greater pharmaceutical relevance.   
 
With respect to the solid-state structure of TRIMEA, it has two-fold rotational 
symmetry, with the opposite glucose residues in a like arrangement.  The glucoses 1 
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and 4 have their C6-O6-Me groups tilted towards the cavity axis, so that they are in 
contact across the narrow end of the CD cavity.5 The glucose residue 2 has its primary 
methoxy group directed inward.  Hence, the overall shape of TRIMEA is not that of the 
normal CD torus, but that of a bowl or a boat. Thus, the molecular cavity is closed at 
the O6 end by a “lid” of primary methoxy groups and this leads to a smaller cavity 
volume relative to α-CD.5 
 
Beta-cyclodextrin (β-CD): The advantages of using β-CD, with reference to 
dissolution characteristics and oral absorbability, can be considered with Phenytoin 
(DPH). DPH produced a higher aqueous solubility and faster dissolution when 
complexed with β-CD compared to DPH alone,6 without damaging the small intestine, 
which in turn indicated a safe estimation for oral use. 
 
β-CD is widely used for improving the solubility and stability of drugs, by forming 
complexes. Complexes are preferably formed in the presence of water since a dehydrated 
β-CD will result in all the water being displaced from the cavity.6 However, β-CD does 
not facilitate fast dissolution of complexes due to its inherently poor water solubility at 
room temperature.  
 
Beta-cyclodextrin Derivatives: 
Hydroxypropyl-β-CD (HPBCD): The main advantage of HPBCD is its significantly 
higher solubilising power compared to β-CD. For most guest molecules, the increase is 
somewhere between 10- and 100-fold. The ability of CDs to stabilise the guest molecule 
is retained in HPBCD. Due to the substitution, binding can be altered, which can cause 
differences in the extent of stability obtained compared to β-CD. 
 
HPBCD is very soluble in water and heat is not needed to increase the solubility of the 
CD. At very high concentrations of HPBCD (60% and more), increased temperature can 
be used to reduce the viscosity of the solution. Increased temperature may also be used 
to increase the solubility of the guest and the rate of complexation.  
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In the oral administration of HPBCD, teratogenicity and embryotoxicity studies have 
been performed at doses up to 5000 mg/kg per day in rats and 1000 mg/kg per day in 
rabbits. No maternal toxicity, embryotoxicity or teratogenicity was found in rats. In 
rabbits, no teratogenicity was observed, but slight maternal and embryotoxicity were 
observed at 1000 mg/kg.7 Consequently, HPBCD is safe for oral use.  
 
Heptakis(2,6-di-O-methyl)-β-CD (DIMEB): DIMEB is formed upon methylation of 
the 2 and 6 hydroxyl groups (Figure 4.1) of β-CD and is suitable for complexation due 
to its relatively high solubility in water and organic solvents.8 In general, methylated 
CDs are exceptionally soluble in water at room temperature, even though they have a 
hydrophobic surface.  
 
Water is the most frequently used solvent in which complexation experiments are 
conducted.  The more soluble the CD is in the solvent, the more molecules become 
available for complexation.  Furthermore, the guest (2ME in this study) must have the 
ability to displace any solvent molecules from the CD cavity, if the solvent forms a 
complex with the CD. Thus, an advantage of using water in complexation techniques is 
that it is easily displaced.5 It has been found that DIMEB is capable of crystallising from 
hot water, without any water of hydration. However, from cold water, only poorly 
ordered crystals of DIMEB have been obtained.5 
 
DIMEB is capable of taking on a round shape, which is effected by intramolecular  
O-H•••O hydrogen bonds between adjacent glucose units. In the crystalline state the 
CD cavity is sterically congested in inclusion complexes (somewhat closed on one end) 
by primary methoxy groups, which are directed towards the molecular axis.  The cavity 
volume that remains free is then occupied by part of the C6-O6-Me rim of a 
neighbouring DIMEB molecule.  The former may be described as ‘self-inclusion.’   
 
Self-inclusion of CD molecules or a complex between the solvent and the CD may result 
during complexation experiments. In establishing complex formation analytically, it is 
important to be able to determine that the complex is not one of self-inclusion or a 
solvent-CD complex, but rather that of the desired included guest molecule and the CD.  
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Owing to the small difference in the hydrophilic nature of the intramolecular and 
intermolecular spaces in DIMEB inclusion complexes, because of the presence of methyl 
groups, guest molecules can be found either in the cyclodextrin cavity or in the 
interstitial positions, with the cavity also being occupied by water molecules.5 
 
Heptakis(2,3,6-tri-O-methyl)-β-CD (TRIMEB): TRIMEB is formed upon 
methylation of the 2, 3 and 6 hydroxyl groups (Figure 4.1) of β-CD and as with DIMEB 
a relatively high solubility in water and organic solvents is observed.  
 
CDs are also useful as drug penetration enhancers. Absorption enhancement occurs by 
the CDs extracting lipids from cell membranes, increasing membrane fluidity and 
permeability.  This action towards biological membranes is connected to the haemolytic 
and cytotoxic effect of methylated β-CDs.9 Therefore, the methylated β-CDs, 
particularly DIMEB and TRIMEB are unsuitable for human consumption, due to their 
marked toxic effects. 
 
In a previous study, methylated CDs were used to determine if membrane proteins exist 
in association with specialized microdomains called lipid rafts, by depleting cholesterol 
found in them.9 Thus, cholesterol, which is also a large steroidal compound, forms 
complexes with CDs in aqueous solution. It has been shown that cholesterol molecules 
can diffuse directly from the plasma membrane into the hydrophobic core of a CD 
molecule, packed near the membrane surface.9 
 
DIMEB and TRIMEB have a deeper cavity and are more hydrophobic than β-CD. 
Hence, these derivatives have a strong ability to form soluble complexes with 
cholesterol, in aqueous solution.  Although HPBCD has a weaker ability to sequester 
cholesterol,10 it is nevertheless known to form inclusion complexes with this steroid. 
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Randomly Methylated β-CD (RAMEB): RAMEB has been proposed to be a good 
carrier to deliver fatty acids to cells in a culture.11 CD complexation of anti-
inflammatory drugs in particular, offers additional advantages such as masking of taste, 
lowering of dose and reduction of side effects, particularly gastric irritation. 
UV absorbers used in sunscreen cosmetics are usually poorly soluble in water, but their 
aqueous solubility can be improved by complexation with different CDs and β-CD 
derivatives. The phase solubility method was applied in a study of UV absorbers and 
different CD interactions. The molar ratio of the UV filter to CD in the solid complex 
was calculated from thermal analysis data. Among the CDs studied, RAMEB showed 
the highest complexing and solubilising power and gave rise to the product with the 
best dissolution profile in the study. 12 
 
Heptakis(2,3,6-tri-O-acetyl)-β-CD (TriAcBCD), Heptakis(2,3,6-tri-O-ethyl)-β-CD 
(TriEtBCD) and Octakis(2,3,6-tri-O-acetyl)-γ-CD (TriAcGCD): These CDs are less 
well-known derivatives and information concerning them is thus limited. Notably 
though, it was found that when placed in water, the aggregation of such CD molecules 
and the interaction of surrounding water molecules, together with the lattice energy in 
the solid state, may be responsible for their solubility differences when compared to 
parent compounds.13,14   
 
Gamma-cyclodextrin (γ-CD): Studies conducted in rats and rabbits with γ-CD at 
doses up to 20% of the diet, did not show any teratogenic effects. Furthermore, in a 12-
month study of toxicity, again rats were fed diets containing up to 20% γ-CD. Minimal 
changes were seen and only at the high dose, probably as a result of the presence of a 
large amount of an osmotically active substance in the large intestine. These changes 
were considered to be brief and not of toxicological significance.8 
 
Following the discussion above, the following CDs were included in the dissolution 
tests of this study: α-, β-, γ-CD, HPBCD and RAMEB. 
 
Since the structure of 2ME was previously described in Chapter 3, it was not considered 
necessary to discuss this potential guest for a second time. 
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4.9  OBJECTIVES OF THE STUDY 
In order to enhance the solubility and dissolution of 2ME with CDs the following 
objectives were identified: 
 To formulate complexes of 2ME with CDs and provide physicochemical 
characterisation of these complexes in the solid state. 
 To determine the solubility of 2ME in the presence of each CD. 
 To determine the dissolution profiles of mixtures of 2ME with selected, non-
toxic oral CDs, if the latter were readily available and relatively inexpensive. 
 To determine the dissolution profiles of the non-toxic 2ME/CD complexes 
formed. 
 
Table 4.1 presents selected results of 2ME/CD complex preparation experimentation 
using various methods. Appendix 2 on the attached CD-rom provides the full spectrum 
of experiments attempted. 
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Table 4.1 Representative cyclodextrin inclusion complex preparation with 2ME 
as potential guest using various methods 
Method 1i: Neat Grinding for 1 hour  
CD Ratio (H:G) Result 
α-CD 1:1 Mixture 
β-CD  1:1 Mixture 
γ-CD 1:1 Mixture 
Method 2i: Kneading into paste with water for 1 hour  
CD Ratio (H:G) Result 
α-CD 1:1 Mixture 
 2:1 Mixture 
β-CD  1:1 Mixture 
 2:1 Complex 
γ-CD 1:1 Mixture 
 2:1 Mixture 
Method 3ii: Slurry method  
Exp. Ratio (H:G) Result 
β-CD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
4C 2:1 No complex 
RT 2:1 No complex 
SC 2:1 Complex 
i Materials prepared using methods 1 and 2 were analysed using PXRD. 
ii Slurries were made with water at given ratios, stirred for 24 hrs at RT and at 60 ºC for β-CD since β-
CD solubility is greater at higher temperatures. Then slow evaporation (RT), rapid cooling (4 ºC), slow 
cooling (SC) and heating at 60 ºC were employed for crystal growth to occur; resulting crystals were 
analysed by single crystal X-ray diffraction and thereafter PXRD to determine bulk consistency. 
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4.10  COMPLEXATION BETWEEN 2ME AND β-CD, 
HPBCD, RAMEB, DIMEB AND TRIMEB 
 
4 .10 .1  β -CD COMPLEX WITH 2ME 
Preparat ion  o f  BCD2ME by  knead ing  
Complex preparation between β-CD and 2ME was achieved by kneading a 2:1 
(mol/mol) host:guest mixture into a paste using water. The cyclodextrin was placed in 
the mortar with a few drops of water and ground to a paste. The guest was added 
slowly with simultaneous kneading until all of the guest was added. The process 
required between 45 min to one hour.  During this time the paste was kept moist by the 
dropwise addition of water. Complexation was confirmed by powder X-ray diffraction 
and the resultant traces were assigned to an isostructural series.15 This complex shall be 
referred to as BCD2ME.  
 
Preparat ion  o f  BCD2ME by  Co-precipitation 
A complex was prepared by stirring an aqueous solution of β-CD (at 60 ºC) with the 
guest compound using a 2:1 (mol/mol) host:guest ratio. The calculated amounts of host 
and guest molecules were agitated intensely at an elevated temperature of 60 ºC to 
achieve the common saturated solution of both the host and guest. The β-CD inclusion 
complex was crystallised from this homogenous solution upon slow cooling. Square, 
plate-like crystals were isolated. Subsequent analysis (see below) revealed that the 
complex BCD2ME obtained by kneading was identical to the crystals obtained by co-
precipitation. Thus, the latter is also referred to as BCD2ME in this chapter. 
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Thermal Analyses 
Hot Stage Microscopy  
HSM was used to analyse the thermal behaviour of the complex upon heating at a 
constant rate of 10 K/min. HSM photographs of BCD2ME are presented below (Figure 
4.3). After removal from mother liquor, the crystals of the complex displayed signs of 
cracking as they began to lose their water of crystallisation. The analysis was performed 
under silicone oil to assess the presence of included water as would be indicated by 
bubble formation. The photographs of the complex were recorded at (a) start of 
analysis, (b) the first sign of bubbling, (c) the time by which extensive crystal 
fragmentation had taken place, (d) the onset of decomposition of complex (indicated by 
colour change of a few crystals to brown) and (e) Decomposition of the entire complex 
with the appearance of bubbling as a result of decomposition.  
 
 
Figure 4.3 HSM photographs of BCD2ME. 
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Figure 4.3 indicated the first signs of release of water from the crystal appearing 
between 65 and 80 °C for BCD2ME and by 120 °C, extensive fragmentation of 
BCD2ME had occurred, a further consequence of dehydration of the crystal. 
Decomposition started at ~305 °C with spontaneous associated bubbling verifying 
extensive decomposition occurring at 340 °C . 
 
Differential Scanning Calorimetry and Thermogravimetric Analysis 
TGA and DSC traces for the BCD2ME complex are presented in Figures 4.4 and 4.5 
below. TGA was used to determine water content of the BCD2ME complex which was 
indicated by the initial mass loss. The TGA trace for BCD2ME showed a mass loss of 
8.8 ± 0.4 % (n=3) in the temperature range 30-150 °C, represented by A in Figure 4.4. 
This established the BCD2ME:H2O molar ratio as 1:13.5 ± 0.6. The second thermal 
event B in the TGA trace represents decomposition of the complex with an onset 
temperature of ~309 °C. 
 
Figure 4.4 TGA trace for BCD2ME. 
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A summary of the observed percentage mass loss over temperature intervals between 
30, 50, 100, 150 and 200°C is presented in Table 4.2. 
 
Table 4.2 Percentage mass loss for the BCD2ME complex at various 
temperatures 
Temperature (°C) Sample mass(%) Δ Mass loss (%)* 
30 100 0 
50 99.64 0.36 
100 93.68 5.96 
150 91.2 2.5 
200 91.1 0.1 
*Δ Mass loss (%) = [Sample mass(%) at temperatures (n-1)] – [Sample mass(%) at temperatures (n)] 
 
In Figure 4.5 the BCD2ME complex shows endothermic events corresponding to water 
loss in the range 30 to 150 °C. The endotherms covered the same range over which 
water loss was observed from TGA (mass loss due to water loss was labelled A for the 
TGA trace). The peak of the water loss endotherm (labelled A in Figure 4.5) occurred at 
95 °C. However this peak contained a number of shoulders occurring at 110, 140 and a 
further peak at ~204 °C (labelled B) indicating that water loss from this complex was 
clearly a multi-stage process. Breakdown of the host framework of the complex 
corresponded with decomposition of the complex molecule which begins above 290 °C 
(labelled C). The region between 290 and 350 °C showed multiple peaks further 
indicating the decomposition of the complex. Very large mass losses were observed in 
the TGA trace from 300°C onwards (labelled B), confirming the decomposition of the β-
CD complex molecules. Disappearance of the guest (2ME) melt peak in Figure 4.5 was 
an added indication of complex formation.  
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Figure 4.5 DSC trace for guest (2ME) and complex (BCD2ME). 
 
 
UV Spectrophotometry 
The host:guest ratios were determined by UV spectrophotometry at 198.5 nm in 
methanol:water (50:50 v/v) solution. The stoichiometric ratio for the BCD2ME 
complex was determined as 2:1. 
 
Experimental PXRD and Isostructurality 
X-ray powder diffraction may be used to establish complex formation.15 Together with 
the principles of isostructurality this allows us to extract space group and unit cell 
information for new cyclodextrin complexes. 
 
Firstly, we note that the experimental PXRD pattern (Figure 4.6) presents a clear 
indication of complexation occurring between the guest and host, with most peaks 
disappearing for parent compounds in the trace for the product obtained by kneading as 
well as in that from the co-precipitation experiment. New peaks appeared at the 
following 2θ values: 7.2, 9.8, 12.0 and 15.7º. Neat grinding produced only a mixture of 
β-CD and 2ME.  
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Figure 4.6 Experimental PXRD patterns of 2ME and β-CD parent compounds and 
various preparations thereof: neatly ground, mixture, kneaded and co-
precipitated materials. 
 
Secondly, PXRD was used as a tool to identify isostructurality between the prepared 
complex and known complexes. In Figure 4.7 we show that the BCD2ME complex is in 
fact isostructural with the known β-CD complex which contains 4-t-butylbenzyl alcohol 
as guest (CSD refcode KOFJEU).16 
0
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Figure 4.7 Calculated PXRD pattern of KOFJEU versus experimental patterns of 
BCD2ME (obtained by kneading and co-precipitation). 
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PXRD as used above is an efficient tool for the identification of cyclodextrin complexes 
but it is limited quantitatively. For example, it provides little information regarding 
guest orientation, crystal water content, stoichiometry and the interaction between 
water and the structure of the complex.  In this regard single crystal X-ray diffraction is 
greatly superior.15 
 
When the assignment of an isostructural series is undertaken, the water content, 
dimensions of the guest and its orientation as well as the temperature at which the data 
were collected affect the peak angular positions in the PXRD trace. Thus, the tolerances 
within which traces are deemed as indicating isostructurality are less rigid than those 
which are normally applied in phase identification by PXRD.15 
 
Noticeably from the comparison in Figure 4.7 there is a reasonably close 
correspondence between the reference trace KOFJEU and the representative trace of 
the kneaded product as well as the co-precipitated product of 2ME with β-CD. The 
estimated unit cell dimensions are listed below in Table 4.3, along with the possible 
space group.  
 
The unit cell parameters for the BCD2ME inclusion complex were deduced from its 
isostructurality with the known inclusion complex whose reference PXRD trace is 
presented in Figure 4.7. 
 
Table 4.3 Possible space group and approximate unit cell parameters for the 
complex BCD2ME 
Space group a (Å) b (Å) c (Å) α (˚) β (˚) γ (˚) Vol. (Å3) 
C2221 19.2 24.4 32.8 90 90 90 15362.3 
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Single Crystal X-ray Crystallographic Analysis of the BCD2ME Complex 
Data-collection 
The unit cell parameters, crystal system and space group were determined using the 
Nonius Kappa CCD diffractometer.  Crystals produced were not of high quality and the 
best crystal for single X-ray diffraction was selected and mounted using Paratone N oil 
and used for data-collection. Table 4.4 compares the unit cell parameters of BCD2ME 
with those of the known complex KOFJEU16 to confirm the unit cell data predicted in 
Table 4.3.  
Even though accurate unit cell dimensions were actually measured, the BCD2ME 
complex was undeniably isostructural with KOFJEU, as illustrated by the PXRD 
patterns which matched the reference trace (Figure 4.7).  
 
Table 4.4 Unit cell parameters for BCD2ME and KOFJEU 
 BCD2ME Known β-CD complex 
REFCODE  KOFJEU16 
Spacegroup C2221 C2221 
a (Å) 19.376(2) 19.196(7) 
b (Å) 24.053(2) 24.393(6) 
c (Å) 32.412(2) 32.808(9) 
α (˚) 90.0 90.0 
β (˚) 90.0 90.0 
γ (˚) 90.0 90.0 
Volume (Å3) 15105.3(2) 15362.3(2) 
Z 8 8 
 
To establish whether any phase changes occurred on cooling, unit cell dimensions for 
BCD2ME were measured at both 21 ºC and -160 º (Table 4.5). No phase change was 
evident. 
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Table 4.5 Unit cell parameters for BCD2ME 
 BCD2ME (21 °C*) BCD2ME (-160 °C) 
Space group C2221 C2221 
a (Å) 19.79 19.376(2) 
b (Å) 24.89 24.053(2) 
c (Å) 32.99 32.412(2) 
α (˚) 90.0 90.0 
β (˚) 90.0 90.0 
γ (˚) 90.0 90.0 
Volume (Å3) 16250 15105.3(2) 
Z  8 
*For room temperature unit cell data, no e.s.d.s are reported since relatively few intensity frames were 
collected 
 
Structure Solution and Refinement 
Since these were only partially successful, a very brief summary follows. The atomic co-
ordinates of the β-CD molecule in the structure of KOFJEU16 were used as a trial model 
for the structural elucidation of BCD2ME. Although the host molecule refined 
successfully, severe disorder of the guest molecule prevented its modelling and further 
attempts to obtain a detailed structure were abandoned in view of this outcome.  
It should be noted, however, that in principle, the known host framework in the crystal 
could in future be used as a template for theoretical calculations in which modelling of 
guest orientation and placement could take place. What can be deduced from the 
isostructurality of BCD2ME with KOFJEU is that the former is thus also a dimeric 
complex i.e. the repeating motif in the crystal is a head-to-head β-CD dimer, whose 
structure is maintained by O-H•••O hydrogen bonds between the secondary rims of the 
two host molecules. The 2ME molecule is encapsulated within the host dimer. 
 
Despite the fact that the exact nature of guest inclusion could not be established due to 
severe guest disorder, the BCD2ME complex was nonetheless sufficiently well 
characterised to pursue other aspects such as its solubility and dissolution profile, as 
described at the end of this chapter. 
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4 .10 .2  HPBCD AND RAMEB COMPLEXES WITH 2ME 
 
Preparation of HPB2ME and RAM2ME  
Complex preparation between HPBCD and 2ME and between RAMEB and 2ME was 
performed by kneading a 1:1 (mol/mol) guest:host mixture into a paste using water. 
In both instances the cyclodextrin was placed in the mortar with a few drops of water  
and ground to a paste.  The guest was added slowly with simultaneous kneading until  
all of the guest was added.  The process usually required between 45 min to one hour.   
During this time the paste was kept moist by the dropwise addition of water. 
 
Experimental Powder X-ray Crystallographic Analysis of HPB2ME and RAM2ME 
prepared by kneading 
PXRD patterns (CuKα radiation with conditions stated in Chapter 2) were obtained for 
all preparations and a number of characteristic 2ME peaks were observed. The 2θ range 
scanned was from 5 to 40° and the sample sizes were all in the range 45-50 mg.  
HPBCD and RAMEB comprise mixtures of a number of isomers which have different 
degrees and patterns of substitution. Both CDs are therefore amorphous and their 
PXRD traces do not display any characteristic sharp peaks.17 Any inclusion complex 
formed with RAMEB and HPBCD will likewise be an amorphous substance. However, 
2ME contains a number of relatively sharp and characteristic PXRD peaks. The 
disappearance of these peaks in patterns of products obtained by kneading was taken as 
evidence for inclusion complex formation. The presence of these peaks in any of the 
preparations analysed signified the presence of uncomplexed drug and incomplete 
formation of an inclusion complex of the stoichiometry of the preparation. Figure 4.8 
shows the PXRD traces of 2ME, HPBCD, a 1:1 neatly ground HPBCD:2ME trace and 
traces of 1:1, 2:1 and 3:2 HPBCD:2ME preparations from kneading experiments. Figure 
4.9 shows the PXRD traces of 2ME, RAMEB, neatly ground 1:1 RAMEB:2ME and a 
1:1 RAMEB:2ME preparation from kneading. It is evident from both figures that the 
characteristic peaks of 2ME are absent from the traces of the 1:1 materials that were 
kneaded and that the patterns resemble those of the parents HPBCD and RAMEB, thus 
providing evidence of  inclusion complex formation. Henceforth, the preparations made 
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by kneading a 1:1 mixture of HPBCD:2ME and RAMEB:2ME will be referred to as 
HPB2ME and RAM2ME, respectively.  
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HPBCD:2ME (1:1) prepared by kneading for 1 h
HPBCD:2ME (1:1) neat grinding for 1 h
HPBCD:2ME (2:1) prepared by kneading for 1 h
HPBCD:2ME (3:2) prepared by kneading for 1 h
 
Figure 4.8 Experimental PXRD traces for 2ME, HPBCD and various preparations 
involving the two components. 
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Figure 4.9 Experimental PXRD traces for 2ME, RAMEB and various preparations 
involving the two components. 
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FTIR Spectra of HPBCD and RAMEB and their Putative 2ME complexes 
FTIR spectra were recorded for all preparations and various IR bands corresponding to 
HPBCD, RAMEB and 2ME were analysed. The IR spectra were obtained using a 
Perkin-Elmer 100 FTIR instrument fitted with UATR and controlled with Spectrum ® 
software for sample analysis. Powder samples were run over the range 400-4000 cm-1. 
Percentage transmittance was recorded against frequency. For the CD complexes 
obtained by kneading, shifts in certain characteristic bands of the 2ME molecule were 
indicative of interaction between CD and drug. 
 
The frequency range scanned for 2ME was between 500 and 4000 cm-1. For 2ME the 
following max bands were identified by Rao et al.18: 3424, 3202, 2905, 2863 and 1607 
cm-1. The experimental FTIR spectra for 2ME confirmed these max values within 
experimental error. We find that for both HPB2ME (Figure 4.10) and RAM2ME 
(Figure 4.11) these bands are either displaced or masked by the CD from the measured 
value for the drug itself. Hence, we can conclude that both HPBCD and RAMEB 
complexed with 2ME during  kneading experiments. 
 
 
Figure 4.10 FTIR spectra of HPBCD and 2ME and that of their putative inclusion 
complex. 
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Figure 4.11 FTIR spectra of RAMEB and 2ME and that of their putative inclusion 
complex. 
 
 
Differential Scanning Calorimetry 
DSC experiments were run for all preparations and the melting endotherm for 2ME 
was monitored. DSC conditions were 10 K/min with temperature range 30 to 300 °C.  
The sample sizes were as follows: RAM2ME (1:1) 6.5 mg and HPB2ME (1:1) 7.8 mg. 
The disappearance of the 2ME melting endotherm was taken as further evidence for  
complex formation. The presence of uncomplexed, crystalline drug in a particular  
preparation was indicated by the presence of the melting endotherm of 2ME. All of the  
2ME was complexed after manual kneading for 1 h for both HPBCD and RAMEB (1:1)  
preparations. Figure 4.12 shows the DSC traces of 2ME, HPBCD, 1:1 physical mixture 
of HPBCD and 2ME and a 1:1 preparation obtained by kneading. Figure 4.13 shows the  
DSC traces of 2ME, RAMEB, 1:1 physical mixture of RAMEB and 2ME and a 1:1  
preparation made by kneading. 
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Figure 4.12 DSC of 2ME, HPBCD, HPBCD:2ME (1:1) mixture and HPB2ME (1:1) 
complex from kneading. 
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Figure 4.13 DSC of 2ME, RAMEB, RAMEB:2ME (1:1) mixture and RAM2ME 
(1:1) complex from kneading. 
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4 .3 .3  DIMEB COMPLEX WITH 2-METHOXYESTRADIOL  
 
Preparation of DIB2ME 
A suspension was prepared by mixing 0.033 mmol (44 mg) of the CD and  
0.033 mmol (10 mg) of 2ME in 3 ml of distilled water. Since methylated CDs have an  
inverse temperature-solubility relationship i.e. their solubility decreases with an  
increase in temperature, the suspension was stirred vigorously at room temperature for  
24 h. After the dissolved CD solubilised the drug and common saturation of both host  
and guest had been achieved, the solution was  filtered (0.45 μm microfilter), and then  
left at 60 C on a hot plate. Single crystals formed after several days. As shown below,  
the crystals are those of an inclusion complex between DIMEB and 2ME. This complex  
shall be referred to as DIB2ME. Large, roughly cubic-shaped crystals of DIB2ME were  
isolated.  
 
Thermal Analyses 
Hot Stage Microscopy 
HSM was used to analyse the thermal behaviour of the complex upon heating at a 
constant rate of 10 K/min. After removal from the mother liquor, the crystals of the 
complex displayed signs of cracking as they began to lose their water of crystallisation. 
The crystals were promptly immersed in silicone oil on a glass slide and photographs 
were taken in the temperature range 30 oC to 400 oC. These HSM pictures are 
presented in Figure 4.14 at various stages of heating. At the start of the analysis the 
crystals of DIB2ME were clear and translucent and the first signs of release of water 
from the crystals appeared at 80 °C. At 290 °C the crystals underwent a colour change 
indicating the onset of decomposition. Spontaneous associated bubbling and brown 
discolouration verified the final decomposition at 400 °C. 
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Figure 4.14 HSM photographs of DIB2ME during heating. 
 
Thermogravimetric Analysis and Differential Scanning Calorimetry 
TGA and DSC traces for the DIB2ME complex are presented in Figure 4.15 and 4.16 
respectively. TGA was used to determine water content of the DIB2ME complex which 
is indicated by the initial mass loss. The TGA trace for the DIB2ME complex showed a 
mass loss of 5.3 ± 0.3 % (n=3) in the temperature range 30-300 °C, which implies 5.1 ± 
0.4 H2O molecules per complex unit. 
  
Dehydration of the complex appeared to occur over a wide temperature range in TGA 
and it was not entirely clear at what temperature it ended. Estimation of the percentage 
mass loss due to dehydration in the TGA trace was thus based on supporting 
information from HSM and DSC data (see below). 
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Figure 4.15 TGA trace for DIB2ME. 
 
Figure 4.16 DSC trace for DIB2ME. 
 
In Figure 4.16 the DIB2ME complex shows endothermic events corresponding to water 
loss in the range 30 to 300 °C. The endotherms covered the same range over which 
water loss was observed from TGA. The peak of the water loss endotherm (labelled A) 
occurred at 80 °C. However, this peak contained a number of shoulders, subsequently 
giving rise to a second, very small peak at 255 °C (labelled B) indicating that water loss 
from this complex was clearly a multi-stage process. The smaller endotherm at  
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287-290 °C (labelled C) indicated the onset of decomposition of the complex. The HSM 
analysis confirmed this visually when the crystals turned brown at these temperatures. 
Breakdown of the host framework of the complex corresponded with decomposition of 
the complex, which begins above 285 °C. The region 290-350 °C showed an exotherm, 
followed by a small endotherm, further indicating the decomposition of the complex. 
Very large mass losses were observed in the TGA trace from 320 °C onwards, 
confirming the decomposition of the DIMEB complex molecules. The absence of the 
guest peak (2ME fusion peak) in the DSC trace of DIB2ME was further evidence that 
the latter represented an inclusion complex. 
 
UV Spectrophotometry 
The host:guest ratio was determined by UV spectrophotometry at 198.5 nm in 
methanol and distilled water (50:50 v/v) for the DIB2ME complex. The stoichiometric 
ratio was established as 1:1. 
 
Experimental PXRD of the DIB2ME Complex 
With notable differences between the patterns of parent compounds and that of 
DIB2ME, PXRD analysis (Figure 4.17) indicated definite complexation of DIMEB with 
2ME using the co-precipitation method. The experimental pattern does, however, show 
relatively low crystallinity, especially at the higher 2θ values. This may be due to 
excessive grinding of the sample for PXRD analysis. Neat grinding and kneading of 
DIMEB with 2ME essentially produced mixtures of the two compounds.  
 
The author is aware that different polymorphs of DIMEB are known, but for simplicity 
only one representative DIMEB PXRD trace is indicated in Figure 4.17. The PXRD 
trace of DIB2ME was, however, compared with those for other polymorphs of DIMEB 
and found not to match any of them. As noted below, the experimental PXRD trace for 
DIB2ME does, in fact, correspond with that computed from the single crystal X-ray 
analysis. 
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Figure 4.17 PXRD patterns of 2ME, DIMEB, 1:1 DIMEB:2ME mixture, kneaded 
material and DIB2ME complex obtained by co-precipitation. 
 
Single Crystal X-ray Crystallographic Analysis of the DIB2ME Complex 
Data-collection  
Preliminary intensity measurements for unit cell determination were recorded on a 
Nonius Kappa CCD diffractometer using graphite-monochromated MoKα radiation at 
room temperature (21 °C) and low temperature (-160 °C). Unit cell determinations were 
performed at both temperatures to ensure that no phase changes were effected on 
cooling the crystals. A full intensity data set was subsequently collected at -160 °C. 
Laue symmetry 2/m was confirmed for the collected intensity data, thus indicating the 
monoclinic system. The space groups P21 and P21/m were indicated by the reflection 
conditions hkl: none; h0l: none; 0k0: k=2n. Inspection of the reciprocal lattice layers 
with LAYER19 confirmed these reflection conditions. The chiral nature of both the CD 
and the guest (2ME) molecule determined the space group as P21. Minor host disorder 
problems were encountered when solving the structure. However, a very good final 
residual factor R1 [F◦ >4σ(F◦)] of 0.0851 was eventually obtained. The complex did not 
indicate isostructurality with any known complexes.16 The unit cell determinations at 
room temperature and low temperature are presented in Table 4.6.  
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Table 4.6 Unit cell parameters for DIB2ME 
 DIB2ME 
(21 °C*) 
DIB2ME 
(-160 °C)  
Space group P21 P21 
a (Å) 13.789 13.5514(1) 
b (Å) 24.956 24.3921(2) 
c (Å) 13.952 13.7237(1) 
α (º) 90 90 
β (º) 97.235 97.0468(3) 
γ (º) 90 90 
Volume 4623.97 4502.06(6) 
*For room temperature unit cell data, no e.s.d.s are reported since relatively few intensity frames were 
collected 
 
Structure Solution and Refinement 
From density considerations, the asymmetric unit was determined to consist of one 
complex unit. From the E-map following structure solution with SHELXD,20 it was  
possible to locate most of the non-hydrogen atoms, whose refinement with SHELXH21 
followed. After the first refinement, remaining non-H atoms revealed themselves and 
were placed. The 2ME molecule and the CD molecule were included in the model with 
their correct known absolute configurations. All non-hydrogen atoms were then refined 
isotropically and subsequently an sotropically. Hydrogen atoms were located in the 
difference electron density maps and were then placed in fixed geometric positions using 
a riding model and were refined isotropically with thermal parameters equal to 1.2-1.3 
times those of their parent atoms. The hydroxyl hydrogen atoms were assigned a 
common variable isotropic temperature factor and were placed using the hydrogen bond 
search model. The absence of heavy atoms led to a Flack parameter value that did not 
indicate absolute structure unequivocally. The Friedel opposites were therefore merged 
(MERG 4 in SHELXH21). Least-squares weights were employed in the final cycles of 
the refinement. The crystal and refinement data for the low temperature structure 
determination are presented in Table 4.7. The ADDSYM function in PLATON22 
indicated no extra crystallographic symmetry, reaffirming the correct choice of space 
group for this structure. Further refinement details, including treatment of water 
molecules, follow. 
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Table 4.7  Low temperature crystal and refinement data of DIB2ME 
Parameter DIB2ME 
Molecular Formula (C57H100O35)·(C19H26O3)·5.1H2O 
Formula Weight/g mol-1 1739.67 
Crystal System Monoclinic 
Space group P21 
a (Å) 13.5514(1) 
b (Å) 24.3921(2) 
c (Å) 13.7237(1) 
α (º) 90 
β (º) 97.0468(3) 
γ (º) 90 
Volume (Å3) 4502.06(6) 
Z 2 
Densitycalc / g cm-3 1.279 
 (MoK) / mm-1 0.105 
F(000)  1868 
Crystal size / mm3 0.22 x  0.29 x  0.32 
Temperature (K) 173 
Range scanned  /  1.00 ≤  ≤ 25.35 
Index ranges  h: -16, 16            k:-29, 28           l:-16, 16 
 scan angle /  1.0 
 scan angle range, frames 362, 362 
 scan angle /  1.0 
 scan angle range, frames 258, 258 
Dx / mm  39.30 
Total no. of reflections collected 15799 
No. of unique reflections 8108 
No. of reflections with I  2(I) 13656 
No. of L.S. parameters 1077 
Rint, Rσ 0.014, 0.023 
S 1.038 
R1 (F◦ >4σ(F◦)) 0.0851 
No. of reflections omitted 102 
wR2 (all reflections) 0.2540 
Weighting scheme a = 0.1810  b = 2.602 
( / )mean  < 0.001 
 excursions / eÅ-3  0.86, -0.65 
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During the refinement, one of the primary methoxy groups (that on residue G6, Figure 
4.18) was found to be disordered over two sites and it was modelled accordingly with 
the major site assigned s.o.f. x and the minor 1-x, the value of x being treated as a least-
squares variable. More significantly, it was found that host residue G1 was methylated 
not only at the O2- and O6-positions, but also at the O3-position. In other words, the 
DIMEB raw material was slightly impure and the complex crystal preferentially 
crystallised with this contaminated isomer. Henceforth, however, we continue to refer 
to the inclusion complex as a ‘DIMEB’ complex. Ten positions were identified as 
possible water molecule sites. Only three (O1-O3) of the ten positions located for water 
molecules could be assigned full site-occupancy factors (s.o.f.s.). It was necessary to 
assign partial site-occupancy factors to water molecules O4-O10. The temperature 
factors of the disordered water molecules were fixed at 0.07 Å2 (the mean of the Uiso 
values for O1-O3) with their partial site-occupancy factors all refining within the range 
0.24584 to 0.47104. From the TG analysis 5.1 ± 0.4 (n=3) water molecules were found, 
while X-ray modelling resulted in 5.3 molecules, which is the same within experimental 
error. The s.o.f.s of the disordered water molecules are listed in Table 4.8.  Seven water 
molecules (O4-O10) were refined isotropically while O1-O3 refined anisotropically.  
Water H atoms could not be located in the electron density maps. Four distance 
restraints were applied to the host molecule, namely C6G6-O6B (1.400 Å, σ =0.005 Å), 
O6B-C9B (1.400 Å, σ =0.01 Å), C6G6-O6G6 (1.400 Å, σ =0.006 Å) and O6G6-C9G6 
(1.400 Å, σ =0.01 Å) to maintain reasonable geometries. 
 
Table 4.8 Refined site-occupancies of disordered water molecules in complex 
DIB2ME 
 
 
 
 
 
 
Atom O4 O5 O6 O7 O8 O9 O10 
s.o.f. 0.47104 0.24584 0.39197 0.30644 0.29328 0.30077 0.24883 
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Modelling of the 2ME Guest 
All the guest hydrogen atoms were placed in idealised positions in a riding model. Uiso 
for the aromatic, methylene and methine hydrogens was 1.2 times that of the parent 
atom and all methyl hydrogens were given thermal parameters 1.5 times the Uiso of 
their parent atoms. The 2ME molecule presents itself at the secondary rim of the host 
with the D-ring of 2ME inserted into the DIMEB cavity (Figure 4.19). 
 
Figure 4.18 Labelling of host - DIMEB. (Note that atom O3 of G1 is methylated 
whereas all other residues have O2 and O6 methylation patterns). 
 
 
Figure 4.19 Stereoview illustrating inclusion of the 2ME molecule in the cavity of 
the host DIMEB molecule.  
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Structural Description 
The glucose units of the DIMEB molecule are designated G1, G2, G3, G4, G5, G6 and 
G7 (Figure 4.18). The asymmetric unit of the DIB2ME complex structure (Figure 4.19) 
contains a single DIMEB molecule, its associated guest molecule and 5.1 water 
molecules.  
 
Primary Methoxyl and Glycosidic Torsion Angles 
The DIMEB molecule retains a ‘round’ shape, as usually observed, owing to the 
existence of an almost complete ring of intramolecular O3(n)-H•••O2(n-1) hydrogen 
bonds that link contiguous rings. These are discussed in detail later. Table 4.9 lists 
selected torsion angles for the glucose units. These torsion angles are defined on page 
21 of Chapter 1. The primary methoxyl group of G6 is disordered over two positions 
(designated as ‘a’ and ‘b’) adopting the (-)-gauche orientation and (+)-gauche orientation. 
Four of the primary methoxyl torsion angles (ω) of DIB2ME (G1, G2, G3, G6a) 
correspond to the (-)-gauche orientation which is the preferred orientation while G4, G5, 
G6b and G7 have the (+)-gauche conformation. All the glucose residues are in the 4C1-
chair conformation.   
 
Table 4.9 Principal torsion angles of DIB2ME 
Glucose 
unit 
ω(°)a ω(°)b Φ(°) Ψ(°) Θ1(°) Θ2(°) 
G1 -70.9(5) - 109.6 121.4 53.8 -53.8 
G2 -68.1(5) - 108.6 127.2 50.4 -56.4 
G3 -67.9(6) - 106.6 125.9 53.3 -57.3 
G4 78.9(5) - 110.5 127.6 53.7 -54.2 
G5 66.2(8) - 107.4 127.2 52.3 -54.6 
G6 -69.1(7) +51.0 113.1 128.0 55.9 -56.9 
G7 67.9(6) - 107.9 127.5 52.3 -51.4 
Mean 60.7(4) - 109.1 126.4 53.1 -54.9 
 
Macrocyclic Symmetry 
The geometrical parameters of the O4 heptagon of the DIB2ME structure are listed in 
Table 4.10. These include the radii (r), side lengths (l), O4•••O4•••O4 angles (a), the 
deviation of each O4 from the mean O4 plane (d) and the O4•••O4•••O4•••O4 torsion 
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angles (t). These parameters are defined and illustrated in Chapter 1.The radii r for 
DIB2ME vary within a range of 5.02 – 5.12 Å.  The lengths l for the complex vary 
within a range of 4.36 – 4.42 Å.    
 
Planarity of the O4-Heptagons 
The mean deviation (d) of the O4 atoms from the mean O4 plane of the host is 0.047 Å. 
In addition, the torsion angles (t) all lie in a range from -6.0 to +3.8˚.    
 
Table 4.10 Geometrical parameters of the O4 polygon for DIB2ME 
Glucose 
unit 
r(Å) l(Å) a(°) d(Å)* t(°) 
G1 5.02 4.38 126.5 0.064 3.8 
G2 5.12 4.37 129.6 -0.096 2.0 
G3 5.03 4.40 128.7 0.016 -5.4 
G4 5.03 4.39 128.7 0.080 3.8 
G5 5.07 4.36 127.4 -0.072 -1.8 
G6 5.10 4.42 129.1 -0.002 3.6 
G7 5.02 4.38 129.7 0.010 -6.0 
Mean 5.06 4.39 128.5 0.047 3.8 
*The average e.s.d.s for d and t are 0.003 Å and o.6 º respectively. 
 
Other useful parameters which describe the overall shape of the macrocycle are the tilt 
angle (τ2), intersaccharidic angle () and the O2•••O3' distances (Table 4.11), all of 
which provide information about the shape of the macrocycle.  For instance, τ2 is the 
angle between the O4 mean plane and the mean plane through O4, C1, C4 and O4'.  For 
DIB2ME τ2 ranges from 8.8 to 14.3˚.  All values of τ2 are positive and the implication is 
that the primary rims of all the glucose residues are inclined towards the centre of the 
cavity. The intersaccharidic angle  ranges from 117.6 to 118.8˚ with an average value 
of 118.3˚.  This is in good agreement with those reported for β-CD.16   
 
The parameters reported here for DIB2ME indicate that the macrocycle is highly 
symmetrical while the mean deviation (d) and torsion angle (t) show a nearly planar 
O4-heptagon.   
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Table 4.11 Intersaccharidic bond angles, O2(n)···O3(n-1) distances and the tilt 
angles for DIB2ME 
CD φ(°) O2(n)···O3(n-1) (Å) τ2(°) 
G1 119.5 2.810(7) +11.0(3) 
G2 117.6 2.768(7) +14.3(2) 
G3 118.1 2.80(1)   +9.7(5) 
G4 117.7 2.807(6)    +13.5(4) 
G5 118.7 2.873(6) +11.9(2) 
G6 118.8 2.788(9) +12.0(3) 
G7 117.6 2.879(6) +8.8(6) 
 
Intra- and Intermolecular Interactions  
Host intramolecular interactions 
The host molecule has 12 intramolecular O-H•••O hydrogen bonds which can be 
divided into two different types. There are six O3(n)-H•••O2(n-1) and six O3(n)-
H•••O4(n-1) H-bonds. Added to the C-H•••O interactions,23 the O-H•••O interactions 
further stabilise the host conformation. The mean O•••O distance for the O-H•••O 
interactions is 2.82 Å (range 2.76 – 2.88 Å) while the mean bond angle is 129.5˚ (range 
103.0 – 169.0˚). Table 4.12 lists these hydrogen bonds.  
 
The host molecule has 11 intramolecular C-H•••O hydrogen bonds which can be divided 
into five different types. There are three C7-H•••O3, three C5-H•••O4, two C4-H•••O6, 
two C6-H•••O5 interactions and one C9-H•••O6 interaction. Seven interactions stabilise 
the host conformation while four occur within a methyl glucose unit (three with C7-
H•••O3 and one with C9-H•••O6). The mean C•••O distance for the C-H•••O 
interactions is 3.06 Å (range 2.79 – 3.48 Å) while the mean hydrogen bond angle is 
120.2˚ (range 100.0 – 157.0˚).   
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Table 4.12 Hydrogen bonding interactions in DIB2ME (colour coded for clarity) 
Hydrogen bond H•••A 
(Å) 
D•••A 
(Å) 
D-H•••A 
(º) 
Symmetry code 
O19 - H19 ••• O4G2         2.42 3.186(8)      151       
O22 - H22 ••• O1     1.89   2.590(9)      140    2-x,-1/2+y,-z 
O3G2 - H3G2 ••• O2G1         1.98    2.811(5)      169       
O3G2 - H3G2 ••• O4G2         2.50    2.888(4)      109       
O3G3 - H3G3 ••• O2G2         1.96    2.767(5)      160       
O3G3 - H3G3 ••• O4G3       2.51    2.848(5)      105       
O3G4 - H3G4 ••• O2G3       2.00   2.797(6)      157       
O3G4 - H3G4 ••• O4G4         2.48    2.807(5)      104      
O3G5 - H3G5 ••• O2G4         2.03    2.807(4)      153      
O3G5 - H3G5 ••• O4G5         2.50    2.833(4)      105       
O3G6 - H3G6 ••• O2G5       2.12    2.874(5)      149      
O3G6 - H3G6 ••• O4G6       2.53  2.845(4)      103       
O3G7 - H3G7 ••• O2G6     2.11 2.788(6)      138       
O3G7 - H3G7 ••• O4G7       2.53   2.831(5)      102       
C9B  - H7B2 ••• O2G7       2.46   3.436(1)      176    2-x,-1/2+y,1-z 
C9B  - H7B3 ••• O6G5        2.41  3.290(1)      149     
C6  - H6B  ••• O3G2         2.60   3.397(6)      138    2-x,-1/2+y,-z 
C2G1 - H2G1 ••• O5G6        2.46    3.407(5)      158    2-x,1/2+y,1-z 
C4G1 - H4G1 ••• O6G1        2.49    2.847(6)      101      
C9G1 - H7GY ••• O2G5         2.57    3.545(8)      171    2-x,1/2+y,1-z 
C2G2 - H2G2 ••• O5G4         2.45    3.314(5)      144    1-x,1/2+y,-z 
C4G2 - H4G2 ••• O6G2         2.48    2.837(6)      101       
C5G2 - H5G2 ••• O4G3         2.43    2.798(5)      101       
C5G2 - H5G2 ••• O19        2.42   3.275(8)      143       
C7G2 - H8G8 ••• O3G6         2.60    3.151(7)      116     
C7G2 - H8G9 ••• O3G2         2.59    3.176(6)      118       
C5G3 - H5G3 ••• O4G4         2.45    2.798(6)      100       
C7G3 - H8GC ••• O3G3         2.50    3.122(9)      121       
C1G4 - H1G4 ••• O5G2         2.52    3.328(6)      138    1-x,-1/2+y,-z 
C6G4 - H6G1 ••• O5G3         2.41    3.346(6)      157       
C7G4 - H8GD ••• O6G2         2.43   3.385(2)      165    1-x,-1/2+y,-z 
C6G5 - H6GY ••• O5G4        2.58    3.456(7)      148       
C7G5 - H7G4 ••• O3G2         2.58    3.227(6)      123     
C7G5 - H7G5 ••• O3G5       2.45    3.074(6)      121      2-x,-1/2+y,-z 
C5G6 - H5G6 ••• O4G7         2.49    2.850(6)      101       
C4G7 - H4G7 ••• O22      2.59    3.591(6)      180    x,y,1+z 
C6G7 - H6GA ••• O5G6        2.58    3.480(8)      152       
C5G2- H5G2•••O19 2.42 3.275(6) 143  
Host-Host intermolecular interactions (C-H•••O)  
Host-Host intramolecular interactions (C-H•••O) and (O-H•••O) 
Host-Guest intermolecular interactions (C-H•••O) and (O-H•••O) 
Guest-Water interactions (O-H•••O) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: 2-Methoxyestradiol Cyclodextrin Inclusion Complexes 
 
 191
Host-Host intermolecular interactions 
DIB2ME has nine intermolecular hydrogen bonds which can be divided into six 
different C-H•••O interaction types. There are two C9-H•••O2, two C2-H•••O5, two C7-
H•••O3, one C1-H•••O5, one C7-H•••O6 and one C6-H•••O5 interactions. The mean 
hydrogen bond distance is 3.36 Å (range 3.15 – 3.54 Å) while the mean hydrogen bond 
angle is 149˚ ranging from 116.0 to 176.0˚.   
 
Host-Water interactions  
DIB2ME has 14 host-water interactions. Five of the interactions are C-H•••OW 
(W=water) interactions with a mean bond distance of 3.26 Å (range 3.07 – 3.38 Å). The 
nine remaining interactions are O•••OW close contacts with a mean distance of 2.87 Å 
(2.75 – 3.21 Å).   
 
Guest Inclusion 
Guest Location 
The guest molecule is orientated with the D-ring moiety buried within the DIMEB 
cavity while the A ring protrudes from the secondary rim, as shown in Figure 4.20. The 
guest is tilted so as to maximally occupy the DIMEB cavity. The water molecules 
interact with both the host and guest, serving to stabilise the complex. Figure 4.21 
provides a full space-filling diagram of both guest and host in the inclusion complex 
viewed from both primary and secondary rims. 
 
Figure 4.20 Illustration of the DIB2ME inclusion complex. Blue spheres represent 
water oxygen atoms. 
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   Primary rim    Secondary rim 
     
Figure 4.21 Space-filling diagrams of DIB2ME, viewed from both primary (left) 
and secondary (right) rims.  The guest molecule is drawn in green with water 
oxygen atoms as blue spheres. 
 
 
Guest Conformation 
Table 4.13 presents selected, representative bond distances and torsion angles of the 
uncomplexed 2ME molecule (described in Chapter 3) and the 2ME molecule included in 
the DIB2ME complex for comparison. The differences between corresponding 
parameters were calculated and are presented in the last column of Table 4.13. This 
geometrical comparison confirms what is illustrated in Figure 4.22 namely that the 
conformations of the steroid molecules in both instances are practically identical. The 
notable consistency of the steroid molecules in each form is indicative of the rigidity and 
the stability of 2ME. One noteworthy difference is, however, the orientation of the O19-
H bond, which occurs since the 2ME molecule engages in different H-bonding 
arrangements in the two crystal structures. Torsion angles C21-O20-C2-C1 and C21-
O20-C2-C3 have a difference of ~18º, even though slight by visual inspection. Other 
than these differences, no significant conformational changes had been effected on the 
2ME molecule when complexed with DIMEB. A full set of the molecular parameters is 
available in Appendix 4 on the CD-ROM provided. 
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C1C2
C3
C4
C5
C6
C7
C8
C15
C17
C9C10
C11
C13
C12
C14
C16
C18
O19
O20
C21
O22
 
Figure 4.22 Overlay of the uncomplexed 2ME molecule (blue) and 2ME molecule 
encapsulated in DIB2ME (yellow). 
 
 
Table 4.13 Common selected geometrical parameters for 2ME in its own crystal 
and in DIB2ME 
Parameter 2ME 2ME of DIB2ME |Δ| 
Selected bond 
distances (Å) 
   
O19-C17         1.431(3)      1.41(1) 0.025 
C13-C18         1.540(3)      1.54(1) 0.005 
O20-C2          1.391(3)      1.367(7) 0.024 
O20-C21         1.432(3)      1.425(8) 0.007 
O22-C3          1.366(3)      1.275(6) 0.091 
C1-C10         1.408(3)      1.398(7) 0.010 
C8-C9          1.546(3)      1.533(7) 0.013 
C13-C14         1.541(3)      1.511(7) 0.030 
Selected torsion 
angles (º) 
   
C21-O20-C2-C1  -20.6(3) 2.1(1) 18.5 
C21-O20-C2-C3       160.8(2) -179.1(7) 18.2 
C15-C16-C17-O19   148.8(2) 144.9(6) 3.9 
C18-C13-C14-C15   -68.9(2) -67.9(6) 1.0 
C1-C2-C3-C4 -1.0(3) -0.2(7) 0.8 
C8-C9-C10-C5         -22.9(3) -24.3(7) 1.9 
C8-C14-C15-C16     -161.8(2) -165.4(5) 3.6 
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Hydrogen Bonding Interactions involving the Guest Molecule 
Host-guest Intermolecular Interactions 
There are four host-guest hydrogen bonds in the structure of DIB2ME. Three are 
C-H•••O hydrogen bonds with a mean C•••O distance of 3.42 Å (range 3.28 – 3.97 Å) 
and a mean hydrogen bond angle of 153.7˚ (range 138.0 – 180.0˚). There is one host-
guest O-H•••O interaction. There are also several host-guest close contacts. Figure 4.23 
includes the most important host-guest interactions, namely the O-H•••O hydrogen 
bond between the hydroxyl group on ring D of the 2ME molecule and a glycosidic O4 
atom, as well as a C-H•••O hydrogen bond from a host methine group to the hydroxyl 
oxygen atom on the D-ring of 2ME. In addition, Figure 4.23 shows the intramolecular 
O-H•••O hydrogen bonds that stabilise the ‘round’ conformation of the DIMEB 
molecule. Only six intramolecular O-H•••O H-bonds do so, however; since O3 of the 
glucose residue 1 is methylated, a seventh O-H•••O hydrogen bond does not exist. 
 
 
Figure 4.23 Stereoview of intermolecular and intramolecular hydrogen bonds in 
DIB2ME viewed from the host primary side.  
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: 2-Methoxyestradiol Cyclodextrin Inclusion Complexes 
 
 195
Guest-Water Interactions 
One hydrogen bond between the guest and included water molecules was observed, 
namely O22-H22•••O1 (2-x,-1/2+y,-z) (Table 4.12). There are 12 guest-water close 
contacts with a mean distance of 2.86 Å (range 1.88 – 3.40 Å).  
 
Water-Water Interactions 
There are four OW•••OW interactions with a mean distance of 2.88 Å (range 2.63 – 
3.05 Å).  
 
Crystal Packing 
DIMEB and its complexes tend to crystallise in the space groups P21 and P212121 and 
their packing arrangements include channel type head-to-tail, modified brick type and 
modified herringbone motifs.  DIB2ME crystallises in the space group P21, the packing 
arrangement being channel-type along [-101] (Figure 4.24a).  
Figure 4.24b serves as visual confirmation that the guests are isolated from 
neighbouring guest molecules although the protruding guest residues are in contact 
with methine groups of the neighbouring host molecules.  
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(a)        
 
Figure 4.24 Packing diagrams of DIB2ME (a) along [-101] and (b) Stereoview of 
guest-host interaction C4G7-H47•••O22 (x,y,1+z) in yellow.  
 
 
y 
o z 
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Experimental and Computed PXRD Traces for DIB2ME 
Calculated and experimental PXRD traces for DIB2ME are shown in Figure 4.25.  
There is a slight shift in the peak positions to lower 2 θ for the experimental trace. This 
is a result of the different conditions under which the data were collected. Data for the 
experimental trace were collected at ambient temperature (294 K) while data for the 
calculated trace were collected at 113 K. The high level of agreement between the two 
traces does, however, confirm that the crystal selected for X-ray analysis is 
representative of the bulk material. 
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Figure 4.25 Experimental versus calculated PXRD patterns for DIB2ME. 
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4.3.4 TRIMEB COMPLEX WITH 2-METHOXYESTRADIOL 
 
Preparation of TRIB2ME 
A suspension was made by combining 0.033 mmol (44.27 mg) of the CD and 
0.033 mmol (10 mg) of 2ME in 3 ml of distilled water. The suspension was stirred  
vigorously at room temperature for 24 h. We ensured that saturation of both host  
and guest had been achieved. The solution was then filtered (0.45 μm microfilter) and  
left at 60 C on a hot plate. Single crystals formed after several days. The crystals are  
those of an inclusion complex between TRIMEB and 2ME. This complex shall be  
referred to as TRIB2ME. Large, approximately cube-shaped crystals of TRIB2ME  
were isolated.  
 
Thermal Analyses 
Hot Stage Microscopy  
HSM was used to evaluate the thermal behaviour of the complex upon heating at a 
constant rate of 10 K/min. The analysis was done under silicone oil to observe bubble 
formation in the event of dehydration and/or decomposition. The HSM photographs of 
TRIB2ME complex are presented below (Figure 4.26). Crystals of the complex showed 
signs of fragmentation upon removal from mother liquor due to dehydration. 
Photographs of the complex were recorded at various stages of thermal behaviour: start 
of analysis, melting of crystal at 170 °C, decomposition of the complex (shown by colour 
change of the melt to brown) and the subsequent appearance of bubbling as a result of 
decomposition.  
 
During HSM analysis it was difficult to detect release of water from the crystal since no 
bubbling was present before the crystal melting stage. Evidently, the amount of water 
present was so small as not to reveal itself through bubble formation. The crystal 
melted at 170 °C and decomposition commenced at ~350 °C with spontaneous 
associated bubbling verifying decomposition occurring between 350 and 400 °C. 
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Figure 4.26 HSM photographs of TRIB2ME during heating. 
    
Thermogravimetric Analysis and Differential Scanning Calorimetry  
TGA and DSC traces for the TRIB2ME complex are presented in Figures 4.27 and 4.28 
respectively. The TGA traces for the TRIB2ME complex showed a mean mass loss of 
1.1 ± 0.24 % (n=3) in the temperature range 30-315 °C, which established the 
TRIB2ME:H2O ratio as 1:1.07. A very small mass loss was identified which not only 
made it quite difficult to establish commencement of complex decomposition but also 
explains the absence of initial bubbling during HSM analysis. Decomposition of the 
crystal commenced at ~310 °C as confirmed by Figure 4.27. Figure 4.28 shows a single 
melt endotherm at 170 °C (onset temperature 165 °C) which correlates well with HSM.  
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Figure 4.27 TGA trace for TRIB2ME. 
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Figure 4.28 DSC trace for TRIB2ME. 
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UV Spectrophotometry 
The host:guest ratio was determined by UV spectrophotometry at 198.5 nm in 
methanol and distilled water (50:50 v/v) for the TRIB2ME complex. A 1:1 host:guest 
stoichiometry was established. 
 
Experimental PXRD of theTRIB2ME Complex 
The PXRD patterns of TRIMEB, 2ME, a mixture of the two compounds, kneaded 
product and the co-precipitated TRIB2ME complex are illustrated in Figure 4.29. Both 
the mixture and the preparation from kneading host and guest produced an amorphous 
pattern for the host whereas 2ME was clearly identified. This may be due to excessive 
grinding of the sample for PXRD analysis. The co-precipitated material indicated 
definite complexation, with distinct differences upon comparison with the PXRD traces  
of the parent compounds. Sample preparation of the co-precipitated material required 
considerable trituration which led to a slightly amorphous product.  
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Figure 4.29 PXRD patterns of 2ME, TRIMEB, mixture, kneaded material and 
TRIB2ME complex obtained by co-precipitation. 
 
Although three forms of TRIMEB are known,16 the PXRD pattern of only one of these 
is included in the above figure for simplicity. The blue PXRD trace had been compared 
with the PXRD patterns of all three forms of TRIMEB, with no correspondence being 
found. As described later in this chapter, the blue trace does, in fact, match the 
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computed trace based on the single crystal X-ray analysis of the TRIB2ME inclusion 
complex. 
 
Single Crystal X-ray Crystallographic Analysis of the TRIB2ME Complex 
Data-collection  
To obtain good structural resolution, intensity data-collection at low temperature was 
desired. The crystal was mounted on a Nonius Kappa CCD diffractometer using 
graphite-monochromated MoKα radiation and the unit cell determined at 21 °C. On 
cooling the crystal, unit cell data were determined again at -160 °C. Cell determinations 
were performed at both temperatures to ensure that no phase changes were effected on 
cooling.   
Laue symmetry1 was confirmed for the collected intensity data, thus indicating the 
triclinic system, for which the possible space groups are P1 and P1. Since both host 
and guest molecules are chiral, P1 was chosen. This choice was confirmed by program 
XPREP.24 A very good final residual factor R1 [F◦ >4σ(F◦)] of 0.0831 was obtained 
even though minor host disorder was encountered when solving the structure. 
Structure solution based on isomorphous replacement was not relevant for this complex 
since none of the known complexes of TRIMEB has similar unit cell parameters.16 The 
unit cell determinations at room temperature and low temperature are presented in 
Table 4.14. 
 
Table 4.14 Unit cell parameters for TRIB2ME 
 TRIB2ME 
(21 °C*) 
TRIB2ME 
(-160 °C)  
Space group  P1 
a (Å) 14.5923 14.1675(2) 
b (Å) 23.9984 23.7963(3) 
c (Å) 28.9756 28.2467(4)  
α (º) 85.6703 85.3799(4)  
β (º) 85.6492 86.3949(4)  
γ (º) 73.2846 73.8357(8)  
Volume 9562.5 9108.6(2) 
*For room temperature unit cell data, no e.s.d.s are reported since relatively few intensity frames were 
collected 
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Structure Solution and Refinement 
This structure presented a significant challenge owing to the unusually large size of the 
crystallographic asymmetric unit. From density considerations, a value of Z=4 1:1 
TRIMEB:2ME complex units (plus ~4.4 H2O molecules) were indicated as comprising 
the asymmetric unit. The structure was solved by direct methods using SHELXD.20 
Most of the non-hydrogen atoms were located in the E-map and the structure was 
developed by successive difference Fourier syntheses. Atoms were initially refined with 
isotropic displacement parameters. The 2ME molecules were included in the model with 
the correct known absolute configuration. Hydrogen atoms located in the difference 
electron density maps were then placed in fixed geometric positions using a riding 
model and were refined isotropically with thermal parameters equal to 1.2-1.3 times 
those of their parent atoms. Hydroxyl hydrogen atoms were placed using the hydrogen 
bond search model. Heavy atoms were not present, which led to a Flack parameter value 
that did not specify absolute structure unequivocally. The Friedel opposites were 
therefore merged (MERG 4 in SHELXH21). Least-squares weights were utilised in the 
final cycles of the refinement. The low-temperature crystal and refinement data for the 
structure determined are presented in Table 4.15. The ADDSYM function in 
PLATON22 indicated no extra crystallographic symmetry, confirming the proper choice 
of space group for this structure and thus the crystallographic independence of the four 
complex units. Further refinement details are given below. 
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Table 4.15  Low temperature crystal and refinement data of TRIB2ME 
Parameter TRIB2ME 
Molecular Formula (C63H112O35)•(C19H26O3)•1.1H2O 
Formula Weight/g mol-1 1751.86 
Crystal System Triclinic 
Space group P1 
a (Å) 14.1675(2) 
b (Å) 23.7963(3) 
c (Å) 28.2467(4)  
α (º) 85.3799(4)  
β (º) 86.3949(4)  
γ (º) 73.8357(8)  
Volume (Å3) 9108.6(2) 
Z 4 
Densitycalc / g cm-3 1.278 
 (MoK) / mm-1 0.100 
F(000)  3780 
Crystal size / mm3 0.18 x  0.23 x  0.26 
Temperature (K) 173 
Range scanned  /  1.00 ≤  ≤ 24.7 
Index ranges  h: -16, 16           k:-28, 28           l:-33, 33 
 scan angle /  1.0 
 scan angle range, frames 362, 362 
 scan angle /  1.0 
 scan angle range, frames 258, 258 
Dx / mm  40.00 
Total no. of reflections collected 62716 
No. of unique reflections 31829 
No. of reflections with I  2(I) 20492 
No. of L.S. parameters 1077 
Rint, R 0.056, 0.085 
S 1.023 
R1 (F◦ >4σ(F◦)) 0.0831 
No. of reflections omitted 54 
wR2 (all reflections) 0.2353 
Weighting scheme a = 0.122 b = 12.024 
( / )mean  < 0.001 
 excursions / eÅ-3  0.99, -0.52 
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At some stage in the refinement in SHELXH,21 a primary –OCH3 group of one of the 
TRIMEB molecules appeared to be disordered over two positions. The disorder 
appeared at site C6D5 (Figure 4.30b, atoms highlighted in yellow) with the O6-CH3 
residue disordered over two positions (viz. methoxy components C7D5 and C7D8). 
Only a single electron density peak qualifying as a water oxygen atom was found at an 
advanced stage of the refinement. It was included with Uiso ~0.16 Å2 and its s.o.f. was 
allowed to refine, yielding a final value of 0.49.  
 
To refine TRIB2ME anisotropically proved to be very challenging since the program 
SHELXH21 could not accommodate the full structure with all four complex units 
refining in this way. The BLOC25 technique was attempted to refine TRIB2ME 
anisotropically but this was abandoned because of extremely long run-times required to 
ensure sufficient mixing of parameters in each BLOC instruction. Hence, a more 
balanced approach was adopted by applying full-matrix refinement by firstly refining all 
four guests, then the side-chains of each glucose molecule of the host. Even after this 
attempt, not all the atoms refined anisotropically. However, a more balanced 
anisotropically refined model was achieved.  Finally the water molecule O1, C6A, C6B 
and 9 atoms on guest D refined isotropically. With regard to the hosts, 37 atoms on 
host A, 37 atoms on host B, 37 atoms on host C and 43 atoms on host D were refined 
isotropically and the rest of the structure refined anisotropically. The one water O atom 
candidate which was located in the difference electron-density map, accounting for 0.49 
water molecules, refined isotropically.  1.07 ± 0.23 water molecules per complex unit 
were found from TG analysis (n = 3).  However, single crystal X-ray diffraction 
indicated only 0.12 (0.49/4) water molecules per complex unit. We account for the 
difference in waters as being due to sample manipulation for single crystal X-ray 
analysis since after multiple readings, TG analysis for water loss did not correlate well 
with the refinement data. Quantification of water content at such a low level (~1% by 
mass) generally presents considerable difficulty. 
 
The complex units comprising the asymmetric unit are designated as A, B, C and D, 
with each glucose unit within each complex numbered 1 to 7 accordingly (Figure 4.30 a 
and b). Fifteen distance restraints were applied to complex D and one to complex A, B 
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and C each, to maintain reasonable geometries. Hence, the following DFIXs were 
applied: C7D1-O6D1 1.4 Å( = 0.008 Å); C6D1-O6D1, C6D5-O6D5,  C6D5-O6D8 1.4 
Å ( = 0.001 Å); C13D-C18D, C13D-C12D 1.5 Å ( = 0.01 Å); C13D-C17D, C13D-
C14D 1.5 Å ( = 0.001 Å); C5D5-C6D5 1.5 Å ( = 0.005 Å); C5D5-O6D5, C6D5-
C7D5, C6D5-C7D8 2.4 Å ( = 0.005 Å); O6D5-C7D5, O6D8-C7D8 1.4 Å ( = 0.005 
Å); O4A2-H19A 2.23 Å ( = 0.005 Å); O4B1-H19B 2.35 Å ( = 0.005 Å); O4C2-H19C 
2.08 Å ( = 0.005 Å); O6D5-H19D 2.3 Å ( = 0.005 Å).  
(a)    
(b)   
Figure 4.30 (a) Labelling of a representative host (TRIMEB) (b) Stereoview  of 
the asymmetric unit illustrating inclusion of the 2ME molecule in the cavity of 
the host TRIMEB molecule. 
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Modelling of the 2-ME Guest 
Atoms C6A, C6B, C6D, C7D, C11D, C12D, C13D, C17D, C18D, C19D and C21D were 
refined isotropically; all other atoms belonging to the guests were refined 
anisotropically. All the guest hydrogen atoms were placed in idealised positions in a 
riding model. Uiso for the aromatic hydrogens was 1.2 times those of the parent atoms 
and all methyl hydrogens were given thermal parameters 1.5 times the Uiso of their 
parent atoms. In all four independent complex units, the 2ME molecule was found at 
the secondary rim of the respective host with the D-ring of 2ME inserted into the 
TRIMEB cavity (Figure 4.30b). 
 
Structural Description 
The asymmetric unit of the TRIB2ME complex structure (Figure 4.30b) contains four 
TRIMEB molecules, four 2ME guest molecules and 0.49 water molecules. The glucose 
units of the TRIMEB molecule are designated A1-A7, B1-B7, C1-C7 and D1-D7 for 
complexes A, B, C and D, respectively (Figure 4.30a).  
 
Primary Methoxyl and Glycosidic Torsion Angles 
Selected torsion angles for the glucose units in complex unit A, B, C and D are listed in 
Appendix 5. For TRIB2ME, sixteen of the primary methoxyl torsion angles (ω)  for 
glucose residues A1, A3, A5, A6, B2, B4, B5, B7 C2, C4, C6 D2, D4, D5b, D6, D7 
correspond to the (-)-gauche orientation which is the preferred orientation while thirteen 
of the primary methoxyl torsion angles (for residues A2, A4, A7, B1, B3, B6, C1, C3, C5, 
C7, D1, D3, and D5a) have the (+)-gauche conformation. The primary methoxyl group 
of D5 is the residue that is disordered over two positions (designated as ‘a’ and ‘b’) 
adopting the (-)-gauche and (+)-gauche conformations. All the residues are in the 4C1-
chair conformation.   
 
Macrocyclic Symmetry 
Appendix 5 lists the geometrical parameters of the O4-heptagon in the four independent 
TRIMEB molecules in the crystal of TRIB2ME. The radii (r) for each complex unit 
within TRIB2ME vary within a range, namely 4.61 – 5.50 Å. The lengths (l) for the 
four complex units are also very similar and vary within a fairly narrow band of  
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4.12 – 4.56 Å. The average glycosidic oxygen angle (a) for the four complex units is 
127.9º while the glycosidic oxygen angles of each unit fall within the range 117.8 - 
139.9º. 
 
Planarity of the O4-Heptagons 
The mean deviation (d) of the O4 atoms from the mean O4 plane of the host is A - 0.277 
Å, B - 0.289 Å, C - 0.238 Å and D 0.106 Å, with an average e.s.d. for all four complex 
units of 0.004 Å. The torsion angles (t) for all four complex units all lie in a range from 
-20.6 to 26.1º. Furthermore, the parameters which describe the overall shape of the 
macrocycle namely the tilt angle (τ2), intersaccharidic angle () and the O2•••O3' 
distances, are all listed in Appendix 5. For TRIB2ME, τ2 magnitudes range from 5.2 to 
50.2º, which is quite a broad range, but typical of this host.16 For host molecules A and 
B, values of τ2 are positive and the primary rims of all the glucose residues are leaning 
towards the centre of the cavity. For host molecules C and D, six tilt angles are positive 
and one is negative. The negative τ2 magnitudes are fairly small (6.0 and 5.2º 
respectively). Thus for molecules A and B the macrocycle has a truncated cone like 
appearance (i.e. wider at the secondary rim and narrower at the primary rim). However, 
molecules C and D, deviate slightly from this arrangement. The intersaccharidic angle 
 ranges from 113.6 to 119.6º with an average value of 116.8º. This is in good 
agreement with those reported for TRIMEB.16 The parameters reported here for 
TRIB2ME indicate that the macrocycle is somewhat distorted.  
 
 
Host Conformations 
Figure 4.31 presents the TRIB2ME structure, with each complex unit of the 
asymmetric unit colour-coded. In Figure 4.32, we see a remarkable similarity in the host 
conformations of complex units A and B.  However, when comparing A and B with C we 
see a distinct difference in overlay. Since complex D presented disorder of one host 
methoxy group (see brown colour of disordered atoms) coincidence of D with any of the 
other complex units was not possible. Nonetheless, complex unit D, if not disordered, 
would present a similar conformation to complex unit C. This implies that there are at 
least two distinct overall conformations of the TRIMEB molecule, which in turn 
suggests somewhat different modes of guest inclusion.  
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Figure 4.31 Colour coded complex units o  TRIB2ME.  
 
 
 
Figure 4.32 Overlay of the host molecules in complex units A and B (left) and A 
and C (right).   
 
A 
B D 
C 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: 2-Methoxyestradiol Cyclodextrin Inclusion Complexes 
 
 210
INTRA- AND INTERMOLECULAR INTERACTIONS (Appendix 4 and 5) 
Host Intramolecular Interactions 
The host conformations of TRIB2ME are stabilised by several analogous 
intramolecular C-H•••O interactions. The host molecules in TRIB2ME engage in 68 
intramolecular C-H•••O hydrogen bonds (18 for host A, 15 for host B, 17 for host C and 
18 for host D) which can be divided into twelve different types.  There are eighteen C6-
H•••O5, thirteen C5-H•••O4,  eleven C9-H•••O2, eight C4-H•••O6, five C1-H•••O6, 
three each of  C6-H•••O6, C1-H•••O3 and C8-H•••O3 and one each of C5-H•••O5, C6-
H•••O4, C4-H•••O2 and C8-H•••O4 interactions. Fifty-three interactions stabilise the 
host conformation while fifteen occur within a methyl glucose unit (C9-H•••O2, C8-
H•••O3 and C8-H•••O4).  The mean bond length for the C-H•••O interactions is 3.04 Å 
(range 2.75 – 3.46 Å) while the mean bond angle is 118.9º (range 100.0 – 163.0º).   
 
Host-Host Intermolecular Interactions 
TRIB2ME has eleven intermolecular hydrogen bonds which can be divided into seven 
different C-H•••O interactions. There are three C2-H•••O5 interactions, two C8-H•••O2 
and two C8-H•••O3 interactions and one each of C1-H•••O6, C4-H•••O6, C7-H•••O3 
and C1-H•••O3 interactions present. The mean hydrogen bond distance is 3.46 Å (range 
3.46 – 3.55 Å) while the mean hydrogen bond angle is 154.0º ranging from 134.0 to 
174.0º.   
 
GUEST INCLUSION 
Guest location 
In Figure 4.33 the guest molecule is partially included in the TRIMEB host with the D-
ring moiety inserted in the cavity. The A, B and C rings protrude from the secondary 
rim. The guest is tilted to allow maximum occupation of the TRIMEB cavity and the 
water molecule present is hydrogen bonded to both host and guest (illustrated and 
discussed clearly later in text). Figure 4.34 provides a full space-filling diagram of both 
host and guest in the inclusion complex viewed from both primary and secondary rims.  
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Figure 4.33 Illustration of the asymmetric unit of the TRIB2ME inclusion 
complex. The guest is viewed in space-filling format and the water molecule 
included is coloured in blue. 
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Error!
 
 
 
Figure 4.34 The asymmetric unit in space-filling mode: complex units A and B 
viewed from their primary rims (top) and complex units C and D viewed from 
their primary rims (bottom). Guest molecules are drawn in green. 
 
 
Complex A 
Complex B 
Complex D 
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Guest conformations 
Common selected bond distances and torsion angles of 2ME (Chapter 3), 2ME in the 
DIB2ME complex and 2ME in the TRIB2ME complex are presented in Table 4.16 for 
comparison. The differences between corresponding parameters were calculated, with 
the mean |Δ| presented in the last column of Table 4.16. The relative conformations of 
the included guest were compared with the uncomplexed guest. There is explicit 
evidence that the steroid molecules in all instances are practically identical. The 
remarkable consistency of the steroid molecules in each form indicates rigidity and 
stability of this arrangement. No significant conformational changes had been effected 
on 2ME when complexed with TRIMEB. A full set of the molecular parameters is 
available in Appendix 4 on the CD-ROM provided. 
 
Figure 4.35 Selected overlays of the 2ME molecule encapsulated in TRIB2ME; 
complex unit A (blue), B (orange), C (pink) and D (green). 
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Table 4.16 Common selected geometrical parameters for 2ME uncomplexed, 
2ME in DIB2ME complex and 2ME in TRIB2ME (complex unit A) 
Parameter 2ME 
uncomplexed 
2ME of 
DIB2ME 
complex 
2ME of 
TRIB2ME 
(complex 
unit A) 
Mean |Δ|* 
Selected bond distances 
(Å) 
    
O19-C17         1.431(3)      1.41(1) 1.44 (1) 0.023 
C13-C18         1.540(3)      1.54(1) 1.54(2) 0.003 
O20-C2          1.391(3)      1.367(7) 1.38(1) 0.016 
O20-C21         1.432(3)      1.425(8) 1.44 (1) 0.011 
O22-C3          1.366(3)      1.275(6) 1.38 (1) 0.071 
C1-C10         1.408(3)      1.398(7) 1.38(1) 0.021 
C8-C9          1.546(3)      1.533(7) 1.56 (1) 0.021 
C13-C14         1.541(3)      1.511(7) 1.54(1) 0.02 
Selected torsion angles 
(º) 
    
C21-O20-C2-C1  -20.6(3) 2.1(8) 6.4(13) 12.3 
C21-O20-C2-C3          160.8(2) -179.0(5) -176.0(8) 12.1 
C15-C16-C17-O19       148.81(2) 144.9(6) 145.3(8) 2.6 
C18-C13-C14-C15         -68.9(2) -67.9(6) -67.5(9) 0.9 
C1-C2-C3-C4 -1.0(3) -0.2(7) 2.2(14) 1.3 
C8-C9-C10-C5          -22.9(3) -24.3(7) -44(1) 14.3 
C8-C14-C15-C16        -161.8(2) -165.4(5) -165.2(8) 2.4 
*|Δ| = |2ME-2ME of DIB2ME complex| + |2ME - 2ME of TRIB2ME (complex unit A)| + |2ME of 
DIB2ME complex - 2ME of TRIB2ME (complex unit A)|/3 
 
HYDROGEN BONDING INTERACTIONS OF THE GUEST 
Host-guest Intermolecular Interactions 
There are ten host-guest hydrogen bonds in the structure of TRIB2ME (Table 4.17).  
Six are C-H•••O interactions and four are O-H•••O hydrogen bonds with mean C•••O 
and O•••O distances of 3.39 and 3.00 Å (ranges 3.25 – 3.53 and 2.87 – 3.18 Å) 
respectively and mean hydrogen bond angles of 148.5º and 155.8º (ranges 130.0 – 164.0º 
and 122 - 170º) respectively (Figure 4.36). There are also several host-guest close 
contacts.  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 4: 2-Methoxyestradiol Cyclodextrin Inclusion Complexes 
 
 215
Three of the O-H•••O hydrogen bonds (complex units A, B, C) involve the –OH group 
on the D-ring of 2ME as donor to a host glycosidic O4 atom (Figure 4.36). In complex 
D however, the –OH group on the D-ring of the guest is a donor to one of the 
disordered methoxy O-atoms on residue D5 while the water molecule O1 is a donor to 
the hydroxyl oxygen atom. 
 
Table 4.17 Host-guest hydrogen bonding interactions for TRIB2ME  
Hydrogen bond H···A (Å) D···A (Å) D-H···A 
(º) 
Symmetry 
codes 
O19A- H19A••• O4A2      2.23    3.062(8)      169       
O19B- H19B ••• O4B1      2.35    3.184(8)      170      
O19C- H19C ••• O4C2      2.08    2.890(8)      162       
O22D-H22D ••• O5B5      2.34   2.873(1)      122   -1+x,y,-1+z 
C21A- H21B ••• O6D4      2.58   3.531(1)      163    x,1+y,z 
C21A- H21C ••• O3B3      2.54   3.253(1)      130    x,1+y,z 
C4B -H4B  ••• O5B1         2.54   3.467(1)      164    1+x,y,z 
C21C - H21I ••• O6D7      2.60   3.521(1)      157      
C7C1- H7C3 ••• O19C      2.49   3.316(1)      142      
C1D5-H1D5 ••• O22D      2.53  3.308(1)      135   1+x,y,z 
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Figure 4.36 TRIB2ME showing the host-guest hydrogen bonds. Hydrogen bonds 
in red and symmetry operator in light blue. 
Complex B Cow,ple,\ A 
Complex B: x-I,y,z-l 
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Guest Intramolecular Interactions 
In TRIB2ME four intramolecular hydrogen bonds were observed for the guest (Table 
4.18), all four being O-H•••O hydrogen bonds with O•••O lengths in the range 2.68 - 
2.72 Å (mean = 2.70 Å) and the hydrogen bond angle ranging from 110.0 to 120.0° 
(mean = 113.5˚). The guest intramolecular interactions stabilise the guest conformation. 
 
Table 4.18 Guest-guest hydrogen bonding interactions for TRIB2ME  
Hydrogen bond H···A (Å) D···A (Å) D-H···A (º) 
O22B- H22B ••• O20B      2.28   2.722(1)      113      
O22C- H22C ••• O20C      2.28    2.695(9)      111      
O22D-H22D••• O20D      2.27   2.676(1)      110      
C18D- H18J ••• O19D      2.09     2.710(3)      120     
 
Guest-Water interactions 
Since there is only one water molecule associated with the very large asymmetric unit, 
water interactions were minimal. The water molecule makes contact with both guest 
(O19D-H19D•••O1) and host (O1-H1•••O6D5) (Figure 4.37). There is only one host-
water O-H•••O interaction present in TRIB2ME with a O•••O distance 2.65 Å. 
 
Figure 4.37 The guest-water and host-water hydrogen bonds in complex unit D of 
TRIB2ME. 
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Crystal Packing 
In Figure 4.38, the cavities are aligned with continuous ‘channels’ down the crystal a-
axis. The packing diagrams serve as visual evidence that the guests are isolated from 
neighbouring guest molecules while the protruding guest residues are in contact with 
methine groups of the neighbouring host molecules.  
 
Figure 4.38 Stereoview of packing diagram of TRIB2ME along a. 
 
 
Experimental and Computed PXRD Traces for TRIB2ME  
The match between the experimental and calculated pattern is very convincing (Figure 
4.39). Specifically, the relative intensity distributions, numbers and 2θ-values of the 
peaks in the patterns are in good agreement. This close agreement is an indication of 
the correctness of the single crystal X-ray structural model. Also, the match proves that 
the single crystal is representative of the bulk sample. 
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Figure 4.39 Experimental versus calculated PXRD pattern for TRIB2ME. 
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4.11  SOLUBILITY STUDIES 
 
Solubility Profile of 2ME in the Presence of CDs 
The aqueous solubility of 2ME in the presence of CDs was determined experimentally 
using the following procedure: A solution having a known arbitrary concentration of 
CD (typically 2%) was prepared by stirring an accurately weighed amount with solvent 
(distilled water) in a small glass vial till all the CD dissolved at 25 °C. For each CD, 
2ME was added in small increments (about 0.0001 g at a time) until saturation 
occurred. A further increment was added beyond saturation to ensure turbidity (since 
undissolved solute was important to ensure saturation) of each sample. Samples were 
firstly analysed turbidimetrically and then 1 ml samples were extracted from each vial 
for UV analysis. It was important not to replace the solvent removed during sampling 
since this would drive the system away from equilibrium.  
 
The 1 ml sample of the saturated solution was obtained for analysis by separating it 
from the undissolved solid. Filtration through a 0.45 μm membrane filter was used and 
precautions were taken to ensure that it was carried out at the temperature of the 
solubility determination, in order to prevent any change in the equilibrium between 
dissolved and undissolved solute. The concentration of 2ME in the saturated solution 
was determined by UV spectrophotometry at 198 nm. A standard curve of 
concentration of 2ME versus absorbance was plotted. The concentration of 2ME was 
subsequently determined from the calibration curve where absorbance was described by 
calibration curve y = 0.0345x – 0.2132 (R2=0.9877), where y=0 and x=0.0005. 
 
Solubility enhancement factors for 2ME by the three parent CDs and eight derivatised 
CDs were determined by dissolving the steroid in a fixed percentage concentration 
aqueous solution of each host compound. Relative to 2ME solubility in water 
(0.005g/L), the enhancement factors obtained at pH 6.8, 25ºC are recorded in Table 
4.19. It is noted that the turbidimetric method of analysis could produce skewed results 
owing to both human error and general light scattering, hence UV analysis was 
employed as an alternative, possibly more accurate, technique. 
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Table 4.19 Solubility profile of 2ME in the presence of CD at 25C* 
2ME with % Concentration of CD 
in water 
2ME 
added 
g/5 ml 
Enhancement 
factor of 2ME by 
UV analysis 
α-CD 2% (0.1 g/5 ml) 0.001 7.5 fold 
β-CD 2% (0.1 g/5 ml) 0.001 10 fold 
γ-CD 2% (0.1 g/5 ml) 0.004 86 fold 
RAMEB 2% (0.1 g/5 ml) 0.0035 156 fold 
DIMEB 2% (0.1 g/5 ml) 0.0045 256 fold 
TRIMEB 2% (0.1 g/5 ml) 0.002 23 fold 
HPBCD 2% (0.1 g/5 ml) 0.003 88 fold 
TRIMEA 0.5% (0.025 g/5 ml) 0.0015 4 fold 
TRiAcBCD 0.001% 
(0.00005 g/5 ml) 
0.003 8 fold 
TriAcGCD 0.0025% (0.000125 g/5 ml) 0.001 2 fold 
TriEtBCD 0.002% (0.0001 g/5 ml) 0.001 0.84 fold, thus no 
effect on solubility 
* All experiments were compared to a control and repeated 3 times 
 
From the results it was determined that all the CDs except TriEtBCD, improved the 
solubility of 2ME, due to one or more molecular interactions between 2ME and the 
particular CD. The modified CDs viz. RAMEB, HPBCD, DIMEB, TRIMEB and the 
natural CD, γ-CD, very significantly increased the solubility of 2ME.  It was evident 
that DIMEB provided the greatest solubilising effect, possibly owing to its cavity size 
being optimal for the entrapment of the 2ME molecule. Hence, methylated CDs, with a 
relatively low molar substitution appear to be the most effective solubilisers. Reduction 
of drug crystallinity on complexation or solid dispersion with CDs also contributes to 
the CD increasing the apparent drug solubility and dissolution rate.  Therefore, CDs, as 
a result of their ability to form complexes in the dissolution medium, can enhance drug 
dissolution, even when there is no complexation in the solid state. 
 
β-CD and its derivative, TriAcBCD, due to their inherently poor water solubility did 
not improve 2ME solubility markedly. α-CD showed a modest increase in 2ME 
solubility; however its derivative, TRIMEA, showed a lower solubilising effect.  
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TriAcGCD produced limited solubility and TriEtBCD showed no improvement in the 
solubility of 2ME.   
 
Ideally, studies using the phase-solubility method developed by Higuchi and Connors26 
would have provided more insight regarding the influence of a solubiliser, in this 
instance, the CD, on the drug being solubilised (2ME). However, due to the relatively 
small mass of 2ME available as a result of the high cost of its synthesis as well as the 
paucity of especially derivatised CDs, phase solubility studies were not feasible. 
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4.12  DISSOLUTION PROFILES OF 2ME WITH 
SELECTED CYCLODEXTRINS 
 
Dissolution studies were conducted using the rotating basket method as described in 
the BP 2005.27 Gelatin capsules containing 5-10 mg of the formulation were made. Tests 
were carried out in the Vankel VK 700 (220 V) dissolution apparatus and with the 
Vankel VK 650 A Heater/Circulator Benchsaver® series used  to regulate temperature 
at 37 ºC. 900 ml flasks filled with distilled water were used and a stirring speed of 100 
rpm was applied. The capsules were enclosed in stainless steel baskets to prevent 
floating. A 3 h run was conducted and at pre-specified times (15 min intervals) 5 ml 
samples were withdrawn and filtered for analysis, with 5 ml of the distilled water being 
replaced to maintain a constant volume. The assay was by UV spectrophotometry at an 
appropriate wavelength for the active ingredient (198 nm for 2ME). 
 
In vitro dissolution studies were conducted using the rotating basket method as 
described in the British Pharmacopeia (BP) 2005.27 The dissolution profiles for the pure 
drug 2ME, a derivative of 2ME called 2MES (Figure 3.2, Chapter 3), and various 
preparations involving 2ME with β-CD are shown in Figure 4.40, and with other 
selected CDs in Figures 4.41 and 4.42. 
 
All of the capsules tested must meet the BP27 requirements wherein 70% dissolution 
must be attained and the percentage must be in terms of the stated amount. This 
pharmacopoeial dissolution requirement is regarded as offering an agreeable degree of 
assurance of 'total dissolution'. A time of 45 min is considered satisfactory for the 
majority of conventional-release (non-modified-release) products. All dissolution 
profiles were repeated three times to establish consistency in results. 
 
Statistical methods based on analysis of variance (ANOVA) were used to determine 
discrimination in dissolution profiles.28 Anova is a statistical method for making 
simultaneous comparisons between two or more means. Repeated measures Two Way 
ANOVA was used to determine how dissolution rate was affected by two factors. The 
percentage dissolved was the dependent variable and time was the repeated factor.  
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Dissolution profiles of 2ME, 2MES and various preparations involving 2ME with 
β-CD. 
Figure 4.40 illustrates that the dissolution rate of the BCD2ME inclusion complex was 
more rapid than that of the uncomplexed drug and its derivative 2MES. The complexed 
drug reached 100% dissolved drug after 15 min while the 2ME and 2MES samples 
reached 25-32% and 45-55% respectively after 15 to 180 min. The physical mixtures of 
2ME: β-CD (1:1) and (1:2) initially hindered the dissolution of 2ME, possibly due to the 
fact that β-CD is not very soluble in water at low temperatures, which in this instance 
was 37ºC. The 2:1 ratio further hinders dissolution due to the greater concentration of 
the β-CD present in each cylinder. Hence, the concentration of the CD definitely affects 
the dissolution profile of 2ME. After 180 min both physical mixtures reached a 32% 
dissolution level. The complex prepared by kneading reached 100% after 45 min, which 
complied with the BP standards. 
Statistically significant differences in dissolution rate w re observed in the Two Way 
ANOVA studies. This was confirmed due to the fact that the P value is <0.05 between 
complexed and uncomplexed material and between complexed material and physical 
mixtures. 
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Figure 4.40 Dissolution profile of 2ME, 2MES and various preparations 
involving 2ME with β-CD. 
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Dissolution Profiles of 2ME, 2MES and Various Preparations Involving 2ME with 
β-CD and Other Selected CDs. 
Figure 4.41 illustrates the dissolution profiles of 2ME versus 2MES versus 2ME/CD 
physical mixtures. The dissolution profile of 2ME improved significantly in the 
presence of nearly all selected CDs. The γ-CD (1:1) physical mixture produced the most 
rapid increase in dissolution with the first withdrawal of sample. The rate of dissolution 
even surpassed the dissolution profile of 2MES. RAMEB (1:1) physical mixture 
improved the profile of 2ME only after 45 min and α-CD (1:1) improved the profile after 
75 min. HPBCD (1:1) and β-CD (1:1 and 2:1) physical mixtures initially had a poor 
dissolution profile compared to 2ME but later equalised the profile after the 3h run.  
 
CDs are able to dissolve rapidly in the dissolution medium, in comparison to the pure 
drug, 2ME. Therefore, it can be assumed that in the early stages of the dissolution 
process, the CD molecules will act locally on the hydrodynamic layer surrounding the 
particles of the drug. The former results in a rapid increase in the amount of drug 
dissolved.   
 
From the results, it was found that 30% of the pure 2ME drug went into solution within 
20 min. The physical mixture of 2ME and γ-CD (1:1) showed that ~55 % of the 2ME 
dissolved within the same time as the former. As the time progressed, the physical 
mixture of 2ME and γ-CD (1:1) exhibited an increase in the percentage of 2ME 
dissolving, with the final percentage concentration reaching 80% within 3 h.  Therefore, 
of all the physical mixtures studied, the γ-CD (1:1) mixture may be pharmaceutically 
useful in the production of controlled release preparations.  
 
Furthermore, the physical mixture of 2ME and RAMEB (1:1) exhibited a 10% 
improvement in the dissolution characteristics of 2ME. At the end of the 3 h dissolution 
run, approximately 40% of 2ME had dissolved.  In contrast, the physical mixtures of β-
CD with 2ME (1:1 and 2:1) and HPBCD with 2ME (1:1), did not significantly affect the 
dissolution characteristics of 2ME, as the same percentage as that of the pure drug was 
dissolved in the dissolution medium at the end of the dissolution run.   
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Figure 4.41 Dissolution profile of 2ME vs 2MES vs 2ME/CD physical mixtures. 
 
In Figure 4.42 we illustrate the dissolution profile of 2ME/CD kneaded materials 
versus BCD2ME co-precipitated complex. It is evident from Figure 4.42 that when a 
drug/CD system is dispersed in a dissolution medium, a very rapid dissolution is 
observed. Rapid dissolution is a key characteristic behaviour of inclusion complexes.  
Kneading was found to be the most suitable method in the preparation of inclusion 
complexes for the selected parent and derivatised CDs α-, β-, γ-, RAMEB and HPBCD.  
Superior dissolution properties of the material prepared by kneading with γ-CD and 
RAMEB showed 100 % of the drug concentration being achieved within 15 min of the 
dissolution run (Figure 4.42).  Similarly, the BCD2ME complex (2:1) prepared by co-
precipitation exhibited identical behaviour to the former material prepared by kneading.  
In contrast, for the 2ME/β-CD (1:1) material prepared by kneading, complete 
dissolution was only reached at 45 minutes.  
 
For the remaining kneaded systems containing α-CD and HPBCD, 100 % drug 
concentration was only attained at 105 and 90 min respectively (not clearly depicted in 
Figure 4.42 due to overlap of dissolution curves). Hence, the material made by kneading 
and the co-precipitated complex all resulted in improved dissolution properties of 2ME 
(compared to only 30 % of pure, uncomplexed 2ME dissolved within 20 min). From 
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theory,29 it was proposed that dissolution rates of drug/CD systems depend on the 
diffusion and dissociation of the complex in the dissolution medium and increased 
wettability of the drug by inclusion complexation which, in this instance, is the possible 
mechanism for better dissolution of 2ME. 
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Figure 4.42 Dissolution profile of 2ME/CD kneaded material vs 2MEBCD 
complex. γ-CD and 2ME (lime) and RAM2ME (blue) not clearly evident in figure 
due to overlap with BCD2ME illustrated in red. 
 
Statistically significant differences in dissolution rate when comparing definitive 2ME 
complexes with β-CD, HPBCD, RAMEB and those preparations obtained from 
kneading with α- and γ-CD were observed in the Two Way ANOVA studies. This was 
confirmed due to the fact that the P value is <0.0001. Application of Two Way ANOVA 
analysis indicated that the CDs had a significant influence on the initial release of drug 
within 15 min from the gelatin capsule (P<0.05). Subsequent application of one-way 
ANOVA, keeping the levels of 2ME fixed, also showed a statistically significant 
difference amongst the observed data for dissolution rate (P<0.05), ratifying the 
significant positive influence of each CD on the dissolution profiles presented. 
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4.13 CONCLUSION 
The intention of this chapter was to give an account of the preparation and 
characterisation of inclusion complexes between 2ME and selected cyclodextrins. The 
reactions of 2ME with β-CD, RAMEB and HPBCD using the kneading method 
produced cyclodextrin inclusion complexes BCD2ME, RAM2ME and HPB2ME. The 
reaction of 2ME with β-CD, DIMEB and TRIMEB by means of co-precipitation yielded 
the cyclodextrin inclusion complexes BCD2ME, DIB2ME and TRIB2ME. Single 
crystal X-ray analysis of complex BCD2ME was partially successful; the host structure 
was completely determined but details of the location of the 2ME guest molecule could 
not be established due to its severe disorder. Instead, the structures of the DIB2ME and 
TRIB2ME complexes were successfully determined, no guest disorder being observed 
in either case.   
 
The physicochemical characterisation of the cyclodextrin inclusion complexes in the 
solid state commenced via single crystal X-ray diffraction, powder X-ray diffraction 
(PXRD), TGA, DSC, HSM and UV spectrophotometry. Furthermore, both mixtures 
and complexes of 2ME with CDs were analysed with regard to solubility and their 
dissolution profiles. HSM, TGA and DSC provided evidence for the thermal stability of 
the complexes while UV spectrophotometry was used to establish the stoichiometry of 
the solid-state complexes. PXRD provided proof that the bulk material was the same 
phase as the crystals selected for single crystal X-ray diffraction.   
 
Literature reports of single crystal X-ray analysis of cyclodextrin inclusion complexes 
of steroids are rare. To date, there is only one known single crystal X-ray structure 
elucidation of a CD/steroid complex, where the steroid rocuronium bromide is 
complexed with 6-perdeoxy-6-per(4-carboxyphenyl)thio-γ-cyclodextrin sodium salt.4 
The CD is a very rare one and the steroid in this instance is also atypical with 
significant chemical modification compared to the classical steroid molecules. It is thus 
important to emphasise the significance of the novel CD/2ME crystal structures 
reported here. We report the isolation of a total of five new cyclodextrin inclusion 
complexes of 2ME, including one with each of β-CD, RAMEB, HPBCD, DIMEB and 
TRIMEB.  
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The two crystal structures reported here (DIB2ME and TRIB2ME) display no guest 
disorder. However, in both instances we report on minor host disorder.  Both structures 
displayed essentially the same mode of guest inclusion, with the D-ring of the guest 
included within the host cavity.   
 
For BCD2ME, the principles of isostructurality were used in the identification of the 
complex prepared by kneading. Its PXRD pattern matched that of the complex with 
CSD refcode KOFJEU.16 This enabled prediction of the space group as well as 
approximate unit cell dimensions of the complex in the absence of high quality single 
crystal X-ray data. The best crystal of BCD2ME available yielded partial solution by X-
ray analysis, but the guest molecule was severely disordered, as mentioned above. 
Nevertheless, the BCD2ME inclusion complex was otherwise fully characterised.  
 
Solubility studies determined that all the CDs included in the study, except TriEtBCD, 
improved the solubility of 2ME, due to one or more molecular interactions between 
2ME and the particular CD. Dissolution studies presented markedly improved profiles 
for 2ME as mixtures with selected CDs, complexes prepared by kneading and the co-
precipitated complex.  
 
Finally, the objectives of this study were achieved, namely the preparation of 
cyclodextrin inclusion complexe  of 2ME via kneading and co-precipitation methods as 
well as their physicochemical characterisation. Structural elucidation by X-ray 
diffraction of CD inclusion complexes of a classical steroid was achieved for the first 
time and more importantly, from an application perspective, solubility and dissolution 
profiles of non-toxic oral CD complexes with 2ME versus untreated 2ME and its 
derivative 2MES, were established.  
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Chapter 5 
CO-CRYSTALLISATION of 
NEVIRAPINE  
with GRAS EXCIPIENTS 
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Chapter 5 presents the results of the co-crystallisation experimentation of nevirapine 
(NV) with selected co-formers having complementary donor and/or acceptor functions. It 
describes the preparation of NV co-crystals and their physicochemical characterisation. The 
investigation of the dissolution characteristics of the NV co-crystals using the BP dissolution 
method as discussed in Chapter 2 is illustrated as well. From the results it is evident that the two 
co-crystals eventually prepared had a significant impact on the nevirapine ‘as received’ upon 
comparison of the pharmaceutically relevant physicochemical characteristics viz. melting point, 
solubility and dissolution profile.   
 
5.1 INTRODUCTION 
Chapter 1 reviewed NV, a potent inhibitor of HIV-1 reverse transcriptase (Figure 5.1), 
as a unique candidate for co-crystallisation experimentation. The existence of the amide 
function CO–NH in the NV molecule indicates the possibility of alternative modes of 
self-association, namely via a dimer or catemer supramolecular synthon, which could 
lead to crystal polymorphism, whereas interaction with solvent molecules having 
complementary donor and acceptor functions could result in the formation of solvates. 
Furthermore, interaction of the NV molecule with molecules that are solid at ambient 
temperature and have complementary donor and acceptor functions, could result in the 
formation of co-crystals. 
 
Twelve compounds were chosen for this study as potential co-formers with nevirapine 
viz. saccharin, nicotinamide, isonicotinamide, succinic acid, tartaric acid (racemic, as well 
as D and L individually), citric acid, oxalic acid, stearic acid, L-aspartic acid and maleic 
acid. These formers were chosen based on the presence of their carboxylic acid and/or 
other potentially complementary functionalities, and because they appear on the GRAS 
(‘generally regarded as safe’) list. Figure 5.1 illustrates the structures of NV and the 12 
co-crystal formers selected for this study. Table 5.1 provides the melting point data, 
uses and solubility of NV and the 12 co-formers selected. An evaluation of both the API 
and co-crystal formers was carried out, including but not limited to, number and 
arrangement of hydrogen bond donors and acceptors, salt forming ability, 
conformational flexibility and solubility requirements.   
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Figure 5.1 Structures of NV and 10 co-crystal formers included in study: 
(1) nevirapine (2) saccharin, (3) oxalic acid, (4) tartaric acid, (5) maleic acid, (6) 
citric acid, (7) nicotinamide, (8) isonicotinamide, (9) succinic acid, (10) L-aspartic 
acid, (11) stearic acid. 
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Table 5.1 Physical properties of NV and co-crystal formers  
Compound Molecular 
formula 
Mp (ºC) Uses Solubility 
in water, pH 
7, 25ºC 
Nevirapine C15H14N4O 247-249 Antiretroviral 
agent 
0.1 mg/mL,  
(highly soluble 
at pH < 3) 
Saccharin 
 
C7H5NO3S 228.8-229.7  
 
Artificial 
sweetener 
1000 mg per 
290 mL 
Tartaric acid 
(Racemic 
mixture, D and 
L) 
C4H6O6 171-174 (D- 
and L-
tartaric) 
206 (DL, 
racemic) 
146–148 
(meso)  
Antioxidant 1390 mg/mL 
(D- and L-)  
and 206 
mg/mL 
racemic 
Citric acid  
(as the 
monohydrate) 
C6H8O7•H2O 135-152 Preservative, and 
adds acidic or sour 
taste to foods 
1630 mg/mL 
Stearic acid C18H36O2 69.6  Emollient Sparingly 
soluble 
Oxalic acid C2H2O4 101-102 Cleaning and 
bleaching agent 
143 mg/mL  
Maleic acid C4H4O4 131-139 Compound used 
for making 
maleate salts of 
bulk-drugs and 
prevents rancidity 
in oils 
780 mg/mL  
Nicotinamide C6H6N2O 129-131 Vitamin B3 1000 mg/mL 
Isonicotinamide C6H6N2O 155-158 Co-crystal former 191.7 mg/mL  
Succinic acid C4H6O4 185-187 
 
Flavourant 76.9 mg/mL  
L-Aspartic acid C4H7NO4 270-271 Amino acid 4 mg/mL 
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Characterisation of Nevirapine  
The sample of NV used was a gift from North-West University (Potchefstroom, South 
Africa), originally supplied by Cipla Ltd. (batch 1001003, Mumbai, India). The 
University of Cape Town was commissioned to synthesise co-crystals of NV, for which 
this study represented the initial phase. A more extended project in this area continues 
within the Centre for Supramolecular Chemistry Research at the University of Cape 
Town for further identification of co-crystals.  For the purposes of this study a 7 g batch 
of NV was provided and its purity confirmed by 1H-NMR analysis. The result of C, H 
and N microanalysis for NV is listed in Table 5.2. The experimental values for NV 
agree with the calculated values within experimental error, thus showing a high degree 
of purity.  
 
Table 5.2 Microanalysis for NV (C15H14N4O)  
Experimental (n=3) Calculated 
%C %H %N %C %H %N 
67.48 5.52 20.85 67.65 5.30 21.04 
 
 
Many experiments, using different techniques and a wide variety of recrystallisation 
solvents, were performed in order to isolate new co-crystals of NV. Some representative 
results are listed in Table 5.3 and a full listing appears in Appendix 3 on the attached 
CD-rom. In the table, the following abbreviations are used for simplicity: nevirapine 
(NV), saccharin (SC), oxalic acid (OA), tartaric acid (TTA-D, TTA-L and TTA-DL), 
maleic acid (MA), citric acid (CA), nicotinamide (NC), isonicotinamide (ISNC), succinic 
acid (SUC), L-aspartic acid (ASP) and stearic acid (STA). 
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Table 5.3 Selected results of attempted co-crystal preparation using various 
methods 
Method 1a: Slow evaporation (192 solvent combinations with varying ratios) 
Drug Co-
former 
Solvent Molar ratio 
NV:co-former 
Result 
NV SC Acetonitrile 1:1 NV 
  Methanol 2:1 Co-crystal 1 (NVSC) 
  Diethyl ether 2:1 Co-crystal 1 
 ISNC n-hexane 1:1 No crystal 
  n-heptane 1:1 Mixture 
  THF 1:2 ISNC 
 NC Methanol 1:1 NV 
  Carbon 
tetrachloride 
1:1 NV carbon tetrachloride 
solvate 
 SUC Ethyl acetate 1:1 NV 
  Methanol 1:1 NV methanol solvate 
  Acetonitrile 1:1 NV hydrate 
 TTA-
(DL) 
Diethyl ether 1:1 NV diethyl ether solvate 
  Toluene 1:1 NV toluene solvate 
  Amyl alcohol 1:1 Co-crystal 2 (NVTTA) 
 CAM Chloroform 1:1 NV 
Method 2b: Neat grinding (manual grinding with varying ratios) 
Drug Co-
former 
Molar ratio NV:co-former Result 
NV SC 1:1 Mixture 
  2:1 NV 
Method 3b: Solvent-drop grinding (manual grinding with varying ratios) 
Drug Co-
former 
Molar ratio 
NV:co-former 
Solvent Result 
NV SC 1:2 Ethanol 1 ml  Mixture 
 ASP 1:2 Ethanol 1 ml  Mixture 
 NC 1:2 Ethanol 1 ml  Mixture 
aProducts obtained by method 1 were analysed by HSM, single crystal X-ray diffraction and PXRD to 
determine bulk consistency. b Products obtained by methods 2 and 3 were analysed by PXRD. 
NOTE: Vapor diffusion was employed when crystals from slow evaporation were too small for diffraction 
purposes. 
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5.2 PREPARATION OF NEVIRAPINE CO-CRYSTALS  
For the most part, experimental methods comprised recrystallisation of solutions 
containing mixtures of the components (NV plus potential co-former) from a wide range 
of single solvents and binary solvent systems at different temperatures and solid-state 
co-grinding. With regard to the two co-crystals produced in this study, the following 
procedures were established as a means of reproducible co-crystal formation, with 
specific differences listed accordingly.       
 
Preparation of NVSC and NVTTA Co-crystal  
For NVSC, 0.076 mmol (20 mg) NV and 0.038 mmol SC (6.7 mg) were weighed and 
each solid was separately dissolved in minimum volumes of methanol at ~10 ºC below 
the b.p. of the solvent. The solution of greater volume was added to that of smaller 
volume and the resultant solution magnetically stirred for ~30 min, filtered (0.45 μm) 
and allowed to crystallise at 20 ºC.  
 
For NVTTA, an analogous procedure was used. 0.038 mmol (10 mg) NV and 0.038 
mmol TTA (5.7 mg) were weighed and each solid was separately dissolved in minimum 
volumes of solvent (amyl alcohol) at ~10 ºC below its boiling point. Again filtration and 
crystallisation were performed as described above. 
 
5.3 THERMAL ANALYSES 
Hot Stage Microscopy 
HSM was used to analyse the thermal behaviour of the two co-crystals upon heating at 
a constant rate of 10 K/min. Single crystals of the two materials were immersed in 
silicone oil and photographs were taken in the temperature range 30 ºC to 350 ºC. 
These HSM pictures are presented in Figure 5.2. The analysis was done under silicone 
oil to assess the presence of included water or organic solvent as would be indicated by 
bubble formation. The photographs of NVSC and NVTTA were recorded at (a) start of 
analysis, (b) the first sign of melting, (c) completion of melt (d) the onset of 
decomposition (indicated by colour change of the crystals to brown or spontaneous 
bubbling). From the photographs, NVSC starts to melt at 223 ºC and decomposes at 
315 ºC. NVTTA melts at 228 ºC and decomposition occurs from 240 ºC.  
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Figure 5.2 HSM photographs of NVSC and NVTTA. 
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Differential Scanning Calorimetry and Thermogravimetric Analysis 
TGA was used to determine the possible presence of included solvent in the crystals of 
NVSC and NVTTA. In neither case did the TGA trace reveal significant mass loss 
prior to degradation at high temperatures, thus confirming that these crystals were 
unsolvated.  
 
The DSC trace for NVSC (Figure 5.3) indicated a melting point at 223 ºC with a single 
endotherm [215-230 ºC]. The DSC trace for NVTTA (Figure 5.3) indicated a melting 
point at 230 ºC with an endotherm appearing between 221 and 236 ºC. In both instances 
the DSC data correspond well with the HSM observations. Furthermore, both of the 
melting points differed significantly from that of the parent API, NV (melting point 
247-249 ºC) and that of the co-crystal formers SC (melting point 228-229 ºC) and TTA-
DL (melting point 206 ºC). However, the melting point of NVSC was lower than those 
of either of the two parent compounds which might suggest lower stability or weaker 
intermolecular forces and therefore greater dissolution rate than untreated NV and SC. 
For NVTTA, the melting point appeared between those of NV and TTA-DL, possibly 
indicating greater stability or stronger intermolecular forces and consequently, lower 
dissolution rate than NVSC. Furthermore, the NVTTA melting point also suggested 
lower stability than NV but greater stability than TTA-DL which suggests greater 
dissolution rate than untreated NV.  
 
For NVTTA, a second endotherm [103-114 ºC] was identified. The endotherm was 
extremely small and was not observed by HSM, but its origin was not pursued. 
Degradation of NVSC commenced from 315 ºC whereas for NVTTA degradation 
commenced soon after melting [240 ºC] which also corresponded well with HSM 
observations. 
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Figure 5.3 DSC of NVSC and NVTTA co-crystals. 
 
 
5.4 MICROANALYSIS 
The result of C, H and N microanalysis for NVSC and NVTTA is listed in Table 5.4. 
The experimental values for both co-crystals agree closely with the calculated values, 
therefore confirming their purity.  
 
Table 5.4 Microanalysis for NVSC [2(C15H14N4O)•C7H5NO3S] and NVTTA 
[C15H14N4O•C4H6O6 ] 
Co-crystal Experimental (n=3) Calculated  
 %C %H %N %S %C %H %N %S 
NVSC 61.73 4.77 17.88 4.62 62.08 4.65 17.61 4.48 
NVTTA 54.59 5.02 13.39 - 54.80 4.84 13.46 - 
 
 
5.5 EXPERIMENTAL PXRD  
First, we note in Figure 5.4 that the PXRD pattern labelled NV:SC (2:1) methanol, 
which is that of the material prepared according to the procedure described in 5.2 above, 
is significantly different from the PXRD curves of the starting components NV and SC. 
This is consistent with the evidence from thermal analysis that this species is a co-
crystal. Secondly, we note that this PXRD pattern closely matches those for the 
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products obtained by the same procedure, except that solvents chloroform and acetic 
acid were employed instead of methanol. Other solvents that produced the same co-
crystal phase include 1,4-dioxane, n-hexane, n-heptane, diethyl ether and amyl alcohol. 
It was of interest to note that solvent choice was not a critical parameter for the 
preparation of the NVSC co-crystal. For consistency, the NVSC co-crystal prepared 
using methanol as solvent is the one that was chosen for all subsequent analyses. 
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Figure 5.4 Experimental PXRD pattern of co-crystal NVSC and patterns of the 
individual co-crystal components NV and SC. 
 
The PXRD pattern for the NVTTA co-crystal (Figure 5.5) likewise differs very 
significantly from those of the components NV and TTA (DL), strongly suggesting the 
presence of a new phase. Several other solvents were tested for co-crystal formation but 
no solvent other than amyl alcohol yielded NVTTA. 
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Figure 5.5 Experimental PXRD pattern of co-crystal NVTTA and patterns of the 
individual co-crystal components NV and TTA (DL). 
 
5.5. X-RAY CRYSTALLOGRAPHIC ANALYSES OF NVSC AND NVTTA 
Data-collection 
Diffraction intensities were collected on a Nonius Kappa CCD diffractometer using 
graphite-monochromated MoK radiation at low temperature (-160 ºC). Unit cell 
determinations were performed at both room temperature (21 ºC) and low temperature 
(-160 ºC) to ensure that no phase changes were effected on cooling the crystals. The 
program XPREP1 was used to determine the space groups of NVSC and NVTTA.  
 
For NVSC, Laue symmetry1 was indicated for the collected intensity data, thus 
confirming the triclinic crystal system and thus implying space group P1 or P1. 
Intensity statistics provided by XPREP1 showed |E2-1| = 1.035 for NVSC indicating 
the centrosymmetric space group P1. This choice was justified by the successful 
solution and refinement of the structure in this space group. 
 
Laue symmetry 2/m for NVTTA was confirmed for the collected intensity data, thus 
indicating the monoclinic crystal system. The space group P21/c was indicated by the 
reflection conditions hkl: none; h0l: l=2n; 0k0: k=2n. No disorder problems were 
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encountered for either structure and the final R1 [F◦ >4σ(F◦)] values were 0.0468 and 
0.0355 for NVSC and NVTTA respectively.  
 
Structure Solution and Refinement 
NVSC includes two NV molecules and one SC molecule in the crystal asymmetric unit 
(ASU) whereas NVTTA contains one NV and one TTA molecule in the ASU. The 
program SHELXS-972 was used for the structure solution of NVSC and NVTTA. 
Direct methods revealed the positions of all the non-hydrogen atoms in the respective 
asymmetric units and allowed their placement. All non-hydrogen atoms were refined 
isotropically on F2 with SHELXL-973 and subsequently with anisotropic thermal 
parameters. Special attention was given to H-atom placement, given the co-crystal 
context. All hydrogen atoms were unequivocally located in difference electron density 
maps and were subsequently placed in fixed geometric positions using a riding model 
and were refined istropically. Uiso values for the aromatic hydrogens were 1.2 times 
those of the parent atoms and all methyl hydrogens were given thermal parameters 1.5 
times the Uiso of the parent atom.   
 
Atomic numbering schemes are shown in Figures 5.6 and 5.7. NV has one donor (N2) 
and three acceptors (O8, N12, N13), SC has one donor (N21) and three acceptors (O26, 
O27, O28). TTA has four donors (O25, , O27, O28, O29) and six acceptors (O25, O26, 
O27, O28, O29, O30). All of these atoms were critical during location of hydrogen 
atoms since, if the latter had not been unambiguously located, the possibility of salt 
formation would have required consideration. All components of the co-crystals were, 
however, found to be neutral (uncharged). 
 
Least-squares weights were employed in the final cycles of the refinement. The unit cell 
determinations at room temperature (21 ºC) and low temperature (-160 ºC) are 
presented in Table 5.5.   
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5: Nevirapine Co-crsytals 
 
 244
Table 5.5 Unit cell parameters for NVSC and NVTTA 
 NVSC (21 ºC)* NVSC (-160 ºC)  NVTTA(21ºC)*  NVTTA (-160 ºC) 
Molecular 
Formula 
2(C15H14N4O)•C7H5NO3S C15H14N4O•C4H6O6 
Space group  P1   P21/c 
a (Å) 9.499 9.5649(5) 9.305 9.8773(2) 
b (Å) 13.699 13.8069(7) 9.416 19.2859(4) 
c (Å) 13.797 13.8726(7) 19.507 9.6971(2) 
α (º) 63.93 64.090(3) 91.65 90 
β (º) 79.19 79.292(2) 90.74 90.665(3) 
γ (º) 82.94 82.686(2) 90.31 90 
Volume 
(Å3) 
1682.4 1616.98(2) 1853.4 1847.10(9) 
*For room temperature unit cell data, no e.s.d.s are reported since relatively few intensity frames were 
collected 
 
The unit cell data of the respective low temperature and room temperature structures of 
NVSC and NVTTA are in close agreement and indicated that no phase changes 
occurred on cooling the crystals. Crystal and refinement data for low temperature 
determinations are presented in Table 5.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5: Nevirapine Co-crsytals 
 
 245
Table 5.6 Crystal and refinement data for NVSC and NVTTA 
Parameter NVSC NVTTA 
Molecular Formula 2(C15H14N4O)•C7H5NO3S C15H14N4O•C4H6O6 
Formula Weight/g mol-1 715.79 416.39 
Crystal System Triclinic Monoclinic 
Space group P1  P21/c 
a (Å) 9.5649(5) 9.8773(2) 
b (Å) 13.8069(7) 19.2859(4) 
c (Å) 13.8726(7) 9.6971(2) 
α (º) 64.090(3) 90 
β (º) 79.292(2) 90.665(3) 
γ (º) 82.686(2) 90 
Volume (Å3) 1616.98(2) 1847.10(9) 
Z 2 4 
Densitycalc / g cm-3 1.470 1.497 
 (MoK) / mm-1 0.163 0.116 
F(000)  748 872 
Crystal size / mm3 0.08 x 0.11 x 0.14 0.26 x 0.27 x 0.42 
Temperature (K) 173 173 
Range scanned  /  2.99 ≤  ≤  26.36 2.06 ≤  ≤  26.35 
Index ranges  h: -11, 11 k:-17, 17 l:-17, 17 h: -12, 12 k:-24, 24 l:-12, 12 
 scan angle /  1.0 1.0 
 scan angle range, frames 363, 363 254, 254 
 scan angle /  1.0 1.0 
 scan angle range, frames 769, 769 258, 258 
Dx / mm  33 36 
Total no. of reflections collected 12967 12293 
No. of unique reflections 6584 3753 
No. of reflections with I  2(I) 4445 3012 
No. of L.S. parameters 471 276 
Rint, Rσ 0.0325, 0.0480 0.030, 0.0295 
S 0.868 1.030 
R1 (F◦ >4σ(F◦)) 0.0468 0.0355 
No. of reflections omitted 15 8 
wR2 (all reflections) 0.1451 0.0876 
Weighting scheme a = 0.0957, b =0.7738 a = 0.0348, b =0.8302 
( / )mean  < 0.001 < 0.001 
 excursions / eÅ-3  0.249, -0.399 0.222, -0.214 
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Description of the Structures 
NVSC crystallises in the triclinic space group P1 with Z=2 co-crystal formula units 
(namely, two nevirapine molecules and one saccharin molecule) per unit cell. NVTTA 
crystallises in the monoclinic space group P21/c with Z=4 1:1 co-crystal units in the 
unit cell.  
 
POV-RAY4 diagrams of the low temperature (LT) asymmetric units of NVSC and 
NVTTA are presented in Figures 5.6 and 5.7. The thermal ellipsoids of the LT 
structures indicate their reduced atomic thermal motion, which led to high precision of 
their structural determinations.  
In Figure 5.6, a pseudo-centrosymmetric hydrogen bonded NV dimer is present with a 
single SC molecule and in Figure 5.7 one NV molecule is linked to a TTA molecule by 
hydrogen bonding. With NV, SC and TTA being strong contenders for co-
crystallisation experimentation, classic supramolecular synthon formation between NV 
and the respective co-crystal formers was expected. We see a homosynthon formation 
for the API NV in NVSC (plus a heterosynthon between NV and SC, shown later) 
whereas in NVTTA there is a heterosynthon between the API (NV) and the co-former 
(TTA). 
 
Figure 5.6 The asymmetric unit of co-crystal NVSC with atoms represented by 
thermal ellipsoids drawn at the 50% probability level. Principal hydrogen bonds 
between the two NV molecules are drawn as dashed lines.  
(Note: The asymmetric unit was chosen as shown here to facilitate the drawing of the packing diagrams 
and does not show the H-bonding between the SC molecule and a molecule of NV. The latter is shown in 
Figure 5.13) 
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Figure 5.7 The asymmetric unit of co-crystal NVTTA with atoms represented by 
thermal ellipsoids drawn at the 50% probability level. Principal hydrogen bonds 
between the NV and TTA molecules are drawn as dashed lines.   
 
Structural Description of Nevirapine (not co-crystallised) 
Conformation of the Nevirapine Molecule (not co-crystallised) 
Figure 5.8 shows the NV molecule as it occurs in a known polymorph of this API (i.e. 
not co-crystallised with a co-former).5-7 The conformation shown in Figure 5.8 was 
compared with those in the co-crystals to establish whether there were significant 
differences. The molecule of NV has relatively little conformational freedom. One major 
possible conformational change is the rotation of the cyclopropyl residue around the 
N5-C18 bond. This is referred to as the ‘principal torsion angle’ henceforth. 
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Figure 5.8 Nevirapine (not co-crystallised)7 with atoms represented by thermal 
ellipsoids drawn at 50% probability level with τ1, principal torsion angle. 
 
Table 5.7 lists the values of the principal torsion angle τ1 of the NV molecule in its own 
crystal, and for NV in co-crystals NVSC and NVTTA. The value of τ1 for NV is 
significantly different from those in the two co-crystals, differing more significantly 
from that in co-crystal NVTTA.  
 
Table 5.7 Torsion angles† for NV molecule (in its own crystal), NV in NVSC  
and in NVTTA. 
Torsion angle (o) NV7 NVSC 
A 
NVSC 
B 
NVTTA 
τ1 (C6-N5-C18-C20) 74.1(1) 75.8(3) 76.3(3) 83.6(2) 
†Since all of the structures are centrosymmetric, for each τ there are two values, one positive and the 
other negative, with the same magnitude. The magnitude is reported in this table.  
 
An overlay (Figure 5.9a) of the two NV molecules (dimer) in the NVSC co-crystal 
clearly illustrates the “butterfly”7,8 conformation of the NV molecule and the adoption of 
a boat conformation by the seven-membered ring. However, the NV molecule labelled A 
(blue) and the NV molecule labelled B (pink) in the NVSC co-crystal are pseudo-
centrosymmetrically related. Upon overlay (Figure 5.9b) of the NV molecule in the 
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NVTTA co-crystal with an NV molecule in the NVSC co-crystal, the “butterfly” 
physical feature is retained.  In the room-temperature structure of NV5,6 the “butterfly 
angle” (that between the pyridine rings) was quoted as 121º. Figure 5.9 includes the 
calculated butterfly angles for NVSC and NVTTA for comparison. The values vary 
over several degrees, indicating some flexibility in the molecules. The butterfly shape of 
nevirapine is essential for the engagement of the molecule at the reverse transcriptase 
inhibition sites.8 The majority of HIV-1 reverse transcriptase inhibitors that act on the 
binding site show a pronounced dependence for their action on major changes in 
molecular conformation which, in turn, are an important part of structure-activity 
relationship studies. The rotation of the cyclopropyl ring around the carbon-nitrogen 
single bond (N5-N18) primarily determines the effective conformational space of 
nevirapine.  
   
   (a)      (b)  
Figure 5.9 (a) Overlay of the two independent NV molecules in the NVSC co-
crystal and (b) overlay of the NV molecules in NVSC (NV molecule labelled B was 
chosen arbitrarily) and in the NVTTA co-crystal. The individual butterfly angles 
are included in the figure. 
 
Geometrical Analysis of NVSC and NVTTA 
Table 5.8 presents selected, representative bond distances and torsion angles of NVSC 
and NVTTA for comparison as well as the distances and angles for representative 
strong intermolecular hydrogen bonds in both forms. The differences between 
corresponding molecular parameters for NVSC and NVTTA are listed in Table 5.8. A 
full set of the molecular parameters is available in Appendix 4 on the CD-ROM 
provided. This geometrical comparison confirms what is illustrated in Figure 5.9, 
namely that the structures of the NV molecules in NVSC and NVTTA are practically 
A - Blue 125.0(1)º 
B - Pink 118.7(1)º 
NV (NVTTA) - Green 121.2(1)º 
B - Pink 118.7(1)º 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 5: Nevirapine Co-crsytals 
 
 250
identical. From this point of view the discussion of the co-crystals will henceforth 
pertain to the relationship of the NV molecule with respect to SC and TTA-DL 
respectively, unless stated otherwise. The remarkable consistency of the structural 
features of the NV molecule in both co-crystals is indicative of the stability of this 
arrangement and therefore closer, detailed investigation of its assembly is warranted. 
 
Table 5.8 Selected geometrical parameters for NVSC and NVTTA 
Parameter NVSC Parameter NVTTA |Δ|mean* 
Selected bond distances (Å)     
O8A-C1A 1.239(3) O8-C1 1.247(2) 0.005 
O8B-C1B 1.239(3)   
N5A-C4A 1.416(3)  N5-C4    1.410(2) 0.008 
N5B-C4B 1.422(3)   
C15A-C16A 1.386(3) C15-C16   1.391(2) 0.008 
C15B-C16B  1.398(3)   
Selected torsion angles (º)     
C3A-N2A-C1A-C7A 11.2(3) C3-N2-C1-C7 -7.6(2) 3.9 
C3B-N2B-C1B-C7B -5.3(3)   
C1A-N2A-C3A-C4A -52.0(3) C1-N2-C3-C4 50.5(2) 1.3 
C1B-N2B-C3B-C4B 50.0(3)   
N2A-C1A-C7A-C6A 39.3(3) N2-C1-C7-C6 -37.4(2) 6.2 
N2B-C1B-C7B-C6B -45.3(3)   
C1A-C7A-C6A-N5A -12.8(3) C1-C7-C6-N5 4.6(2) 5.5 
C1B-C7B-C6B-N5B 12.7(3)   
N2A-C3A-C4A-N5A 8.8(4) N2-C3-C4-N5 -10.6(2) 1.2 
N2B-C3B-C4B-N5B -8.8(3)   
C7A-C6A-N5A-C4A -54.1(3) C7-C6-N5-C4 61.2(2) 2.7 
C7B-C6B-N5B-C4B 58.2(3)   
C3A-N4A-C5A-C6A 57.5(3) C3-N4-C5-C6 -57.9(2) 2.0 
C3B-N4B-C5B-C6B -60.5(3)   
C4A-N5A-C18A-C19A 72.8(3) C4-N5-C18-C19 -66.9(2) 6.4 
C4B-N5B-C18B-C19B -76.5(3)   
C6A-N5A-C18A-C20A -75.8(3) C6-N5-C18-C20 83.6(2) 5.2 
C6B-N5B-C18B-C20B 76.3(3)   
D-H•••A (Å)     
N2A-H2A•••O8B 2.975(3) N2-H2•••O26 2.974(2) 0.045 
N2B- H2B•••O8A 2.907(3)     
D-H•••A (º)     
N2A-H2A•••O8B 166 N2-H2•••O26 158 9 
N2B-H2B•••O8A 171   
*|Δ| = (|NVA-NVB (NVSC)| + |NVA(NVSC)-NVTTA| + |NVB(NVSC)-NVTTA|)/3 
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Overall Description of Co-crystals NVSC and NVTTA 
The nevirapine molecule consists of three fused rings (Figure 5.8) with two flanking 
pyridine rings and a central seven-membered ring. In both NVSC and NVTTA, the 
seven-membered ring is angular with a boat conformation and the pyriding rings are 
planar. Furthermore, the NV molecule has a carbonyl oxygen atom attached to C1, a 
cyclopropyl ring attached to N5 and a methyl group attached to C16. 
 
As an introduction to this section, a few points relating to the co-formers tartaric acid 
and saccharin follow. 
 
The saccharin molecule in NVSC consists of two fused rings (Figure 5.10a) with both 
rings planar and a carbonyl oxygen at C25. The –NH function is the donor to a pyridine 
N acceptor of NV in co-crystal formation, as described further below. 
 
  
      (a)       (b) 
 
Figure 5.10 (a) Structure of the saccharin molecule as found in co-crystal NVSC, 
(b) One of the tartaric acid molecules of the racemic pair in co-crystal NVTTA.  
 
Naturally, tartaric acid can exist as three stereoisomers (Figure 5.11 and Table 5.9), 
namely the meso-compound and either one of the enantiomers, constituting a pair of 
diastereomers. The physical properties of the enantiomers are identical, while the 
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physical properties of the diastereomers are different. Also, the physical properties of 
the racemic mixture differ from the physical properties of either of the enantiomers. 
levotartaric acid 
(D-(−)-tartaric acid) 
dextrotartaric acid 
(L-(+)-tartaric acid) 
mesotartaric acid 
   
DL-tartaric acid (racemic acid) 
(when in 1:1 ratio) 
 
Figure 5.11 Stereoisomers of tartaric acid with tartaric acid (D and L) crystals 
seen through light microscope. 
 
Table 5.9 Physical properties of stereoisomers of tartaric acid 
Stereoisomers of Tartaric acid Melting 
point 
[α] Solubility, g/100 g 
H2O at 15°C 
(2R,3R)-(+)-
tartaric acid 
L- 170 +11.98° 139 
(2S,3S)-(–)-
tartaric acid 
D- 170 -11.98° 139 
(2R,3S)-
tartaric acid 
meso 140 0° 125 
(±)-tartaric 
acid 
Racemic 
mixture (D,L) 
206 0° 20.6 
 
The tartaric acid molecule in NVTTA (Figure 5.10b) consists of two central carbons 
with a hydroxyl group attached to each and, at each end a carboxyl group. The carbon 
chain is staggered. Since the starting material for TTA was a racemic mixture, either D- 
or L- TTA could have been included in the co-crystal. However, the crystal of NVTTA 
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is centrosymmetric, which therefore requires the presence of an equal number of the two 
TTA enantiomers (Figure 5.12). 
 
Figure 5.12 D- and L- tartaric acid molecules occurring in the NVTTA co-crystal.  
 
Hydrogen Bonding Motifs in NVSC and NVTTA  
In the NVSC structure (Figure 5.13) the two independent NV molecules form a pseudo-
centrosymmetric dimer via two N-H•••O hydrogen bonds, giving rise to the ring motif 
with graph descriptor R2 2(8).9 In addition, a molecule of SC is linked to a pyridine N 
atom of molecule A of NV via a hydrogen bond N-H•••N.  
 
Figure 5.13 Hydrogen bonding motif in NVSC.  
R2 2(8) 
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In the NVTTA structure (Figure 5.14), the primary supramolecular synthon is that 
between the amide group of NV and a carboxylic acid group of TTA. This synthon has 
a graph-set analysis descriptor R2 2(8). This API- co-former association mode is that 
which was contemplated originally when the author considered carboxylic acids as 
potential co-crystal formers with nevirapine. In examining the crystal structure further, 
one notes the formation of other ring motifs, one involving intramolecular stabilisation 
of the TTA molecule (graph-set descriptor S 11 (5)) and the other, a motif R
2 
2(7) that is 
formed between two enantiomeric TTA molecules related by a centre of inversion. In 
addition, a hydrogen bonded ring with graph set descriptor R2 2(10) is generated between 
these enantiomers. 
 
 
Figure 5.14 Hydrogen bonding motifs in NVTTA.  
R2 2(8) 
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Hydrogen Bonding Interactions in NVSC and NVTTA   
Table 5.10 lists all the hydrogen bonds for both NVSC and NVTTA as calculated by 
PLATON.10 It is evident from Table 5.10, Figure 5.13 and Figure 5.14 that the NVSC 
co-crystal results through formation of the H-bond N21-H21•••N13A (1+x,y,z) while 
the NVTTA co-crystal forms through formation of H-bonds N2-H2•••O26 and O25-
H25•••O8 and O29-H29•••NO8 (1+x,y,-1+z). The formation of the NV dimer in NVSC 
is effected via H-bonds N2A-H2A•••O8B and N2B-H2B•••O8A. 
 
Table 5.10 Hydrogen bonding interactions in NVSC and NVTTA 
Hydrogen bond H···A (Å) D···A (Å) D-H···A (º) Symmetry codes 
NVSC     
N2A-H2A•••O8B 2.11 2.975(3) 166  
N2B-H2B•••O8A 2.04 2.907(3)   171  
N21-H21•••N13A 2.09 2.952(3) 167 1+x,y,z 
C14A-14A•••O8A 2.47 3.361(3) 156 -1+x,y,z 
C19A-19B•••O27 2.38 3.299(3) 154 -1+x,y,z 
C29-H29•••O27 2.53 3.424(3)   156 1-x,1-y,2-z 
C30-H30•••N13B 2.57 3.451(3) 154 -1+x,y,1+z 
NVTTA     
N2-H2•••O26 2.14 2.974(2) 158  
O25-H25•••O8 1.80 2.629(2) 171  
O27-H27•••O28 2.52 2.819(2) 103  
O27-H27•••O28 2.04 2.855(2) 162 1-x,-y,1-z 
O28-H28•••O30 2.17 2.650(2) 116  
O28-H28•••O26 2.15 2.882(2) 145 1-x,-y,1-z 
O29-H29•••N13 1.79 2.609(2) 167 1+x,y,-1+z 
C10-H10•••O27 2.55 3.399(2)   150 1-x,1/2+y,3/2-z 
C11-H11•••O27 2.58 3.313(2)   134 -1+x,1/2-y,1/2+z 
C17-H17B•••O26    2.53 3.327(2) 139  
C18-H18•••O29 2.47 3.148(2) 125 -1+x,y,1+z 
C22-H22•••N12 2.53 3.435(2) 150 1+x,1/2-y,-1/2+z 
Symmetry operator applies to hydrogen bonding acceptors. 
Bonds in bold are intramolecular bonds.  
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In NVSC, SC is the co-crystal former and acts as the hydrogen bond donor to NV(A) H-
bond N21- H21•••N13A (1+x,y,z) as indicated in Figure 5.13. It is noted that rather 
than behave as a co-crystal former, SC may act as a weak acid when it is co-crystallized 
with APIs that contain a sufficiently basic centre.11 In this instance protonation of the 
API by saccharin is easily accomplished and instead of co-crystals, API saccharinates 
are formed.11 For NVSC, a true co-crystal was indeed formed since there was no proton 
transfer from the SC molecule to the NV molecule. In addition to the three classical 
hydrogen bonds (two N-H•••O, one N-H•••N) occurring in co-crystal NVSC, there are 
three C-H•••O hydrogen bonds and one C-H•••N hydrogen bond (Table 5.10). 
In co-crystal NVTTA, hydrogen bonding is more extensive owing to the presence of 
TTA, with a high hydrogen bonding capacity. Thus, a total of seven classical H-bonds 
(N-H•••O, O-H•••O, O-H•••N) occur and are complemented by a C-H•••N H-bond and 
four C-H•••O H-bonds (Table 5.10). 
 
Crystal Packing of NVSC and NVTTA 
Figures 5.15, 5.16, and 5.17 present crystal packing diagrams of NVSC and NVTTA 
respectively. In Figure 5.15, we view NVSC crystal packing along [010] which shows 
the SC molecules overlapping in column formation and surrounded by the NV 
molecules. The SC molecules, occurring in pairs across a centre of inversion, associate 
via intermolecular (phenyl)C-H•••O(sulfonyl) hydrogen bonding, giving rise to a ring 
motif R2 2(10) (not shown). As noted earlier, a pseudo-centrosymmetric dimer occurs 
between the crystalloraphically independent NV molecules.   
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Figure 5.15 Stereoview of NVSC down b-axis (SC in green). 
 
For NVTTA we view the co-crystal units down the c-axis (Figure 5.16). The TTA 
molecules are aligned parallel to the y-direction forming a ribbon in the centre of the 
cell. NV molecules are attached to this ribbon by hydrogen bonds.   
 
Figure 5.16 NVTTA packing diagram down the c-axis (TTA in turquoise). 
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In Figure 5.17, a view down the a-axis, co-crystal units are packed in a layered 
formation with inversion-related TTA molecules hydrogen bonding to one another, and 
NV molecules hydrogen bonding to TTA molecules (R2 2(8)  motifs). The NVTTA co-
crystal units are linked by an O-H•••N hydrogen bond. 
 
 
Figure 5.17 Stereoview of NVTTA packing diagram down the a-axis (TTA in 
turquoise). 
 
 
5.7 CALCULATED PXRD 
The computed and experimental patterns of NVSC and NVTTA are presented below 
(Figures 5.18 and 5.19). In each case, the computed pattern is based on the final, refined 
single crystal X-ray parameters for these phases. 
 
In Figure 5.18, the experimental pattern presented a very close match with the 
computed pattern. There are two small peaks in the 5-10º range indicated in both traces. 
However, the experimental trace presented a high signal-to-noise ratio in this angular 
range. Further along the trace, distinct peaks in the regions 2θ = 12.2, 14.3, 15.9, 16.7, 
17.6, 22.3, 24.5, 25.6, 27.3º are presented, which match clearly in both traces and with a 
much better signal-to-noise ratio. Significant intensity differences occur, indicating 
some preferred orientation in the sample. The slight shifts of the experimental pattern 
with respect to the computed pattern to lower 2θ are due to the temperature differences 
at which the respective traces were obtained. 
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Figure 5.18 NVSC calculated versus experimental PXRD patterns. 
 
In Figure 5.19, the experimental pattern matched the calculated pattern with slight 
differences at 9.2, 10.1, 27.6, 30.8, 33.7, 36.4, 38.9, 39.3º 2θ values. These peaks were of 
relatively low intensity in the calculated trace and practically indiscernible in the 
experimental trace, presumably due to residual preferred orientation. The coincidences 
for the stronger peaks in the traces are very convincing, even though we see slight 
shifts of the experimental pattern with respect to the computed pattern to lower 2θ 
values, again accounted for by the temperature differences at which the respective traces 
were obtained.  
 
The general correspondence between the experimental and computed PXRD patterns 
for each of NVSC and NVTTA does, nevertheless, provide a strong assurance that the 
respective single crystals analysed truly represented the bulk phases. 
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Figure 5.19 NVTTA calculated versus experimental PXRD patterns. 
 
5.8 DISSOLUTION 
In vitro dissolution studies were conducted using the rotating basket method at 37 ºC as 
described in Chapter 2. The dissolution profiles for the pure drug NV, NV:co-crystal 
former physical mixture (1:1) and co-crystal are shown in Figures 5.20 and 5.21 for 
saccharin and DL-tartaric acid respectively. The assays were performed by UV 
spectrophotometry at 234 nm for NV in distilled water as the dissolution medium. A 
standard curve of absorbance of NV in distilled water versus concentration was plotted. 
Where co-crystal formers (SC and TTA-DL) were used to form physical mixtures and 
co-crystals, a UV-VIS scan of NV and the respective co-crystal formers was run and a 
standard curve of absorbance, in the presence of the respective co-crystal formers, 
versus concentration was plotted. The wavelength for the assay by UV remained 234 
nm for NV in the presence of SC and TTA-DL, and hence 234 nm was retained for co-
crystals as well.  
 
The time for each dissolution run was 3 h. According to the BP,12 45 min is considered 
satisfactory for the majority of conventional-release (non-modified-release) products. 
Each of the capsules tested should yield a dissolution of 70 % and the percentage of the 
drug tested should be in terms of the stated amount. Taking account of permissible assay 
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ranges and content uniformity, this pharmacopoeial dissolution requirement is 
considered to offer an acceptable degree of assurance of  'total dissolution'.  
 
The dissolution profile of NV clearly increases in the presence of SC and TTA-DL as a 
(1:1) mixture and is further increased as a co-crystal. NVSC reached 75 % dissolution 
after 45 min and 100 % dissolution after 160 min (Figure 5.20). In contrast, NVTTA 
only reached 75 % dissolution after 120 min (Figure 5.21).   
 
Compared to NV, at 15 min, the values of % dissolved are 35, 55 and 39 %, respectively 
for NV, NVSC and NVTTA.  After 3 h we see a significant increase in dissolution of 
both NVSC and NVTTA, with 69 % dissolution for NV after 3 h versus 100 % for 
NVSC and 83 % for NVTTA. NVSC reached 75 % dissolution after 45 min and 100 % 
dissolution after 160 min (Figure 5.20), whereas NVTTA reached 75 % dissolution after 
120 min and only 83 % dissolution after 180 min (Figure 5.21).  
 
Both physical mixtures NV:SC and NV:TTA demonstrate an improved dissolution 
profile compared to NV alone, yielding a ~10 % increase in dissolution after 3 h. 
However, when comparing the physical mixtures to the co-crystals, we find that the 
NVSC co-crystal profile (Figure 5.20) has a higher dissolution rate (~20 % difference 
compared to the physical mixture) and the NVTTA profile (Figure 5.21) being ~10 % 
higher than that of the physical mixture. Finally, we also note that the NV:TTA 
physical mixture initially hinders dissolution of NV (Figure 5.21), but subsequently 
(time ~90 min) NV dissolution starts to improve in the presence of TTA. The 
dissolution rates of the co-crystals were, in both cases, higher than those for the 
untreated NV and NV:co-crystal former physical mixtures (1:1). 
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Figure 5.20 Dissolution of NV vs NV:SC (1:1) mixture vs NVSC co-crystal (2:1). 
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Figure 5.21 Dissolution of NV vs NV:TTA-DL (1:1) mixture vs NVTTA co-
crystal (1:1). 
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For the two co-crystals (Figure 5.22), NVSC passed the BP test by displaying 76 % 
dissolution after 45 min whereas NVTTA failed the test with 61.7 % dissolution after 
45 min. Initially there is a ~10 % difference in dissolution between NVSC and NVTTA, 
but by 105 min we see a dissolution difference of ~20 %. 
 
The melting points of co-crystals NVSC and NVTTA were established as ~223 and 
~228 ºC respectively. Though the m.p. difference is small, the expected trend viz. lower 
m.p. – higher dissolution rate, is nevertheless borne out by this pair, as predicted earlier 
in this chapter. 
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Figure 5.22 Dissolution of NVSC co-crystal versus NVTTA co-crystal. 
 
Statistical methods based on ANOVA were used to determine discrimination in 
dissolution profiles.13 Repeated measures Two Way ANOVA were used to determine 
how dissolution rate was affected by two factors. The percentage dissolved was the 
dependent variable and time was the repeated factor. Statistically significant dissolution 
rates between NV untreated and the two NV co-crystals were observed in Two Way 
ANOVA studies. This was confirmed due to the fact that the P value is <0.0001.  
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5.9 SOLUBILITY PROFILE OF NV IN THE PRESENCE OF CO-FORMERS 
Co-crystallisation, as a rediscovery, poses as a powerful technique to modify key solid-
state properties of pharmaceutical compounds such as solubility, stability and 
dissolution rate.14 From a supramolecular viewpoint, predictable structural motifs can 
be introduced by design, offering at least a partial solution to the problem of controlling 
crystal structure. However, the element of predictability may be misinterpreted as 
leading to the formation of firstly a single structure and therefore lack of crystal 
polymorphism and secondly, the control of the dosage regimen. The subject of co-
crystal polymorphism was addressed by Porter III et al.,15 and in this section, we 
address and question the relevance of the co-crystal supramolecular modification 
approach with regard to dosage regimen. 
The adult dosage regimen for NV is 200 mg daily for 14 days, then 200 mg twice daily. 
The paediatric dose (age 15 days to adolescence) is 150 mg/m2 daily for the first 14 
days, then 150 mg/m2 twice daily. The maximum total daily dose is 400 mg. NV is 
manufactured as a tablet, elixir and suspension dosage form. The side-effects of NV 
include hepatotoxicity and skin reactions and overdose may result in chest pain, cough, 
weight loss, and other adverse conditions.  
For the co-formers in this study, saccharin is generally used as an artificial sweetener 
and reports of cancer with minor side-effects such as headaches and  diarrhoea (possibly 
due to the presence of the sulfonamide group) and even weight gain, have appeared even 
though saccharin may be regarded as a sugar replacement for dietary purposes.16 The 
maximum safe dose recommended by WHO is 2.5 mg/day/kg body weight. TTA is 
regarded as being metabolically inert in man and appears to have no significant side-
effects, with an acceptable dose of 0.3 mg/day/kg body weight reported by WHO.17 
When a dosage regimen for a particular dosage form has been decided upon after 
clinical trials, it is assumed that this is the most effective dose for maximum 
pharmacological activity. Each excipient included in the dosage form is carefully 
selected and its dose is carefully monitored. Upon co-crystallisation, monitoring 
concentrations of the co-former will undergo the same vigilance. However, to control 
the excipient dose if co-crystallised (as in this instance SC and TTA with NV) poses a 
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problem, especially if the excipient presents certain toxic effects at elevated 
concentrations. A suggestion would be to co-crystallise the established required amount 
of active ingredient (NV in this instance), then establish a safe dose of excipient (co-
formers SC and TTA), then co-crystallise as much active with co-former dose suggested 
and if more co-former is required for desired effect, an alternative safe excipient (not co-
crystallised) should be included in the dosage form. 
 
In this section the aqueous solubility of NV in the presence of co-formers was 
determined experimentally using the following procedure: A fixed concentration of the 
co-formers SC and TTA (i.e. exact amount as used for preparation of each co-crystal) 
was prepared by stirring each of these with solvent (distilled water) in a small glass vial 
till all the co-former dissolved at 25 °C. For each co-former, NV was added in specific 
ratio (exact amount used to make co-crystal) until saturation occurred. A further 
increment was added beyond saturation to ensure turbidity (since undissolved solute 
was important to ensure saturation) of each sample. Samples were analysed by UV 
spectrophotometry at 234 nm for NV. Absorbance was monitored at this wavelength in 
order to eliminate the effects of both SC and TTA, which do not absorb significantly at 
this wavelength. 
 
A 1 ml sample of the saturated solution was obtained for analysis by separating it from 
the undissolved solid. Filtration through a 0.45 μm membrane filter followed and 
precautions were taken to ensure that it was carried out at the temperature of the 
solubility determination, in order to prevent any change in the equilibrium between 
dissolved and undissolved solute. The concentration of NV in the saturated solution was 
determined by UV spectrophotometry at 234 nm. A standard curve of concentration of 
NV versus absorbance was plotted.  
 
Nevirapine has an aqueous solubility of 0.1 mg/mL at 25 ºC. The solubility 
enhancement factor for NV, by SC, established by dissolving the API in a 2:1 aqueous 
solution of the co-crystal former, was 46-fold. By TTA(DL) the enhancement factor was 
16-fold at 25C in a 1:1 aqueous solution of the API and co-crystal former. Table 5.11 
indicates that NV aqueous solubility improves in the presence of both co-crystal 
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formers. The results were further confirmed by the dissolution profiles of both NV:SC 
and NV:TTA mixtures presented earlier. 
 
Table 5.11 Solubility of the API NV in the presence of co-crystal formers 
 Use Mp/ºC Water solubility (mg/mL) 
at 25 ºC 
NV antiretroviral agent 247-249 0.1 mg/mL 
SC Artificial sweetener 228.8-229.7 3.4 mg/mL 
TTA (DL) antioxidant 206 (DL, 
racemic) 
206 mg/mL 
NV:SC - - 4.6 mg/mL 
NV:TTA - - 1.6 mg/mL 
 
Almarson and Zaworotko have emphasised that enhanced water solubility is a desirable 
property of API co-crystals;18 however, it was found that the enhancements in solubility 
are greater in API saccharinates (i.e. salts) than in cases where saccharin acts merely as 
a hydrogen bonded co-crystal former. This was exemplified by the 
carbamazapine/saccharin co-crystal, which is as insoluble in water as untreated 
carbamazepine. However, saccharinates of haloperidol, mirtazapine and quinine are 
freely soluble in water.11 In the same study, a piroxicam/saccharin co-crystal was used 
to prove that co-crystals are less soluble than salts when compared with the 
saccharinates of haloperidol, mirtazapine and quinine.11 In the present study we find 
that the NV:SC  and NV:TTA mixtures improve the solubility of untreated NV and that 
SC enhances the solubility of NV three times more than TTA.  
 
Based on the dissolution and solubility enhancement studies, we conclude that the 
solubility of NV was enhanced in the presence of both SC and TTA. Therefore, both 
these ingredients may be used as either a co-crystal former or as an excipient in the 
production of dosage forms. However, the question of whether the co-former solubility 
is enhanced as well remains unknown. Hence, further studies in this regard are 
warranted, when the dosage regimen is considered. Furthermore, the solubility and 
dissolution rate would be greatly dependent on the particle size of the samples included 
in the study (uniformity of particle size in the present study was indicated in Chapter 2). 
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5.10  CONCLUSION 
Two of the twelve co-formers selected for this study produced co-crystals with 
nevirapine. These co-crystals were isolated and characterised by thermal and X-ray 
diffraction methods.  
 
NVSC crystallises in the triclinic space group P1 with a = 9.5649(5) Å, b = 13.8069(7) 
Å, c = 13.8726(7) Å, α = 64.090(3)º, β = 79.292(2)º, γ =82.686(2)º with two co-crystal 
formula units per unit cell. NVTTA crystallises in the monoclinic space group P21/c 
with a = 9.8773(2) Å, b = 19.2859(4) Å, c = 9.6971(2) Å, β = 90.665(3)º with four co-
crystal formula units per unit cell.  
 
The geometrical features of the nevirapine molecule were found to be essentially the 
same in both co-crystal NVSC and NVTTA, despite the fact that the drug molecule 
interacts with different molecules in these species. Experimental PXRD patterns of the 
co-crystals were found to be consistent with respective computed patterns, allowing 
these to serve as reliable references for co-crystal identification. 
 
In considering possible further development of the co-crystals, both saccharin and 
tartaric acid are listed as GRAS compounds and therefore would not need exhaustive 
and separate clinical trials, barring perhaps toxicological studies. As a co-crystal former, 
SC may not be ideal for injectable or drop formulations due to limited water solubility 
compared to saccharinates. Saccharin is a potent sweetener and it masks the bitter taste 
of many drugs, which is very useful in paediatric formulations. If the pH is in a 
reasonable range (i.e. pH 5-6) then injectable forms of the co-crystal would not cause 
any undue irritation and other undesirable side-effects on the skin. 
 
The most salient feature of the NVTTA and NVSC co-crystals is that they, by 
definition, consist of two components, each of which is capable of independent existence, 
as opposed to saccharinates, which consist of cations and anions, incapable of separate 
existence. 
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One can clearly see a place for co-crystals within the pharmaceutical market. On the 
basis of the limited examples available, some general comments can be made on the 
physicochemical properties of co-crystals.19 Melting points are altered for most co-
crystals, with approximately 51 % having melting points between those of the API and 
co-former and 39 % having lower melting points.19 Correlations with other parameters, 
such as solubility, are limited and will be complex due to the multi-component nature of 
co-crystals. In many cases, improved stability, such as resistance to hydrate formation, 
has been shown for co-crystals. However, general trends are not evident and each 
system needs to be evaluated to determine if improvements are obtained. Improved 
solubility for poorly soluble compounds has been achieved using co-crystals. Limited 
studies suggest that salts will provide a larger increase in solubility if they are available. 
For poorly soluble neutral compounds, co-crystals are a very feasible approach to 
improving solubility (as observed in the present study). Co-crystals can provide higher 
and lower dissolution rates compared to the API. Dissociation is an important 
consideration in analyzing data from these experiments. It was shown that significant 
increases in bioavailability are possible with co-crystals, even when dissociation of the 
co-crystal is known to occur from in vitro studies.19 
 
Other aspects of development, such as polymorphism and scale-up, will need to be 
examined for each candidate co-crystal. Processes to produce co-crystals on a large scale 
will likely require different approaches, such as those based on ternary solubility phase 
diagrams. Co-crystals will provide additional options for IP, regulatory, and lifecycle 
management for new and old drugs and will provide additional challenges as they 
continue through the development process.19 
 
To date, no co-crystal drug products appear to be on the market, although there is no 
doubt that co-crystals are present in pharmaceutical drug pipe-lines and it is only a 
matter of time before this application becomes a reality. Finally, it should be made clear 
that no one particular strategy offers a solution for property enhancement of all APIs. 
Each API must be examined and evaluated on a case-by-case basis in terms of molecular 
structure and desired final properties. 
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Given the surge of activity in the field of co-crystals (molecular complexes of an API 
with one or more solid components), it has become an emerging class of pharmaceutical 
materials susceptible to design by crystal engineering. This implies that the functional 
properties of APIs (e.g. solubility and physical stability) can potentially be built in 
during the solid-state synthesis. The relevance of a potential co-crystal former becomes 
a crucial issue at this stage, which is clearly demonstrated in this study.  
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Chapter 6 presents the concluding remarks of this thesis with recommendations for 
further studies. 
 
Three aspects of supramolecular chemistry were investigated in this study, namely 
polymorphism, cyclodextrin inclusion and co-crystallisation. Firstly, we synthesised and 
characterised a range of novel ‘supramolecularly modified’ forms of the 
pharmacologically active molecules 2-methoxyestradiol (2ME), 2-methoxyestradiol-bis-
sulfamate (2MES) and nevirapine (NV). Furthermore, we established their thermal 
stabilities and dissolution properties. In total, the study investigated twelve new 
compounds of which five were identified by polymorphism studies, five by cyclodextrin 
inclusion studies and two by co-crystallisation studies. Of these, seven compounds were 
subjected to single crystal X-ray analysis and their structures were elucidated. Where 
appropriate, attempts were made to reconcile physical behaviour with crystal structures.  
 
POLYMORPHISM 
The drug 2-methoxyestradiol (2-ME), a potent anti-cancer agent with possibly further 
encouraging pharmacological activities,1 is available as a capsule (Panzem®) 
formulation and NanoCrystal® dispersion (NCD) formulation. In the Phase II trial of 
the NCD formulation it was found that 2ME was well tolerated and had better 
bioavailability than the capsule formulation.2 Several structural modifications have been 
initiated to improve its pharmacological activity. However, the present study was 
undertaken to highlight the possibility that supramolecular (i.e. non-covalent) 
modification of 2ME might significantly affect its physicochemical properties and 
consequently its pharmaceutical characteristics related to delivery. 2ME has decreased 
stability when compared to derivative molecules and by sulfamoylation,3 an increased 
cytotoxic and cytostatic activity, plasma half-life and bioavailability are evidenced. The 
sulfamoylated analogue of 2ME, 2-methoxyestradiol-bis-sulfamate (2MES) was thus 
included in this study as well.  
In the chapter dealing with polymorphism, the author investigated using various 
isolation techniques, different forms of 2ME and 2MES. Firstly, it should be noted that 
no previous solid-state characterisation of 2ME or 2MES has been reported in the 
literature thus far and that the phenomenon of polymorphism in steroidal compounds is 
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not uncommon. It is reported that 67% of steroidal molecules can occur in different 
forms given ‘due diligence’ in attempts to isolate them. This study elucidated the crystal 
and molecular structures of the starting materials of both 2ME and 2MES accurately by 
single crystal X-ray determination. Furthermore, 2ME presented a chloroform solvate 
(Form III) by recrystallisation from CHCl3 and an amorphous form (Form II) by melt 
studies. 2MES, in the form of the hemihydrate, after having proven to be very difficult 
to isolate as a single crystal, was eventually and accurately characterised only after four 
sets of X-ray intensity data had been collected, the last involving a non-twinned 
specimen.   
 
Isolation and Characterisation of 2ME Forms I, II and III 
The three modifications of 2ME (Forms I, II, and III) were isolated and characterised 
by thermal and X-ray diffraction methods. Form I was recrystallised from diethyl ether, 
Form II was established as an amorph by DSC melt studies of the melted Form I, and 
Form III was recrystallised from chloroform solvent. Both thermal and PXRD analysis 
showed that Form I corresponded very well with the originally synthesised crystalline 
material. Form II, a molten glassy mass, was identified as an amorphous form by both 
DSC and PXRD analysis. Form III was identified as an unstable chloroform solvate, as 
evidenced by HSM, TGA, PXRD and single crystal X-ray analysis. From the thermal 
analysis, Form I remained relatively stable throughout the heating process with no 
change until it melted at 185 °C and decomposed at 200 °C. Form II (amorphous 
phase), also identified as an unstable form, became opaque at 112 °C during HSM and 
DSC analysis, whereupon transition to a crystalline form occurred, the latter melting 
and decomposing within the same temperature range as the originally prepared Form I. 
This indicated that Form II, a metastable form, reverts to the more stable form, Form 
I.   Form III, the unstable solvated crystal became opaque at 65 °C indicating loss of 
the chloroform solvent. On heating, the crystal collapsed and the resulting powder then 
melted and decomposed within a similar temperature range as Form I, again verifying 
that Form I is the most stable form identified in this study. 
 
The powder X-ray patterns of Forms I, II and III differed significantly showing that 
these can serve as references for their identification. The trace for Form II had no 
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peaks, indicating a vitreous phase. Controlled desolvation of Form III yielded a powder 
which displayed the same PXRD pattern as Form I, an outcome consistent with HSM 
analysis.  
 
Form I of 2ME crystallises in the monoclinic space group P21, with two molecules per 
unit cell. Form III crystallises in the triclinic space group with one formula unit   
2ME•2CHCl3 per unit cell. The conformations of the 2ME molecules were found to be 
identical in both forms. In Form I, the 2ME molecules associate as hydrogen bonded 
dimers which stabilise its layered packing arrangement. In Form III, two 
intermolecular hydrogen bonds appear which, by co-incidence, correspond with two of 
those identified in Form I. These two bonds allowed the formation of continuous 
ribbons of 2ME molecules in the structure. The 2ME molecule is linked to the 
chloroform molecules via hydrogen bonding to the ribbon-like arrangement, creating 
layers between the ribbons. One of the CHCl3 molecules engages in hydrogen bonding 
to the 2ME layer (bifurcated C-H•••O), while the other is involved in a C-H•••π 
interaction with the (aromatic) A-ring of the 2ME molecule. No guest-guest 
interactions are observed within the layers. It was also noted that the layers provided 
distinct diffusion paths for CHCl3 molecules out of crystals of Form III and their 
presence was consistent with the spontaneous desolvation observed for this solvate 
when removed from its mother liquor. 
 
Isolation and Characterisation of 2MES hemihydrate (Form I) 
2MES hemihydrate was recrystallised from amyl alcohol. Even though only this single 
form of 2MES (Form I) was isolated and characterised, we emphasise the difficulty it 
presented in its structural elucidation by single crystal X-ray diffraction. The 
recrystallised 2MES hemihydrate sample did match the original starting material and 
this was verified by elemental analysis, HSM, TGA, DSC and PXRD. Single crystal X-
ray diffraction was essential for establishing the supramolecular interactions in the 
crystal. From the DSC trace it was evident that the compound spontaneously degrades 
upon reaching its melting point (175 ºC) and it is noteworthy that 2MES hemihydrate 
discoloured when exposed to light and had to be stored under special conditions to 
minimise photodegradation.  
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The PXRD patterns of Form I (those of both the originally synthesised material and 
the material recrystallised from amyl alcohol) were practically indistinguishable and 
serve as references for this phase.  
 
After several data-collections and structure refinements, Form I was eventually found 
to crystallise in the orthorhombic space group P212121 with eight 2MES molecules and 
four water molecules per unit cell. The reason that many data-collections were 
performed was the need to overcome a crystal twinning problem. Form I was classified 
as a growth twinned crystal and hence X-ray diffraction results from apparently single 
crystals were quite deceptive. Prior to establishing the true orthorhombic symmetry, 
computations persistently presented a monoclinic unit cell and a structural model which 
did not refine satisfactorily. Upon careful examination of the reciprocal lattice, the 
twinning was revealed and a very thin lamina section was then selected for data-
collection and this showed no indication of twinning, yielding the orthorhombic unit 
cell and the correct space group.  
 
The asymmetric unit (ASU) comprises two 2MES molecules and one water molecule. 
The molecular structures of the two 2MES molecules were practically identical, with 
the same geometrical features as the parent steroid 2ME with respect to ring 
conformations. At each end of the 2MES molecule, there is a sulfamate group rendering 
the 2MES molecule more soluble in aqueous media than the parent 2ME steroid 
molecule. The hydrophilic sulfamate groups also engage in extensive hydrogen bonding 
in the crystal. 
 
In its packing arrangement, 2MES molecules pack head-to-head in a herring-bone style. 
An individual 2MES molecule bonds with a symmetry-related 2MES molecule at either 
end through bridging hydrogen bonds mediated by a water molecule. Water molecules 
are located in isolated sites in the crystal of 2MES hemihydrate, accounting for its 
thermal stability. The ribbon-like feature observed in the crystal structures of 2ME and 
its chloroform solvate does not feature here, however.  
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The basic steroid structure, determined by X-ray analysis, was superimposable for 2ME 
Form I, Form III and 2MES Form I, with minimal conformational differences existing, 
illustrating the rigidity of the steroid backbone. 
 
Experimental PXRD patterns were found to be consistent with computed patterns 
based on single crystal X-ray diffraction data, allowing these to serve as reliable 
references for future identification of the respective 2ME and 2MES phases. 
 
Comparative Solubility and Dissolution of 2ME (Forms I and II) with 2MES 
hemihydrate 
The aqueous solubility of 2MES hemihydrate was determined experimentally and was 
found to be twice that of 2ME, a result which was confirmed by in vitro dissolution 
studies conducted in aqueous medium at 37 ºC. A significant increase in dissolution rate 
and extent of both 2MES hemihydrate and amorphous 2ME compared to 2ME alone 
was recorded, with amorphous 2ME being the most significant. After the 3 h 
dissolution run, both 2MES and amorphous 2ME had twice the dissolution of 2ME 
alone. 
 
Future Work 
The most significant result from this study was the fact that the amorphous 2ME 
(Form II) and 2MES hemihydrate had greater dissolution rates than 2ME (Form I). 
The author recommends that once the capsule (Panzem®) formulation and 
NanoCrystal® dispersion (NCD) formulation are readily available, a comparative study 
with these formulations should be carried out. Comparisons should be made with due 
regard to particle size, form (especially the amorphous form of 2ME) and the desolvated 
material of 2ME (Form III) since desolvation of solvates may improve flowability and 
modify the average particle size4 of the original material. However, complete removal of 
the chloroform must be validated prior to the comparison since chloroform is not a 
pharmaceutically acceptable solvent. These comparisons would provide much insight 
into the solubility and wettability aspects of the various solid-state forms and dosage 
forms currently available for 2ME and 2MES hemihydrate.  
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CYCLODEXTRIN INCLUSION 
Cyclodextrin inclusion of drug molecules into CD cavities results in the improvement of 
the physicochemical properties of drugs. Such improvements include: improving the 
stability, taste, odour, solubility and ultimately the bioavailability. With the non-polar 
cavity available in the CD molecule, inclusion complexes with many hydrophobic guest 
molecules are facilitated. Our literature review regarding 2ME reported the poor 
aqueous solubility and dissolution rate of 2ME, which is generally common for steroidal 
molecules. Thus, the possibility of forming inclusion complexes between 2ME and CDs 
was considered, with the intention of improving the solubility of 2ME. It was also 
considered that successful structural elucidation of CD-2ME inclusion complexes might 
serve as very useful reference structures for those engaged in molecular modelling 
studies involving CD-inclusion of related steroids. It should be noted that at the 
beginning of this study, no single crystal X-ray structures of CD-steroid complexes 
were known. In this study we isolated two such novel crystal structures prepared with 
the methylated CDs DIMEB and TRIMEB. However, during this study, a report of a 
single crystal X-ray structure of a steroid appeared but the complex comprised a highly 
derivatised, charged CD molecule and a modified steroid in the form of its bromide salt,5 
thus representing a very atypical CD-steroid system.   
 
β-CD complex with 2ME  
β-CD complexed with 2ME by kneading and by co-precipitation methods and the 
resulting inclusion complex was designated BCD2ME. Confirmation of water content 
was by TGA and both TGA and DSC indicated that water loss from this complex was a 
multi-stage process. X-ray powder diffraction was used to establish complex formation 
and the complex stoichiometric ratio was established as 2:1 by UV-spectrophotometry. 
In combination with the principles of isostructurality, the X-ray powder diffraction 
pattern permitted deduction of the correct crystal system, space group and unit cell data 
of the new cyclodextrin complex. Isostructurality with a known β-CD complex which 
contains 4-t-butylbenzyl alcohol as guest (CSD refcode KOFJEU) was confirmed.6 The 
β-CD molecule in the structure of KOFJEU6 was used as a trial model for the structural 
elucidation of BCD2ME. Although the host molecule refined normally, the steroid 
molecule was severely disordered, preventing its modelling. However, vital information 
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deduced from the isostructurality of BCD2ME with KOFJEU is that the former 
complex exists as a dimer whose structure is maintained by O-H•••O hydrogen bonds 
between the secondary rims of the two host molecules and that a single 2ME molecule 
is encapsulated within this dimer. Once again, the use of PXRD coupled with 
isostructurality concepts has been invaluable in identifying genuine CD inclusion 
complexes in the absence of single crystals and enabling reliable predictions of the 
crystal parameters.7 
 
HPBCD and  RAMEB Complexes  wi th  2ME 
Both HPBCD and RAMEB complexed with 2ME by kneading each of the CDs with the 
drug in a 1:1 molar ratio in the presence of water. Both CDs are amorphous and their 
PXRD traces do not display any sharp peaks: upon complex formation, essentially no 
change was evident in the resulting PXRD pattern and this was taken as preliminary 
evidence for inclusion complex formation. FTIR spectra of the complexes confirmed our 
observations since shifts in certain characteristic bands of the 2ME molecule were 
indicative of interaction between the CDs and the drug. Finally, the disappearance of the 
2ME melting endotherm in DSC traces of putative complexes was taken as further 
evidence for complex formation.  
 
DIMEB and TRIMEB Complexes with 2ME  
The DIMEB and TRIMEB complexes with 2ME (DIB2ME and TRIB2ME 
respectively) were prepared by co-precipitation methods. TGA was used to determine 
their respective water contents as 5.1 ± 0.4 H2O molecules per DIB2ME complex unit 
and for TRIB2ME the complex:H2O ratio was 1:1.07. Dehydration of the DIB2ME 
complex occurred over a broad temperature range and for TRIB2ME not much water 
loss was observed, which is common for TRIMEB complexes. Both complexes 
presented a 1:1 CD-2ME stoichiometric ratio. The PXRD technique indicated definite 
complexation using the co-precipitation method.  
 
For DIB2ME the asymmetric unit (ASU) was determined to consist of one complex unit 
while for TRIB2ME as many as four independent complex units comprised the ASU. 
Consequently, solving the TRIB2ME structure was quite challenging owing to the 
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abnormally large size of the crystallographic asymmetric unit. Also, to refine TRIB2ME 
anisotropically proved to be very challenging due to limitations of the program 
SHELXH.8 After full-matrix least-squares refinement with atoms treated isotropically, 
a partially anisotropic model was introduced and sequential full-matrix refinement of all 
four guest molecules and the side-chains of each glucose molecule of the host followed. 
In the analysis of DIB2ME, one glucose molecule of DIMEB was found to be 
methylated not only at the O2- and O6- positions, but also at the O3-position, 
indicating impurity of the parent host used in this instance. The 2ME molecule is found 
at the secondary rim of the host in both DIB2ME and TRIB2ME with the D-ring of 
2ME inserted into the host cavity. For DIB2ME, the primary rims of all the glucose 
residues are inclined towards the centre of the cavity and the parameters reported 
indicate that the macrocycle is quite symmetrical, despite the singularity in one glucose 
ring. In the complex TRIB2ME, molecules A and B in the asymmetric unit have a 
truncated-cone appearance and molecules C and D deviate slightly from this 
arrangement. The parameters reported for TRIB2ME indicated that the macrocycle is 
somewhat distorted. The host conformations in complex units A and B are quite similar 
but those in units B and C were noted to have distinct differences. The host D presented 
a somewhat different conformation as well as different host-guest interactions from 
those in A, B and C.   
 
In the crystal of complex DIB2ME, the water molecules interact with both the host and 
guest, serving to stabilise the complex. The conformations of the steroid molecules in 
2ME, DIB2ME and TRIB2ME were found to be practically identical. However, small 
variations in guest inclusion were evident. Furthermore, the sterically bulky steroid 
molecule 2ME, having a fairly sizeable residue (ring-A) that protrudes from the 
secondary side of the host, was seen to induce new types of CD complex crystal packing 
arrangements. DIB2ME crystallises in the space group P21 while TRIB2ME 
crystallises in the space group P1, both packing arrangements being roughly classed as 
‘channel-type’. Not surprisingly, neither of these complexes is isostructural with any 
known DIMEB and TRIMEB complexes. The match between the experimental and 
calculated PXRD patterns for each of DIB2ME and TRIB2ME was very convincing, 
indicating the correctness of the single crystal X-ray structural models. Complexation 
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of 2ME with these CDs definitely resulted in novel complex PXRD patterns that will be 
incorporated into the reference patterns for isostructurality series. These may well be 
employed in future identification of isostructural inclusion complexes containing other 
steroidal guest molecules that are available only in microcrystalline form. 
 
Solubility and Dissolution studies of 2ME and 2MES with CDs 
The solubility and dissolution profiles of 2ME and 2MES with CDs were studied using 
mixtures as well as inclusion complexes. Results were compared with those for the 
parent compounds 2ME and 2MES. This is the first time that a detailed study of the 
dissolution profiles of these compounds has been undertaken and the effect of CDs on 
their dissolution profiles investigated. The main finding was that the aqueous solubility 
of 2ME was significantly improved via both CD complexation and when 2ME was a 
component of a physical mixture with the CD. It was determined that all the CDs, 
except TriEtBCD, improved the aqueous solubility of 2ME while other derivatised CDs 
viz. RAMEB, HPBCD, DIMEB and TRIMEB, as well as the natural CD, γ-CD, very 
significantly increased the solubility of 2ME. The methylated CDs proved to be the 
most effective solubilisers, DIMEB displaying the greatest solubilising effect. The 
dissolution studies yielded markedly improved profiles for 2ME as mixtures with 
selected CDs, as complexes prepared by kneading and as complexes prepared by co-
precipitation.   
 
Future Work 
Phase-solubility studies, developed by Higuchi and Connors,9 would  provide more 
insight regarding the solubilising influence of the CDs investigated in this study of 
2ME. Reduction of drug crystallinity on complexation or solid dispersion with CDs 
definitely increased the apparent drug solubility and dissolution rate.  Thus, CDs, as a 
result of their ability to form complexes in the dissolution medium, can enhance drug 
dissolution, even when there is no complexation in the solid state. These data should be 
viewed in the light of the future work recommended for the polymorphism section of 
this study, since once again particle size and dosage form variation are of utmost 
importance when the delivery of the drug is considered. Cyclodextrin inclusion by itself 
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may allow for better dissolution, but if the incorrect dosage form is chosen, then our 
purpose is defeated.  
Since the present work has revealed new insights into the nature of CD-steroid complex 
crystal packing, further applications of the available crystallographic data to other 
included steroids is feasible. As noted earlier, if isostructurality of putative CD-steroid 
complexes with these known complexes is established, much useful structural 
information could be extracted from a single experimental PXRD pattern. (The 
procedure employed to do this was demonstrated earlier in this thesis in the case of the 
β-CD inclusion complex of 2ME).    
 
CO-CRYSTALLISATION 
The final objective of this study was to make co-crystals of nevirapine (NV) with GRAS 
excipients or compounds that presented themselves as good co-crystal formers. Twelve 
such co-crystal formers were investigated in this study. Two novel NV co-crystals, 
containing the GRAS co-formers rac-tartaric acid nd saccharin, were prepared by co-
precipitation methods. As far as the author is aware, these are the first reported 
examples of co-crystals of NV. Nevirapine, the potent inhibitor of HIV-1 reverse 
transcriptase, contains an amide function CO–NH and this was exploited in the design 
of the resulting co-crystals.10 
 
Isolation and Characterisation of NVSC and NVTTA Co-crystals 
The successful isolation of the co-crystals between NV and saccharin (NVSC) and 
between NV and rac-tartaric acid (NVTTA) vindicated the original proposal of using 
GRAS carboxylic acids as potential co-formers. Such co-crystals would not need 
exhaustive and separate clinical trials, barring perhaps toxicological studies.  
TGA did not reveal any solvent in these co-crystals and their melting points were 
significantly different (223 ºC for NVSC, 230 ºC for NVTTA). Both melting points and 
PXRD traces differed quite significantly from those of the parent API and the co-crystal 
formers, strongly suggesting co-crystallisation, which was ultimately and definitively 
proven by single crystal X-ray analysis.   
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NVSC includes two NV molecules and one saccharin (SC) molecule in the crystal 
asymmetric unit (ASU) whereas NVTTA contains one NV and one TTA molecule in 
the ASU. Careful crystallographic studies were undertaken to ensure unequivocal 
location of H atoms that enabled the author to identify these phases as genuine co-
crystals rather than salts.   
 
In the ASU of NVSC, a pseudo-centrosymmetric hydrogen-bonded NV dimer is present 
together with a single saccharin (SC) molecule. In NVTTA, the ASU comprises one NV 
molecule and one of the enantiomers of TTA.  Supramolecular homosynthon formation 
involving the CO-NH functions of the two NV molecules occurs in NVSC, which 
features also a supramolecular heterosynthon between NV and SC. In contrast, in 
NVTTA there is a heterosynthon between NV (providing the CO-NH) function and the 
co-former TTA (providing the –COOH function). This API- co-former association 
mode is that which was envisaged originally when the author considered using 
carboxylic acids as potential co-crystal formers with nevirapine.  
 
The well-known “butterfly” conformation10 of the NV molecule and the adoption of a 
boat conformation by the seven-membered ring featured in both co-crystal structures. 
The butterfly shape is essential for the engagement of the molecule at the reverse 
transcriptase inhibition sites.11  
 
In co-crystal NVSC, the -NH function of the SC co-former acts as the hydrogen bond 
donor to a pyridine nitrogen atom on the nevirapine molecule. It is known that SC may 
alternatively behave as a weak acid when it is co-crystallized with APIs that contain an 
adequately basic centre and in such cases protonation of the API by saccharin may 
occur, giving rise to API saccharinate salts.12 For NVSC, a true co-crystal was indeed 
formed since there was no proton transfer from the SC molecule to the NV molecule.  
 
Dissolution of Co-crystals 
Both physical mixtures NV:SC and NV:TTA as well as the co-crystals NVSC and 
NVTTA demonstrated an improved dissolution profile compared to untreated NV. 
NVSC passed the BP test by displaying 76.0 % dissolution after 45 min whereas 
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NVTTA failed the test with only 61.7 % dissolution after the same period. The melting 
points of the co-crystals, established as ~223 and ~228 ºC respectively by thermal 
analysis, were consistent with the predicted behaviour in dissolution experiments, the 
lower melting solid having a significantly higher dissolution rate.   
 
Future Work 
On the basis of the dissolution rate studies, we conclude that SC and TTA may be used 
either as co-crystal formers or as excipients in the production of dosage forms. 
However, the question of whether the co-former solubility is enhanced should be 
investigated when a dosage regimen is considered. This is suggested given the toxicity 
profiles of high doses of the co-former. Furthermore, the solubility and dissolution rate 
would be greatly dependent on the particle size of the samples included in the study.  
 
The study of the co-crystallization potential of nevirapine, presented as part of this 
thesis, has laid the foundation for a more comprehensive programme that should extend 
to other antiretrovirals and it is suggested that an in-depth investigation of their co-
crystal solubility profiles and other pharmaceutically relevant properties (e.g. 
flowability, compaction) be undertaken. An additional recommendation is that a series of 
GRAS amides should be considered as an alternative potential series of co-formers for 
systematic investigation of co-crystallisation with NV. Other aspects of development, 
such as polymorphism and scale-up, will need to be examined for each candidate co-
crystal. Processes to produce co-crystals on a large scale will likely require different 
approaches, such as those based on ternary solubility phase diagrams. Furthermore IP, 
regulatory, and lifecycle management for new and old drugs will provide additional 
challenges as they continue through the development process. 
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The Appendix folder on the disk attached to the inside back cover of this thesis 
contains: 
 
Appendix 1: A full list of the outcomes of recrystallisation of 2ME and 2MES from a 
range of solvents/solvent mixtures, as well as the results from other methods of 
polymorph preparation.   
 
Appendix 2: A full list of the outcomes of cyclodextrin inclusion experiments with 2ME. 
 
Appendix 3: A full list of the outcomes of co-crystal formation experiments with NV. 
  
Appendix 4: Supplementary crystallographic information for solved structures in this 
thesis is saved in a subfolder named according to the designation used in this thesis.  
The files may be viewed with WORDPAD or NOTEPAD. 
 
Appendix 5: Supplementary crystallographic information for the cyclodextrin complex 
TRIB2ME. Included is a table with the hydrogen bonds, a table with the primary 
methoxyl and glycosidic torsion angles, a table with the geometrical parameters of the 
O4-heptagon in the four independent TRIMEB molecules in the crystal of TRIB2ME 
and finally a table illustrating the  planarity of the O4-heptagons. 
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Hydrogen bonding interactions for TRIB2ME with symmetry codes 
Hydrogen bond H···A (Å) D···A (Å) D-H···A (º) Symmetry codes 
O19A- H19A••• O4A2         2.23    3.062(8)      169       
O19B- H19B ••• O4B1         2.35    3.184(8)      170      
O22B- H22B ••• O20B         2.28   2.722(1)      113       
O19C- H19C ••• O4C2         2.08    2.890(8)      162       
O22C- H22C ••• O20C        2.28    2.695(9)      111       
O19D-H19D ••• O152 2.30   3.095(2)      158       
O22D-H22D ••• O5B5         2.34   2.873(1)      122   -1+x,y,-1+z 
O22D-H22D••• O20D         2.27   2.676(1)      110       
C6D6 - H2  ••• O5D5         2.33   3.048(1)      129       
C21A- H21B ••• O6D4        2.58   3.531(1)      163    x,1+y,z 
C21A- H21C ••• O3B3         2.54   3.253(1)      130    x,1+y,z 
C1A1- H1A1 ••• O3B4         2.58   3.353(1)      134   -1+x,1+y,z 
C4A1- H4A1 ••• O6A1         2.46  2.838(1)      102       
C6A1- H6A4 ••• O5A7        2.47   3.277(1)          139  
C9A2- H9A6 ••• O2A2         2.45   3.009(1)      116       
C2A3- H2A3 ••• O5C3         2.51   3.502(1)      171       
C4A3- H4A3 ••• O6A3         2.44   2.803(1)      101       
C5A3- H5A3 ••• O4A4         2.47   2.821(1)      100       
C6A3- H6A8 ••• O5A2         2.37   3.077(1)      128      
C6A3- H6A8 ••• O6A2         2.50  3.463(1)      163   
C7A3-H7AX ••• O3C4         2.57   3.545(1)      174     
C5A4- H5A4 ••• O4A5         2.37  2.802(1)      105      
C6A4- H6A9 ••• O4A4        2.57   2.978(1)      104       
C8A4-H8AY ••• O3B1         2.59   3.492(1)      153    1+x,y,z 
C9A4-H9AZ ••• O2A4         2.47   2.955(1)          110  
C4A5-H4A5•••O6A5         2.54   2.887(1)      100       
C5A5- 5A5 ••• O4A6         2.46   2.830(1)      101       
C6A5-H6AZ ••• O5A4         2.30   3.099(1)      137       
C1A6-H1A6 ••• O3A7         2.50   3.118(1)      120       
C5A6-H5A6 ••• O4A7         2.50    2.850(8)      100       
C6A6-H6AB ••• O5A5         2.32   3.072(1)      132       
C8A6-H8AD ••• O2C6         2.51  3.346(1)      143   1+x,y,1+z 
C1A7-H1A7 ••• O6A1         2.48   3.306(1)      139       
C9A7-H9AI ••• O2A7        2.54   3.098(2)          116  
C4B -H4B  ••• O5B1         2.54   3.467(1)      164    1+x,y,z 
C9B1- H9B3 ••• O2B1         2.50   3.013(1)      112      
C1B2- H1B2 ••• O3B3         2.58   3.152(1)      116       
C2B2- H2B2 ••• O5D3         2.52  3.499(1)      166       
C5B2- H5B2 ••• O4B3         2.40   2.778(1)      102       
C6B2- H6B6 ••• O5B1         2.37   3.055(1)      126       
C6B2- H6B6 ••• O6B1         2.43   3.380(1)      161       
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
C5B3- H5B3 ••• O4B4         2.39   2.814(1)      105       
C8B3- H8B8 ••• O3A2         2.51   3.392(1)      149    1+x,-1+y,z 
C9B3- H9B9 ••• O2B3         2.47   2.951(1)      110       
C4B4- H4B4 ••• O6B4         2.55   2.895(1)      100      
C5B4- H5B4 ••• O4B5         2.51   2.868(1)      101       
C6B4- H6BX ••• O5B3         2.28   3.079(1)      137      
C5B5- H5B5 ••• O4B6         2.42    2.823(8)      103      
C6B5- H6BZ ••• O5B4         2.38   3.066(1)      126     
C1B6- H1B6 ••• O6B7         2.50   3.336(1)      140       
C2B6- H2B6 ••• O5D6         2.58  3.540(1)      162    x,y,1+z 
C9B6- H9BF ••• O2B6         2.50   3.096(2)      119       
C4B7- H4B7 ••• O6B7         2.42   2.827(1)      104       
C21C - H21I ••• O6D7         2.60   3.521(1)      157      
C51- H5C1 ••• O4C1         2.49  2.845(1)      101      
C7C1- H7C3 ••• O19C         2.49   3.316(1)      142      
C8C1- H8C3 ••• O3C1         2.47  3.055(1)      118      
C1C2- H1C2 ••• O6C2         2.58   2.933(1)      101      
C4C2- H4C2 ••• O2C1         2.48   3.053(1)      116      
C5C2- H5C2 ••• O4C2         2.53   2.873(1)      100      
C6C2- H6C6 ••• O5C3         2.35   3.174(1)      140      
C8C2- H8C4 ••• O3C3         2.60   3.376(1)      136      
C8C2- H8C4 ••• O4C3         2.58   3.127(1)      115     
C9C2- H9C6 ••• O2C2         2.58   3.164(1)      118     
C1C3- H1C3 ••• O6A3         2.58   3.479(1)      149      
C6C3- H6C7 ••• O5C4         2.49   3.321(1)      142      
C1C4- H1C4 ••• O6C4         2.49   2.876(1)      102     
C6C4-H6CX ••• O5C5         2.44   3.229(1)      137      
C1C6-H1C6 ••• O6C6         2.54   2.927(1)      103      
C6C6- H6CB ••• O5C7         2.45   3.175(1)      130     
C9C6- H9CF ••• O2C6         2.54   3.106(1)      117      
C6C7- H6CC ••• O5C1         2.42   3.308(1)      148      
C9C7- H9CI ••• O2C7         2.53   3.125(1)      119     
C18D- H18J ••• O19D         2.09     2.710(3)      120      
C5D1-H5D1 ••• O4D2         2.50   2.868(1)      101      
C6D1-H6D3 ••• O5D7         2.33  3.241(1)      153     
C4D2-H4D2 ••• O6D2         2.47  2.870(1)      103      
C6D2-H6D6 ••• O5D1         2.33  3.086(1)      132      
C6D2-H6D6 ••• O6D1         2.45  3.351(1)      150      
C4D3-H4D3 ••• O6B2         2.47  3.381(1)      151      
C6D3-H6D7 ••• O5D2         2.49  3.323(1)      142      
C8D3-H8D8 ••• O2A2         2.55  3.375(1)      142   x,-1+y,z 
C9D3-H9D9 ••• O2D3         2.57  3.150(1)      118      
C1D4-H1D4 ••• O3D5         2.38  3.063(1)      124      
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C5D4-H5D4 ••• O4D5         2.44  2.817(1)      102      
C6D4-H6DX••• O5D3         2.36  3.224(1)      145      
C8D4-H8DZ••• O3D4         2.56  3.125(1)      116      
C1D5-H1D5 ••• O22D         2.53  3.308(1)      135   1+x,y,z 
C5D5-H5D5 ••• O4D6         2.35  2.750(1)      103      
C9D5-H9DC••• O2D5         2.47  3.083(1)      120      
C4D6-H4D6 ••• O6D6         2.50  2.847(1)      100      
C5D6-H5D6 ••• O4D7         2.44  2.818(1)      101      
C4D7-H4D7 ••• O6D7         2.52  2.881(1)      101      
C6D7-H6DB••• O5D6         2.49  3.176(1)      126      
C321#-H531#••• O2C1         2.55  3.163(1)      121   -1+x,y,z 
C328#-H546# ••• O6D3         2.46    3.340(2)      150      
O1-H1•••O6D5     
O19D-H19D•••O1     
Host-Host intermolecular interactions (C-H•••O) 
Host-Host intramolecular interactions (C-H•••O)  
Guest-Guest intramolecular interactions (C-H•••O) and (O-H•••O) 
Host-Guest intermolecular interactions (C-H•••O) and (O-H•••O) 
Host-Water interactions (O-H•••O) 
Guest-Water interactions (C-H•••O 
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Principal torsion angles of TRIB2ME 
CD ω(°)a ω(°)b Φ(°) Ψ(°) Θ1(°) Θ2(°) 
A1 -74.4 - 88.7 108.1 49.5 -54.0 
A2 62.4 - 102.9 146.3 50.6 -55.8 
A3 -80.0 - 95.8 101.2 50.3 -53.2 
A4 81.7 - 101.6 152.9 44.6 -60.7 
A5 -70.5 - 98.7 142.2 50.7 -54.4 
A6 -66.5 - 90.4 97.2 52.2 -57.4 
A7 74.8 - 111.9 164.5 44.2 -45.9 
B1 59.9 - 102.8 145.8 50.0 -54.3 
B2 -78.9 - 95.3 99.0 50.4 -55.3 
B3 79.0 - 103.3 151.4 41.6 -59.2 
B4 -69.7 - 96.1 142.5 52.2 -55.7 
B5 -70.8 - 91.0 103.1 49.9 -58.3 
B6 66.5 - 120.4 156.5 46.8 -49.8 
B7 -72.6 - 89.8 108.6 49.4 -53.3 
C1 65.6 - 106.3 134.0 51.5 -55.7 
C2 -72.1 - 92.3 96.7 48.8 -52.7 
C3 64.1 - 105.3 156.9 48.4 -50.7 
C4 -66.4 - 97.3 126.6 58.3 -54.8 
C5 67.7 - 108.7 137.5 51.1 -54.7 
C6 -79.3 - 92.6 110.8 47.4 -51.7 
C7 65.6 - 104.5 149.4 52.1 -51.8 
D1 77.4 - 97.8 139.8 52.9 -57.6 
D2 -69.5 - 96.0 123.5 57.6 -53.6 
D3 65.9 - 111.7 155.8 49.6 -50.8 
D4 -64.6 - 85.4 94.7 46.7 -55.5 
D5 75.3 -62.6 102.3 149.9 47.2 -57.8 
D6 -75.0 - 97.1 128.0 47.7 -54.3 
D7 -67.6 - 98.5 134.6 51.0 -53.5 
 
Geometrical parameters of the O4 polygon for TRIB2ME 
Glucose unit r(Å) l(Å) a(°) d(Å) t(°) 
A1 5.25 4.49 137.8 0.3362 (0.0042)   -14.0 
A2 4.74 4.43 120.5 0.4157 (0.0041)   -10.3 
A3 5.25 4.35 131.3 0.1098 (0.0037)   7.4 
A4 5.05 4.56 125.8 -0.3712 (0.0041)   14.3 
A5 5.14 4.44 124.9 -0.0414 (0.0041)  -20.1 
A6 5.08 4.53 135.3 0.4442 (0.0040)   -1.5 
A7 4.91 4.12 118.7 -0.2209 (0.0041)   24.2 
Mean 5.06 4.42 127.8 0.2771(0.0041) 13.1 
B1 4.83 4.40 120.4 0.4055 (0.0043)   -10.6 
B2 5.29 4.37 132.1 0.1440 (0.0039)   5.9 
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B3 5.00 4.57 126.8 -0.3598 (0.0043)   15.5 
B4 5.11 4.49 123.4 -0.0872 (0.0043)   -17.4 
B5 5.19 4.51 133.1 0.4609 (0.0040)   -6.2 
B6 4.97 4.17 123.3 -0.1719 (0.0042)   26.1 
B7 5.09 4.44 134.9 -0.3916 (0.0046)   -12.6 
Mean 5.07 4.42 127.7 0.2887(0.0042) 13.5 
C1 4.98 4.45 117.8 0.4079 (0.0044)   0.8 
C2 4.61 4.30 126.8 -0.1490 (0.0043)   10.6 
C3 5.44 4.49 133.1 -0.2731 (0.0042)   0.2 
C4 5.23 4.48 131.7 0.2224 (0.0043)   -15.2 
C5 4.78 4.39 118.2 0.2021 (0.0044)   4.9 
C6 4.96 4.35 128.7 -0.3067 (0.0046)   15.4 
C7 5.50 4.50 139.9 -0.1036 (0.0045) -20.6 
Mean 5.07 4.42 127.9 0.2378(0.0044) 9.7 
D1 5.13 4.55 130.9 -0.0343 (0.0048)   -10.5 
D2 4.99 4.52 127.6 -0.0942 (0.0046)   6.1 
D3 5.21 4.29 122.5 0.1846 (0.0042)   8.0 
D4 5.26 4.44 139.7 -0.0317 (0.0040) -15.3 
D5 4.71 4.39 122.3 -0.1930 (0.0044)   9.3 
D6 5.24 4.44 128.2 0.1850 (0.0044)  -3.9 
D7 5.23 4.48 127.3 -0.0165 (0.0048)   5.6 
Mean 5.11 4.44 128.4 0.1056 (0.0046) 8.4 
 
 
Intersaccharidic bond angle, O2(n)···O3(n-1) distances and the tilt angle  for TRIB2ME 
CD φ(°) O2(n)···O3(n-1) (Å) τ2(°) 
A1 113.6 3.42 +10.20 (0.45) 
A2 117.9 3.46 +24.97 ( 0.41 ) 
A3 116.8 3.31 +15.70 ( 0.37 ) 
A4 116.5 3.51 +43.34 ( 0.32 ) 
A5 117.2 3.49 +16.40 ( 0.37 ) 
A6 115.7 3.49 +9.12 ( 0.38 ) 
A7 119.6 3.91 +50.23 ( 0.23 ) 
B1 117.1 3.49 +23.75 ( 0.41 ) 
B2 116.7 3.33 +15.45 ( 0.39 ) 
B3 117.0 3.49 +43.79 ( 0.32 ) 
B4 117.7 3.55 +17.98 ( 0.38 ) 
B5 116.4 3.41 +9.31 ( 0.36 ) 
B6 118.9 3.51 +45.53 ( 0.24 ) 
B7 114.5 3.45 +10.96 ( 0.48 ) 
C1 115.1 3.23 +34.99 ( 0.37 ) 
C2 119.1 3.66 -5.99 ( 0.50 ) 
C3 117.2 3.24 +31.07 ( 0.26 ) 
C4 116.5 3.27 +24.03 ( 0.31 ) 
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Cyclodextrin inclusion complex preparation with 2ME as potential guest using 
various methods 
Method 1i: Neat Grinding for 1 hour  
CD Ratio (H:G) Result 
α-CD 1:1 Mixture 
β-CD  1:1 Mixture 
γ-CD 1:1 Amorphous pattern 
DIMEB 1:1 Mixture 
TRIMEB 1:1 Mixture 
RAMEB 1:1 Mixture 
HPBCD 1:1 Mixture 
TRIMEA 1:1 Mixture 
TRIAcBCD 1:1 Mixture 
TRIAcGCD 1:1 Mixture 
TRIEtBCD 1:1 Mixture 
 
Method 2i: Kneading into paste with water for 1 hour  
CD Ratio (H:G) Result 
α-CD 1:1 Mixture 
 2:1 Mixture 
β-CD  1:1 Mixture 
 2:1 Complex 
γ-CD 1:1 Mixture 
 2:1 Mixture 
 3:2 Mixture 
DIMEB 1:1 Mixture 
TRIMEB 1:1 Mixture 
RAMEB 1:1 Complex 
HPBCD 1:1 Complex 
 2:1 Mixture 
 3:2 Mixture 
TRIMEA 1:1 Mixture 
 2:1 Mixture 
TRIAcBCD 1:1 Mixture 
TRIAcGCD 1:1 Mixture 
TRIEtBCD 1:1 Mixture 
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Method 3ii: Slurry method  
Exp. Ratio (H:G) Result 
α-CD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
4C 2:1 No complex 
RT 2:1 No complex 
SC 2:1 No complex 
60C 2:1 No complex 
β-CD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
4C 2:1 No complex 
RT 2:1 Mixture complex and no complex 
SC 2:1 Complex 
γ-CD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
4C 2:1 No complex 
RT 2:1 No complex 
SC 2:1 No complex 
60C 2:1 No complex 
4C 3:2 No complex 
RT 3:2 No complex 
SC 3:2 No complex 
60C 3:2 No complex 
TRIMEB   
4C 1:1 No complex 
RT 1:1 No complex 
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SC 1:1 No complex 
60 C 1:1 Complex 
DIMEB   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 Complex 
TRIMEA   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
40C 1:1 No complex 
TRIAcBCD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
TRIAcGCD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
TRIEtBCD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
HPBCD   
4C 1:1 No complex 
RT 1:1 No complex 
SC 1:1 No complex 
60C 1:1 No complex 
4C 2:1 No complex 
RT 2:1 No complex 
SC 2:1 No complex 
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60C 2:1 No complex 
4C 3:2 No complex 
RT 3:2 No complex 
SC 3:2 No complex 
60C 3:2 No complex 
i Materials prepared using methods 1 and 2 were analysed using PXRD. 
ii Slurries were made with water at given ratios, stirred for 24 hrs at RT and at 60 ºC for β-CD since β-
CD solubility is greater at higher temperatures. Then slow evaporation (RT), rapid cooling (4 ºC), slow 
cooling (SC) and heating at 60 ºC were employed for crystal growth to occur; resulting crystals were 
analysed by single crystal X-ray diffraction and thereafter PXRD to determine bulk consistency. 
 
 
